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ABSTRACT 
The interaction of some halogenated anaesthetic aaents 
with hepatic drug metabolizing enzymes 
This thesis comprises a report of investigations into 
the interaction of the volatile anaesthetic agents, 
fluroxene, 2,2,2-trifluoroethyl ethyl ether(TFEE), methoxy-
flurane and enflurane, with hepatic drug metabolizing 
enzymes in vivo and in vitro. Each of the anaesthetic 
* agents interacts with the type P-450 cytochromes of 
hepatic microsomes in vitro resulting in the appearance 
of a type I dlfference spectrum, enhancement of NADPH 
oxidation and production of potentially toxic metabolites, 
2,2,2-trifluoroethanol (TFE) (from fluroxene and TFEE) 
and -free fluoride ion (from methoxyflurane and enflurane). 
Values of K , ~A , K · and V have been determined 
s max m max 
for these interactions of the anaesthetic agents with the 
type P-450 cytochromes in microsomes from uninduced, 
polycyclic hydrocarbon induced and phenobarbital induced 
male Wistar rats. 
Biphasic Hanes or Eadie-Hofstee plots were obtained with 
uninduced and polycyclic hydrocarbon.induced microsomes 
for oxidation of NADPH and production of trifluoroethanol 
in the presence of TFEE, and for the production of free 
* -In this abstract, 'type P-450 cytochrorne(s)' refers to 
any (or.all) mernber(s) of the group of heterogeneous heme 
<:proteins of that name; 'cytochrome P-450' and 'cytochrome 
P-448' refer selectively to specific type P-450 cytochromes. 
iv 
and acid-labile fluoride from methoxyflurane; two sets of 
K and V values were calculable in these cases. 
m max 
On the 
basis of linearity of Hanes plots and identity of K or K 
s m 
values in different types of microsomes, it appears that 
for fluroxene and enflurane, cytochrome P-450 is the pre-
dominant type P-450 cytochrome involved in t:he bi~ding and 
metabolism of the agent in uninduced, polycyclic hydro-
carbon induced and phenobarbital_ induced microsomes. Cyto-
chrome P-448 appears to play~no role in these interactions. 
Although activity of cytochrome P-450 also appears pre-
dominant in the spectrally observable binding of TFEE, 
involvement of at least one other type P-450 cytochrome in 
uninducedand polycyclic hydrocarbon induced microsomes is 
evident from the biphasic Hanes plots for NADPH oxidation 
and trifluoroethanol production. Differences in the type 
P-450 cytochromes involved in the binding and metabolism of 
methoxyflurane by microsom~s from differently pretreated 
animals are also evident. In this case, cytochrome P-450 
appears to play a predominant role only in phenob_arbi tal 
induced microsomes; other type P-450 cytochromes are impli-
cated in the binding and metabolism of methoxyflurane in 
uninduced and 3~methylcholanthrene induced microsomes. 
For the interaction of fluroxene o~ TFEE with the type P-450 
cytochromes of phenobarbital induced microsomes, the re-
lationship K = K (NADPH oxidation) = K (TFE production) 
s m m _ 
is observed. This same relationship is also evident for 
fluroxene with uninduced and 3-methylcholanthrene induced 
microsomes. For interactions of methoxyflurane and enflurane 
with the type P-450 cytochromes of hepatic microsomes, simple 
v 
correlations of this nature between values of K and K 
s m 
are not apparent and this situation probably reflects 
the greater complexity of the microsomal metabolism of 
these two agents relative to that of fluroxene or TFEE. 
The stoichiometry of NADPH oxidation and metabolite 
(trifluoroethanol or fluoride) production was calculated 
from V values. For fluroxene and TFEE the observed 
. max 
stoichiometry of NADPH .: TFE is 1 : 1-2; for methoxy-
flurane and enflurane the stoichiometry of NADPH : freeF is 
13 : 1 and 140 : 1, respectively. The observed stoichio-
metry for NADPH : p- is not in agreement with that predicted 
by the postulated pathways of metabolism of methoxyf lurane 
-
and enflurane. We suggest" that spontaneous hydrolysis to 
fluoride of primary produc;:ts of the microsomal metabolism of · 
methoxyflurane does not occui, and propose th~t enflurane 
interacts with the type P-450 cytochromes of hepatic micro-
sames to a large extent as ah uncoupler of substrate oxidation 
and NADPH and oxygen consumption. ~~~~-~~~~~~·-4.-
~~~~~~~~~~ 
Fluroxene in the presence of NADPH mediate.s the degradation 
of the type P-450 cytochromes in vitro. The process of 
degradation requires concomitant metabolism of fluroxene 
but is not related to the production.of trifluoroethanol 
in different types of microsornes. 
The interaction of trifluoroethanol, the toxic metabolite 
of fluroxene and TFEE, with hepatic enzymes postulated to 
be responsible for its metabolism was investigated. It 
appears that a pathway by which the alcohol may 
,-
vi 
be oxidatively metabolized involves the activity of the 
type P-450 cytochromes mixed function oxidation system. 
Trifluoroethanol exhibits a type I difference spectrum 
with hepatic microsomes and enhances microsomal NADPH 
oxidation with K = K (NADPH oxidation) = 25 mM. Tri-
s m 
fluoroethanol appears not to be a substrate for alcohol 
dehydrogenase in vitro although it competitively inhibits 
this enzyme with K. = 6.4 x 10-6 M. In addition, tri-
1 
fluoroethanol is a non-competitive inhibitor of the activity 
of catalase in vitro with Ki = 28 mM. Metabolism of 
trifluoroethanol may also occur via a conjugation reaction 
in vivo,but glucuronidation of this alcohol in vitro was 
not observable in hepatic microsomes from the rats under 
investigation. 
Conflicting reports have appeared in the literature on the 
ability of the anaesthetic agents to induce enzymes of the 
type P-450 cytochromes mixed function oxidation system. 
We have conducted an exhaustive investigation into the 
effects of methoxyf lurane and enf lurane on the hepatic 
drug metabolizing enzymes in vivo. Anaesthesia with 
either agent for four to sixteen days at sub-anaesthetic 
-. -~---~-~ ·-- -~ --- - -~- ----- ------ ----- ---
- --~~~~~ntra-tions (0 .1 MAC) results in few changes in the levels 
---·--~--~-- ---~~-·---- ---~ ~ -·----- ---- ---~-
or activities of drug metabolizing enzymes relative to 
those in unanaesthetized control animals. Anaesthesia 
with methoxyflurane for one to four days at anaesthetic 
concentrations (1.0 MAC) results in a small increase in 
NADPH-cytochrome £ reductase activity on the third day only. 
Vii 
Enflurane anaesthesia for one to four days at 1.0 MAC 
results in an increase in p-nitroanisole 0-demethylation 
activity which is not paralleled by any increases in total 
type P-450 cytochromes, cytochrome £5 or NADPH-cytochrome 
c reductase. We have concluded that fluroxene, methoxy-
flurane and enflurane may not be classified as inducers 
of hepatic drug metabolizing enzymes including enzymes 
responsible for conjugation with glucuronic acid of 
glutathione. 
viii 
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I. INTRODUCTION 
1. Review of hepatic metabolism of xenobiotics 
Pathways of metabolism of nutrient carbohydrate, fat and 
protein are well documented and a large number of enzymes 
responsible for these metabolic transformations have been 
isolated and studied. These enzymes generally catalyse a 
single type of reaction and are specific for one particular 
type of substrate. In addition to ingesting compounds 
which have a role in life processes, living organisms are 
also subjected to a wide range of chemical compounds which 
are foreign to their normal biochemical functioning. Most 
of these drugs, carcinogens, environmental pollutants, and 
other xenobiotics are now known to be biochemically trans-
formed by animals and man. The study of the processes 
involved has led to the growth over the past 20 to 30 years 
of such fields of research as biochemical pharmacology, 
molecular pharmacology, drug metabolism and disposition, 
and toxicology. 
Some xenobiotics re,semble sub.stances normally synthesized 
and catabolized in the body and thus are metabolized by 
specific enzymes which synthesize and catabolize substances 
such as catacholamines, indoles, nucleic acids, amino acids, 
steroids, and fats {!). Most xenobiotics,however,have no 
endogenous analogue and are metabolized by non-specific 
enzymes. 
In manunals, the liver is the major site of metabolism of 
I 
2 
xenobiotics by non-specific enzymes although some activity 
is also to be found in extrahepatic organs and tissues such 
as the kidney, intestines, lungs, adrenals, blood and skin. 
* The most common reactions of drug metabolism involve 
oxidation, reduction, hydrolysis or conjugation. A drug 
may be subjected to two or more competing pathways simul-
taneously; alternatively its metabolic transformations 
may occur sequentially (2). A summary of the biochemical 
transformations of drugs and the hepatic enyzmes respon-
sible is shown in Table 1, the information for which was 
drawn from the Handbook of Experimental Pharmacology (3). 
MiarosomaZ metabolism of drugs. Enzymes located in the 
endoplasmic reticulum of hepatic cells catalyse the 
majority of reactions of drug metabolism. On homogeniza-
tion of the liver, the endoplasmic reticulum is disrupted 
giving rise to small vesicles which may be separated from 
the homogenate by high-speed ultracentrifugation (4), gel-
filtration (5) or calcium precipitation (6); the resultant 
subcellular fraction is known as 'microsomes'. Many of 
the reactions undergone by drugs can be demonstrated in 
vitro with preparations of hepatic microsomes and suitable 
co-factors. 
The microsomal enzymes protect the organism against an 
accumulation of lipid-soluble exogenous compounds by 
* The term 'drug metabolism' is synonymous with 'metabolism 
of xenobiotics 1 ; the former term is in more general usage 
than the latter. 
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Table 1. Hepatic Metabolism of Drugs 
Reaction 
Oxidation of aliphatic 
and aromatic groups, 
N-oxidation, sulphoxida-
tion, oxidative dealkyl-
ation, epoxidation 
Reduction of azo-, 
nitro- compounds 
Oxidation and reduction 
of alcohols, aldehydes 
and ketones 
Oxidation of amines 
Hydrolysis of esters 
Conjugation with 
glucuronic acid 
Conjugation with 
glutathione 
Conjugation with 
sulphate, glycine, 
other amino acids; 
acetylation and 
methylation 
Hydration of 
epoxides 
Enzyme 
Cytochrome P-450 
Flavin enzymes 
or cytochrome 
P-450 
Alcohol dehydro-
genas e, aldehyde 
dehydrogenase 
e._g_. Monoamine 
oxidases 
Ester as es 
UDP-glucuronyl 
transferases 
Glutathione-S-
transferases 
Various trans-
ferases 
Major subcellular 
location of enzyme 
Endoplasmic 
reticulum 
Endoplasmic 
reticulum 
Soluble fraction 
Mitochondria 
Soluble fraction 
and various 
organelles 
Endoplasmic 
reticulum 
Soluble fraction 
Soluble fraction 
and various 
organelles 
Epoxide hydratase Endoplasmic 
reticulum 
' 
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converting them to more polar molecules which can be more 
readily excreted by the kidney. Some normal constituents 
of the body such as steroids, cholesterol, fatty acids, 
thyroxine and bilirubin are also substrates for these 
enzymes (7). The pathway by which most lipid-soluble 
compounds are rendered more water-soluble involves an oxi-
dative reaction catalysed by the cytochrome P-450 drug 
metabolizing system. The oxidized compound may then be 
excreted without further change or may undergo a conjugation 
reaction, usually with glucuronic acid, to yield an even 
more polar metabolite. The enzymes of both the cytochrome 
P-450 system and those responsible for glucuronidation are 
tightly bound in the lipid portion of the endoplasmic 
reticulum (8,9). 
Although oxidation mediated by the cytochrome P-450 enzyme 
system usually leads to detoxification or to inactive 
metabolites, there are a nu,'TI.ber of compounds which are con-
verted to toxic or more active metabolites; for instance, 
vinyl chloride monomer becomes carcinogenic only after 
metabolic activation by microsomal enzymes (10); carbon 
tetrachloride is believed to be metabolized to highly 
reactive free radicals cc1; and c1· (11); and the volatile 
anaesthetic agent, fluroxene is metabolized to the toxic 
compound, trifluoroethanol (12). in addition, during the 
metabolism of a compound by cytochrome P-450 a reactive 
metabolite may be formed such that destruction of cytochrome 
P-450 itself occurs (13,14,15). 
5 
In general, conjugation of drugs (or their oxidized products) 
with glucuronic acid or sulphate leads to pharmacologically 
inactive and highly polar compounds which are very readily 
excreted. There have been a few reports, however, of 
reactive metabolites formed during conjugation reactions; 
the_ glucuronide and sulphate conjugates of N-hydroxy-2-
acetylaminofluorene (16) and N-hydroxyphenacetin (17, 18) 
have been found to bind covalently to protein. 
Although the deleterious effects of a number of xenobiotics 
are now known to occur as a result of metabolism of these 
compounds by microsomal enzymes, the role of other enzymes 
e.s_._ glutathione-S-transferases and epoxide hydratase, in 
protecting the cell against the effects of toxic or reactive 
metabolites is beginning to be understood (19,20). 
The major enzyme systems of drug metabolism will be discussed 
at greater length in the following sections entitled: 
a. The cytochrome P-450 drug metabolizing system 
b. Conjugation with glucuronic acid 
c. Conjugation with glutathione. 
a. The Cytochrome P'-450 Drug Metabolizing System 
Since the first reports of reductive and oxidative metabolism 
of foreign compounds by hepatic microsomes (21,22), attention 
has been focused on the metabolism of drugs and other com-
·pounds by a group of non-specific enzymes in liver endoplas-
.mic reticulum. The remarkable versatility of these enzymes 
with respect to choice of substrate is shown by their . 
ability to catalyze such diverse reactions as those 
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illustrated in Figure 1 (2,23,24). Despite the diversity 
of these reactions they may all be regarded as proceeding 
via hydroxylation reactions. 
Figure 1. Reactions catalysed by the cytochrome P-450 
drug metabolizing system. 
Aromatic hydroxylation 
(OH] 
CH 3CO-NH-C6H5 ---? CH 3-CO-NH-C6H4-0H 
Aliphatic hydroxylation 
[OH] 
R-CH 3 > R-CH 2-0H 
N-Dealkylation 
[OH] 
R-NH-CH 3 [R-NH-CH20H] ·~ RNH 2 + CH 2o 
0-Dealkylation 
R-0-CH 3 
[OH) 
Deamination 
[R-O-CH 20H] 
(OH] 
R-CH(NH2 )-CH3 > (R-C(OH) (NH2 }-CH3) 
Sulphoxidation 
• [OH) + 
R-S-R' > (R-SOH-R '] ~--.;> R-SO-R' + H+ 
N-Oxidation 
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In addition, these enzymes may catalyse reductive reactions 
such as the reduction of azo- and nitro- compounds to 
primary aromatic amines and possibly the reductive cleavage 
of halogenated alkanes, such as carbon tetrachloride, to 
free radicals (25,26). 
Since the oxidative reactions (Figure 1) in the hepatic 
endoplasmic reticulum require both NADPH and oxygen, the 
enzyme system responsible is frequently called a 'mixed . 
function oxidase' according to the nomenclature of Mason 
( 24) . The enzyme system is also sometimes referred to as 
a 'monooxygenase' because the enzymes catalyse the consump-
tion of one molecule of oxygen per molecule of substrate, 
one oxygen atom appearing in the product and the other 
being incorporated into a water molecule (24). The overall 
reaction is generally accepted to be of the following form: 
SH + NADPH + H+ + o2 ~ SOH + NADP+ + H2o (1) 
where SH represents the lipophilic substrate and SOH its 
hydroxylated product. NADH may replace NADPH as electron 
donor but the rate of reaction is reduced by about 85% (27). 
The metabolism of a substrate by the hepatic microsomal 
mixed function oxidase system may be.monitored in an in 
vitro system comprising microsomes, substrate, NADPH and 
oxygen, by measuring NADPH oxidation, oxygen consumption, 
disappearance of substrate or formation of product (28). 
The theoretical stoichiometry for the microsomal mixed 
function oxidation reaction (equation 1) is a 1:1:1 
consumption of substrate, NADPH and oxygen. In order to 
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demonstrate stoichiometry between disappearance of substrate 
(or appearance of product) and NADPH oxidation in hepatic 
microsomes, however, correction must be made for endogenous 
NADPH oxidation not related to substrate hydroxylation. 
Stripp et al. (29) have described one such correction based 
on the effects of carbon monoxide on substrate hydroxyla-
tion and NADPH oxidation. 
Cytochrome P-450, a b type cytochrome, is now known to be 
the terminal oxidase for the electron transport system 
which is responsible for many of the diverse oxidative 
reactions by which xenobiotics may be metabolized (24). 
The cytochrome was so named because of the appearance of a 
difference spectral band at 450 nm when the reduced heme 
protein binds carbon monoxide (30). Cytochrome P-450 is 
no longer regarded as a single enzyme; evidence has accumu-
lated which suggests the existence of multiple forms of the 
heme protein in liver microsomes. (See Induction of enzymes 
of the cytochrome P-450 drug .metabolizing system below). 
'Cytochrome P-450' is then a collective term used for the 
. group of microsomal heme proteins which function as terminal 
oxidase in drug hydroxylations. 
Present also in hepatic microsomes is a flavoprotein called 
NADPH-cytochrome £ reductase (or NADPH-cytochrome P-450 
reductase) which serves as an electron carrier between NADPH 
and cytochrome P-450 (31). Both names for this enzyme are 
used in the literature, the choice of name being dependent 
usually on the heme protein acceptor present in the assay 
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for the enzyme. Several lines of evidence suggested that 
this enzyme was involved in the hydroxylation of drugs by 
hepatic microsomes (31); studies with antibodies to NADPH 
cytochrome £ reductase (32) and with purified components 
of the cytochrome P-450 drug metabolizing system (33,34) 
have established definitely the role of this enzyme in 
hepatic microsomal drug hydroxylation. 
The isolation of components of the hepatic microsomal drug 
hydroxylating system in pure or partially pure form has 
been of great importance to the understanding of this 
enzyme system. Cytochrome P-450, NADPH-cytochrome E 
reductase, and a lipid fraction have been isolated from 
hepatic 'microsomes by detergent solubilization and DEAE-
cellulose chromatography (35,36). All three components 
are required for the metabolism of fatty acids and drug 
substrates (33,34). The active constituent in the lipid 
fraction has been identified as phosphatidylcholine and has 
been shown to be essential for electron transfer from NADPH 
to cytochrome P-450 (37,38). 
In addition to the NADPH-dependent cytochrome P-450 mixed 
function oxidase system, hepatic microsomes also contain 
(amongst many other enzymes) an NADH-dependent electron 
transport system which functions in desaturation of fatty 
acids ( 31 , 3 9 ) • The components of this system consist of 
the flavoprotein NADH-cytochrome £5 reductase, cytochrome £5 , 
and a non-heme iron protein known as the cyanide-sensitive 
factor (40). It appears that the components of the NADH-
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and NADPH-dependent electron transport pathways interact 
with each other; both cytochrome P-450 and cytochrome £5 
can be reduced by either NADPH or NADH (31) (Figure 2). 
Figure 2. Cytochrome .P-450 and b 5 electron transport 
systems in hepatic microsomes (31). 
NADPH ~---> NADPH-cyt. c ---"") Cyt . P-450 
·reductase ~l 
NADH > NADH-cyt. £5 
reductase 
> Cyt. £5 ~ CN-sensitive ~ o2 
factor 
The role of NADH and cytochrome £5 in cytochrome P-450 
dependent drug hydroxylation reactions is still a matter 
of uncertainty. Although NADPH is the preferred source 
of reducing equivalents for cytochrome P-450 linked hydroxy-
lations, the use of both NADPH and NADH together as co-
factors in studies in vitro has long been known to produce 
greater than additive hydroxylation activity in many cases 
(27,39,4D- It was originally suggested by Hildebrandt and 
Estabrook (42) that cytochrome b 5 could provide the second 
electron for microsomal hydroxylation from either NADPH or 
NADH (see Figure 3). The involvement of cytochrome b 5 
in hydroxylation of substrates has been disputed in many 
cases however (39) and is clearly not required for hydroxy-
lation reactions mediated by reconstituted systems com-
prising purified cytochrome P-450, NADPH-cytochrome £ 
reductase and lipid (43). Nevertheless, in view of evidence 
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showing cytochrome £5 to be obligatory in certain reactions, 
it has been suggested that cytoch~ome b 5 involvement in 
NADH or NADPH supported microsomal hydroxylation is depen-
dent on the specific reaction studied and also on the 
particular species of cytochrome P-450 catalysing the 
reaction (39). 
A generalized scheme describing the mechanism of cytochrome 
P-450 mediated hydroxylation of an organic compound has been 
developed by Estabrook and co-workers (44) and extended by 
others ( 4 5, 4 6, 4 7) . The reaction sequence shown in Figure 
3 depicts the individual reaction steps which may be des-
cribed as follows: 
1. A substrate (SH) for microsomal mixed function oxidation 
interacts directly with the low spin form of ferricyto-
chrome P-450 to form a high-spin ferricytochrome P-450 
enzyme-substrate complex (see Binding of organic com-
pounds to cytochrome P-450 below). 
2. The enzyme-substrate complex was originally postulated 
to undergo a one electron reduction to a f errocyto-
chrome P-450 substrate complex (44,48). It has been 
suggested recently, however, that cytochrome P-450 is 
capable of accepting two electrons at a time, one by 
the heme iron atom and one by an acceptor which has not 
yet been identified (49,50). 
3. The ferrous enzyme-substrate complex reacts with molec-
ular oxygen to form an 6xyferrous enzyme-substrate 
complex (51,52). 
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Figure 3. Proposed mechanism for mixed function oxidation 
reactions catalysed by cytochrome P-450 
~H-j P-f 50 j3+] 
0 
SH 
jP-4501 3+~ 
SH-( P-4501 3+ 
2 ~NADPH 
SH-I P-4501 2+ 
3 
e 
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4. The oxyferrocytochrom~ P-450 - substrate complex 
undergoes a second stage of reduction, forming a super-
oxide ferrous enzyme-substrate intermediate which is 
a resonance form of the hydroperoxo ferric enzyme-
substrate complex (45·, 46). Whether this second elec-
tron is transferred from a separate electron carrier 
(e ·.9:.· cytochrome ;e,5 or NADPH-cytochrome p·-450 reductase) 
or from an unknown electron· carrier already within the 
complex is uncertain (46). 
5. It is proposed that the hydroperoxo ferric enzyme-
substrate complex decomposes readily by heterolytic 
scission of the 0-0 bond to produce water and a ferric 
enzyme-monooxygen species which is a resonance form of 
4+ -the ferryl ion complex (Fe O ). This highly electro-
philic species is presumed to be the actual hydroxy-
lating agent (45,47). 
6. The hydroxylated product is released from the site of 
binding on cytochrome P-450 and cytochrome P-450 in 
the low spin ferric state is regenerated. 
Binding of organic compounds to cytochrome P-450. It was 
first reported in 1966 that drugs and other foreign com-
pounds combine with oxidized hepatic microsomal cytochrome 
P-450 to produce characteristic difference spectra (53,54). 
These spectral changes have been interpreted as a ref lec-
tion of the binding of substrates or inhibitors to the 
oxidized form of cytochrome P-450 and are classified into 
three categories termed type I, type II and modified type II, 
I 
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based on the form of the spectral change resulting from 
interactions with different compounds (55). The modified 
type II change is also designated reverse type I (56). 
The three types of difference spectra are illustrated in 
Figure 4. The magnitude of the spectral change (the 
difference in absorbance between the peak and the trough) 
for all types of difference spectra is dependent on cyto-
chrome P-450 content and substrate concentration, as well 
as the substrate employed (55). 
The similarity observed for many substrates between the 
type I difference spectral dissociation constant (Ks) and 
the Michaelis constant (K ), obtained by determination of 
m 
rates of metabolism,. gave rise to the conclusion that the 
type I change was a spectral manifestation of the enzyme-
substrate complex. Because of the observation that com-
pounds with widely differing chemical structures and modes 
of metabolic reaction give rise to the same spectral change 
(i.~. type I), it has been suggested that all substrates 
eliciting a type I spectrum interact at the same site on 
cytochrome P-450 (57). The type I difference spectrum 
has been shown to arise from substrate-induced conforma-
tional changes in the protein which alter the heme environ-
ment rather than from direct interaction of substrate with 
the heme (58). Nebert et al. have postulated that binding 
of type I substrates by cytochrome P-450 leads to loss of 
the sixth ligand (OH moiety from adjacent amino acid resi-
due or group of similar ligand field strength) because of 
conformational changes in the protein (59). 
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Figure 4. Difference spectral changes in h~patic microsomes. 
Sample cuvette contains microsomes and compound, and reference 
cuvette microsomes alone. Spectral changes represented: 
type I (--); type II (----); and modified type II (-;-·-·). 
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Type II spectral changes result from interaction of compounds 
with the cytochrome P-450 heme iron, resulting in formation 
of a modified ferri-hemochrome in the low-spin state with the 
type II compound as the sixth ligand (54,55,59,60). All type 
II compounds can provide a free el~ctron pair, such as that 
from a heteroatom or a carbene, for liganding with the heme 
iron atom. These compounds ca.n replace carbon monoxide as 
the ligand to iron in the ferrocytochrome P-450 - CO complex 
(61,62,63). Al£hough the type II difference spectrum is a 
spectral manifestation of binding which does not lead to 
hydroxylation of the bound compound (Si), a number of substrates 
are able to elicit a type II difference spectrum (59,61). In 
this case the resultant type II spectrum may be readily re-
cognizable as such, ~.g. the binding of aniline (60), or it 
may be obscured to a varied extent by the type I spectrum of 
the compound, ~.g_. the binding of amphetamine (64). Ullrich 
recommends that the terms 'type I' and 'type II' be replaced 
by the more descriptive terms 'substrate-binding' and 'ligand-: 
binding' spectra respectively (62). 
The modified type II spectrum, elicited by both substrates 
and non-substrates of cytochrome P-450 was initially pos-. 
tulated to reflect displacement by these compounds of some 
previously bound substrate at the type I site of the 
enzyme (57). Other workers have concluded more recently, 
however, that this is not the case and that modified type 
II compounds bind as sixth ligand to the cytochrome P-450 
heme iron atom (59,61). As in the case of a type II 
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spectrum a modified type II spectrum can also occur 
simultaneously with a type I spectrum (57,61). 
Induction of enzymes of the cytochrome P-450 drug metaboli-
zing system. The concentrations of cytochrome P-450 and 
other components of the microsomal electron transport 
system in animals and man are affected by a number of fac-
tors. A wide variety of drugs, carcinogens and other 
xenobiotics (65,66) as well as environmental factors such 
as exposure to low temperatures (67) and gamma irradiation 
(68), are able to induce the synthesis of components of 
the microsomal mixed function oxidase system thereby in-
creasing rates of drug metabolism. 
The extent of the increase in the rate of drug metabolism 
after induction of cytochrome P-450 is dependent not only 
on the inducing agent but also on the substrate whose 
metabolism is monitored. Chemical inducing agents have 
therefore been grouped into two categories: (1} those 
that are able to stimulate the metabolism of a large variety 
of substrates ~·.9:· phenobarbital, and (2) those that stimu-
late the metabolism of only a limited number of compounds 
~-~· the polycyclic hydrocarbons, such as 3-methylcholan-
threne (31}. Administration of phenobarbital or 
3-methylcholanthrene to animals leads to elevated levels 
of hepatic microsomal cytochrome P-450; in addition 
phenobarbital but not 3-methylcholanthrene treatment re-
sults in proliferation of the endoplasmic reticulum and 
increased levels of NADPH-cytochrome c reductase (65,66). 
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There is considerable evidence demonstrating that the 
cytochrome P-450 induced by phenobarbital differs quali-
tatively from that induced by 3-methylcholanthrene, and 
that both differ from the predominant type P-450 cytochrome 
of uninduced animals (31). The cytochrome induced by 
3-methylcholanthrene has been named cytochrome P-448 
because its reduced CO-difference spectrum is located at 
448 nm, in contrast to the peak at 450 nm found for the 
type P-450 cytochrome(s) in liver Ihicrosomes from untreated 
or phenobarbital treated animals (69). Schenkman et al. 
{70) have described a cytochrome P-450 species induced by 
pregnenolone 16a-carbonitrile which differs from the cyto-
chromes P-450 and P-448 induced by phenobarbital and 
3-methylcholanthrene respectively. Their tentative desig-
* nation for this enzyme is cytochrome P-449 . 
The technique of isolation and purification of components 
of the cytochromes P-450 drug metabolizing system has been 
used effectively as a probe into the multiplicity of cyto-
chromes P-450 isolated from animals treated with different 
inducers (71,72). The spectral and catalytic properties 
of cytochromes P-45U purified from phenobarbital induced 
* From this point, the terms 'cytochrome P-450' and 'cyto-
chrome P-448' will be used to refer to the specific 
enzymes induced by phenobarbital and 3-methylcholanthrene 
respectively, and the terms 'cytochromes P-450' or 'type 
P-450 cytochrome{s)'will be used for the heterogeneous 
group of hemoproteins of that name. 
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rats and from 3-methylcholanthrene induced rats are quite 
different (71). From studies using antibodies raised 
against purified cytochrome P-448 (73), it is evident that 
cytochrome P-448 is immunochemically different from cyto-
chrome P-450 from phenobarbital-treated rats. Moreover, 
from the available evidence it appears that multiple forms 
of the type P-450 cytochromes exist in hepatic microsomes 
from either untreated, phenobarbital induced or 3-methyl-
cholanthrene induced animals and that each form poss~sses 
different or overlapping substrate specificities. Micro-
somes from untreated animals contain at least two types 
of cytochromes P-450 (74,75) and at least two also can 
be separated from hepatic microsomes of phenobarbital or 
3-methylcholanthrene induced rats (76) and four from 
hepatic microsomes of phenobarbital or 3-methylcholanthrene 
induced mice (71). 
b. Conjugation with glucuronic acid 
Conjugation with glucuronic acid'occurs in man and most 
mammalian species and is the most widespread and versatile 
of the conjugation reactions. Many compounds, with widely 
different molecular structures, can be metabolized by 
glucuronidation (77). In order for glucuronidation to 
occur, the glucuronic acid must be in the form of the high 
energy compound, uridine diphosphoglucuronic acid (UDP-
glucuronic acid). The microsomal enzyme UDP-glucuronyl 
transferase catalyses the reaction which may be represented 
as follows (78): 
COOH 
SCH+ UUGH 
OH H 
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COOH 
~~~~~ + UDP + H+ S~OH H 
H H HO OH 
OH H 
[2] 
where SOH represents a suitable substrate for the reaction. 
The activity of UDP-glucuronyl transferase in hepatic micro-
somes may be measured by monitoring the disappearance of 
aglycone or the appearance of the glucuronide conjugate 
following incubation of microsomes, aglycone and UDP-
glucuronic acid. 
There is considerable evidence which indicates that rather 
than being a single enzyme UDP-glucuronyl transferase is 
heterogeneous (77,79). The existence of multiple forms 
of this enzyme was originally postulated to explain the finding 
that several animal species lack glucuronidating activity 
towards particular substrates (80). Further evidence for 
the multiplicity of the enzyme has accumulated mainly from 
studies of the kinetics and activation of UDP-glucuronyl 
transferase in. vitro and from investigations into the develop-
transferase 
ment of UDP-glucuronyl;activities in the foetus and neonate 
( 77) • The isolation and purification of UDP-glucuronyl 
transferase(s} which could provide final evidence for the 
multiplicity of this enzyme has not yet been achieved. 
UDP-glucuronyl transferase activities in hepatic microsomal 
preparations can be activated in vitro with agents which 
tend to disrupt the organization of the microsomal membrane. 
\ 
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Treatment of microsomes with detergents (81,82), phospho-
lipases, trypsin (83), organic solvents (84) and mild 
alkali (85) have been shown to enhance considerably the 
activity of UDP-glucuronyl transferase relative to that 
observed in untreated microsomes. Some form of activa-
tion, usually that by detergent, is common practice in 
assays of UDP-glucuronyl transferase activities in vitro. 
UDP~glucuronyl transferase activity is enhanced by treat-
ment of animals with a number of agents which are known 
to induce the cytochromesP-450 oxidation system. This 
enhancement of qctivity is ascribed to induction of UDP-
glucuronyl transferase and is observed after treatment of 
animals with such compounds as phenobarbital, 3-methyl-
cholanthrene (77), a polychlorinated biphenyl (86), or a 
chlorinated dibenzodioxin (87). 
c. Conjugation with glutathione 
Conjugation of compounds with glutathione by glutathione-
S-transferases serves as a protective mechanism against 
the potential toxic effects of numerous reactive compounds 
( 88) • Glutathione-S-transferases located in the soluble 
fraction of liver and other organs appear to catalyse two 
main types of reaction with glutathione: (1) nucleophilic 
substitution, typified by the conjugation of glutathione 
with alkyl, aryl or aralkyl halides neutralizing their 
electrophilic sites, and (2) nucleophilic addition, typi-
fied by the conjugation of glutathione with epoxides or 
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as-unsaturated compounds (88). The conjugation of 
l-chloro-2,4-dinitrobenzene with glutathione provides an 
example of the first type of reaction (89): 
0 0 
II II 
C-glycine 
I 
+ HCCH2SH I 
HN-y:-glutamic 
C-glycine 
I~ HCCH2s '---._/N02 I N02 
[3] 
acid 
HN-y-glutamic acid 
Assay of glutathione-S-transferase activity in vitro may be 
undertaken using a wide variety of substrates; the disap-
pearance of substrate or formation of conjugate may be 
monitored in a system comprising soluble fraction isolated 
from liver, substrate and glutathione (90). The measure-
ment of hepatic glutathione depl~tion in vivo can provide 
a useful indication of the protective role of glutathione 
against potentially toxic foreign compounds (91). 
Glutathione conjugates are thought to be metabolized further 
by cleavage· of the glutamate and glycine residues, followed 
by acetylation of the resultant free amino group of the 
conjugated cysteinyl residue to yield finally a mercapturic 
acid which is then excreted in the urine (92). 
Six glutathione-S-transferases each with overlapping sub-
strate specificities have been identified in the soluble 
fraction of rat liver (90,93). One of the five enzyme 
species that have been obtained in homogeneous form has 
been shown to be identical to ligandin (93,94) an organic 
anion binding protein which also exhibits glutathione-S-
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transferase activity. Jakoby et al. (93) consider the 
glutathione-S-transferases to be a family of 'catalytic 
binding proteins' which also deactivate potentially toxic 
compounds by mechanisms other than conjugation with gluta-
thione. Additional protection from toxic compounds arises 
(1) from the binding by these enzymes of compounds ('ligands') 
which do not contain a sufficiently electrophilic centre to 
undergo a conjugation reaction and (2) from the covalent 
linkage to these enzymes of compounds which are reactive 
(and which may also function as substrates if bound non-
covalently) • 
Induction of hepatic glutathione-S-transferase activities 
by phenobarbital, 3-methylcholanthrene and 3,4-benzpyrene 
has been shown to occur in the rat (95,96,97). 
2. Metabolism of volatile anaesthetic agents 
Inhalation anaesthetics were considered as classic examples 
of pharmacologically active compounds that did not undergo 
metabolic transformation. Since 1964, however, investi-
gations into the metabolism of anaesthetics in man and 
animals have been performed demonstrating that these com-
pounds do in fact undergo biotransformations in the same 
manner as other xenobiotics. A number of reviews on the 
subject have been published (98-104). 
An investigation into the interaction of four volatile 
anaesthetic agents with drug metabolizing enzymes of the 
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liver is reported in this thesis. The compounds studied · 
are all halogenated ethyl ethers (Figure 5) and, except 
for 2,2,2-trifluoroethyl ethyl ether (TFEE), have been 
synthesized commercially and widely used as volatile anaes-
thetics. Fluroxene has recently been removed from the 
market but is still in clinical use to a limited extent. 
Investigations of the metabolism of. fluroxene, methoxy-
flurane and enflurane in vivo and in vitro have led to the 
identification of metabolites which indicate that these 
compounds generally undergo reactions involving ether 
cleavage (0-dealkylation) and dehalogenation (104). 
Figure 5. Structures of anaesthetic agents 
CHC1FCF20CHF2 
Fluroxene 
2,2,2-Trifluoroethyl ethyl ether 
(TFEE) 
Methoxyf lurane 
Enf lurane 
a. Metabolism of fluroxene and 2,2,2-trifluoroethyl ethyl ether 
During its use from 1953 as an anaesthetic, fluroxene acquired 
a reputation for safe clinical usage in man with no evidence 
of organ toxicity (105,106). Recent laboratory investigations 
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have shown however, that fluroxene anaesthesia of animals 
may result in liver damage or death under certain circum-
stances (107,108,109); in addition, reports of fluroxene 
toxicity in man have also appeared (110-113). 
The hepatotoxicity of fluroxene has been related to its 
metabolic transformation rather than to fluroxene itself. 
Factors k:r:iown to affect drug metabolizing enzymes affect 
the toxicity of fluroxene,~·~· induction of drug metabo-
lizing enzymes by phenobarbital potentiates the toxic 
effects of the anaesthetic while treatment of animals with 
agents that destroy drug metabolizing enzymes decrease the 
toxic effects (lri7,114,115,116). Blake et al. (12) 
identified trifluoroethanol glucuronide and trifluoroacetic 
acid as urinary metabolites of fluroxene in dogs and mice 
and subsequently postulated that the toxicity of fluroxene 
arises from its metabolic conversion to trifluoroethanol 
( 117) • Treatment of animals with trifluoroethanol itself 
results in toxic symptoms identical to those that develop 
. . 
after fluroxene anaesthesia (117). The possibility that 
the vinyl moiety of fluroxene is responsible for the toxic 
effects of the anaesthetic was dismissed as a result of 
investigations in our laboratory demonstrating that TFEE 
anaesthesia of rats is also lethal under certain conditions 
(116). The toxicity of both fluroxene and TFEE is there-
fore considered to arise from metabolism of the trif luoro-
ethyl moiety cominon to both agents. 
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A scheme for the postulated pathways of biotransformation 
of fluroxene and TFEE is shown in Figure 6 (102). 
Figure 6. Postulated pathways of metabolism of fluroxene 
and TFEE. 
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It has been postulated that cytochromes P-450 are responsible 
for the first step in the metabolism of the anaesthetic. 
The vinyl carbon atoms (c14 ) of fluroxene are recovered only 
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as C o2 in mice and dogs after fluroxene anaesthesia (12). 
Defluorination of fluroxene does not appear to occur (118) 
and this observation is in keeping with the generally 
a~cepted concept of the stability of the carbon-fluorine 
bond in the trifluoromethyl group (119). 
Possible pathways for metabolism of the primary metabolite 
trifluoroethanol include conjugation with glucuronic acid 
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catalysed by UDP-glucuronyl transferase and oxidation to 
trifluoroacetaldehyde (120). 
Investigations into the mechanism of fluroxene toxicity 
have led to the proposal that further metabolism of 
trifluoroethanol is required before toxic symptoms develop 
(117,120). Various compounds known to inhibit the oxida-
tion of alcohols have been shown to protect animals against 
the toxicity of fluroxene and trifluoroethanol (Table 2). 
Production of trifluoroacetaldehyde therefore has been 
suggested as the likely cause of the toxic effects arising 
after administration of fluroxene or trifluoroethanol to 
animals (125). As a result of studies with enzyme inhi-
bitors in vivo, alcohol dehydrogenase and catalase have 
been implicated in the metabolism of trifluoroethanol; 
the most important pathway from trif luoroethanol to tri-
fluoroacetaldehyde is postulated to be mediated by alcohol 
dehydrogenase (120). No conclusions regarding the activity 
of one particular enzyme in the metabolism of trif luoro-
ethanol can validly be drawn from these studies because 
the agents used have been shown to inhibit microsomal drug 
metabolizing enzymes in addition to the specific enzymes 
usually held to be inhibited (Table 2). 
The relative lack of toxicity of fluroxene in man compared 
to animal species has been ascribed to differences in the 
pathways of metabolism of the anaesthetic (125,131). The 
major metabolite in the urine of man after fluroxene 
anaesthesia is trifluoroacetate with free and conjugated 
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Table 2. Modification of the toxicity of f luroxene and 
2,2,2-trifluoroethanol by compounds postulated to alter 
metabolism of these agents 
Compound Modification of toxicitya Action of modifying 
. Fluroxene .TFE compound 
Allopurinol 
3-Arnino-1,2,4-
triazole 
Disulphiram 
Ethanol 
Isoniazid 
Phenobarbital 
Pyrazole 
+(120) 
+(120) 
+(125) 
+(120) 
+(117) 
t{l21) 
+ (117) 
+(117) 
+(117, 
121) 
+(121) 
xanthine oxidase in-\ 
hibitor (121); also 
inhibits hepatic mic-
rosomal drug metab-
olism? 
Catalase inhibitor; 
also inhibits 
hepatic microsomal 
drug metabolism(l22) 
Acetaldehyde oxidase 
inhibitor; also 
inhibits hepatic 
microsomal drug 
metabolism -c 12 3, 124) 
Competes with TFE 
for alcohol dehydro-
genase, catalase 
or MEOS? 
Carbonyl reggent 
binding TFA (121); 
also inhibits hepatic 
microsomal drug 
metabolism (126) 
+(127)- Increases hepatic 
drug metabolizing 
activity (65); also 
increases activities 
of aldehyde dehydro-
genase (128,129)&UDP-
glucuronyl transfer-
ase (77) 
+(121) Alcohol dehydrogen- j 
ase inhibitor; also 1 
inhibits hepatic ) 
microsomal drug i 
metabolism (130) I 
.__·_·~~~~~~--L~~~--~~~~~~~~~~L----~~~~~~~~--·~ 
a Symbols: toxicity increased, t; toxicity decreased, +. 
References quoted in brackets. 
b Abbreviation': trifluoroacetaldehyde, TFA. 
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trifluoroethanol occurring as minor metabolites (132); in 
animals, trifluoroethanol glucuronide is the major urinary 
metabolite (12). Results of investigations into the 
metabolism of f1uroxene in man have been included in Table 
3 for comparison with methoxyflurane and enflurane. 
b. Metabolism: of methoxyflurane and enflurane 
Soon after the introduction of methoxyf lurane as a volatile 
anaesthetic agent in 1960 (133), several reports linked the 
use of this drug to a renal syndrome known as 'high output 
renal failure' (134). It has now been established that 
this syndrome is due to high levels of inorganic fluoride 
that result from metabolism of methoxyflurane (135,136). 
Another renal toxin identified as a metabolite of methoxy-
f1urane in the sera and urine of man and.animals anaesthetized 
with this agent is oxalic acid (137,138). Methoxyflurane, 
still in clinical use, is expected to be withdrawn from the 
market shortly. 
Utilizing the basic methyl ethyl ether structure of methoxy-
fl urane, researchers investigated modifications of the 
molecule which would result in an effective anaesthetic 
agent but possessing fewer of the undesirabl~ properties 
of methoxyflurane. Enflurane has recently been introduced 
as an alternative anaesthetic agent to methoxyflurane (134, 
139) • Def luorination of enf lurane does occur in animals 
and man but peak serum inorganic fluoride levels in man 
are rarely above 50 µM/l (140,141,142) whilst those observed 
after methoxyflurane are usually greater than 100 µM/l (143). 
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A summary of results of investigations into the metabolism 
of methoxyflurane (144) and enflurane (145) in man is 
shown in Table 3 which includes for comparative purposes 
the results of similar studies with fluroxene (132). A 
considerable percentage of the anaesthetic agent remains 
unaccounted for particularly in the cases of methoxy-
fl urane and fluroxene (Table 3). It has been postulated 
that a portion of the unrecovered anaesthetic becomes 
permanently bound to the tissues (132,144,146) but further 
investigations are required in order to confirm this. 
Methoxyflurane is metabolized to a much greater extent 
than enflurane in man (Table 3) and in animals(l47,148,149). 
Confirmation of the greater susceptibility of methoxy-
flurane than of enflurane to metabolic transformation is 
obtained from the quantum chemical studies of Loew et al. 
(150); in these studies the feasibility of ether cleavage 
and dechlorination reactions in methoxyflurane, enflurane, 
and in their metabolites was considered on the basis of 
ease of insertion of active oxygen into C-H bonds. 
Pathways for the metabolism of methoxyflurane have been 
proposed (Figure 7) on the basi~ of metabolites identified 
in Vivo and in vitro (143,150). Parallel pathways have 
been proposed (Figure 8) for the metabolism of the struc-
turally similar enf lurane although much less is known 
about metabolites of this agent(l47,150);inorganic fluoride 
ion and uncharacterized organic fluoride compounds are the 
only metabolites of enflurane identified as yet (145). 
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Table 3. Recovery of anaesthetic agents and their 
metabolites in man. 
Methoxyfluranea Enflurane b Fluro:Xenec 
% dose absorbed 
Anaesthetic exhaled 19 83 58 
unaltered 
Non-volatile urinary 
metabolites: 
Total 43.8 2.4 10.6d 
Inorganic fluoridee 7.7 0.5 -
Organic fluoride 29.0 1.9 -
Oxalic acid 7.1 - -
Unrecovered 37 15 32 
anaesthetic 
a From reference 144; dose absorbed 18 'g. 
b From reference 145; dose absorbed 18 g. 
c From reference 132; dose absorbed 32 g. 
d Trifluoroacetic acid, 7.2%; free and conjugated trif luoro-
ethanol, 0.6%; and unidentified organic compounds, 2.6%. 
e Values should possibly be doubled in order to account for 
the free fluoride uptake from blood to bone '(154). 
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Figure 7. Postulated pathways for metabolism of methoxy-
flurane (143, 150) 
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Postulated pathways of metabolism of enflurane(l50) 
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The metabolism of both methoxyflurane and enflurane is 
thought to be initiated by cytochromes P-450 with either an 
0-dealkylation or a dehalogenation reaction (Figures 7 and 
8). Pathway I is believed to be favoured for methoxyflurane 
metabolism and pathway II for enflurane metabolism (150). 
The ether cleavage of either anaesthetic is postulated to 
result in an unstable 1,1-difluoroethyl alcohol which spon-
taneously decomposes to form a dihaloacetic acid with loss 
of 2 equivalents of inorganic fluoride. The compound 
dichloroacetic acid has in fact been identified as a metabolite 
of methoxyflurane (151). A dehalogenation reaction of the 
dihaloacetic acid possibly leads to the formation of oxalic 
acid. 
In pathway II, the initial dehalogenation reaction is proposed 
to result in formation of a methoxyhaloacetic acid. After 
methoxyflurane anaesthesia, methoxydif luoroacetic acid has 
been detected (151) but the corresponding metabolite for 
enflurane has not. Ether rileavage of the methoxyhaloacetic 
acid intermediates leading to the formation of oxalic acid 
is then postulated to occur. 
The finding of excessive amounts of urinary oxalic acid after 
methoxyflurane anaesthesia (143) is consistent with the 
proposed pathways for the metabolism of methoxyflurane. 
Oxalic acid has not been found in significant amounts, how-
ever, after enflurane anaesthesia (142) and Loew et al. 
have concluded _that it is unlikely that further metabolism 
of the products of the initial reactions postulated in the 
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pathways of Figure 8 occurs (150). 
Induction of hepatic drug metabolizing enzymes in animals 
by phenobarbital pre-treatment leads to an increased rate 
of whole-body uptake of methoxyflurane, increases its 
metabolism to fluoride and oxalic acid and potentiates the 
nephrotbxic effects of the anaesthetic (138,148,153,154,155). 
Phenobarbital pretreatment,however,does not increase the 
defluorination of enflurane by rats in vivo (148) although 
' it does increase fluoride deposition in.bones of mice (but 
not of rats) after enflurane anaesthesia (154). 
Metabolism of both methoxyflurane and enflurane has been 
demonstrated in vitro. The 0-dealkylation, dechlorination 
and defluorination reactions of methoxyf lurane have been 
shown to occur in rat hepatic microsomal preparations in 
the presence of NADPH (152,156,157); the defluorination of 
enflurane has been similarly demonstrated (157). 
3. The interaction of volatile anaesthetic agents with hepatic 
drug metabolizing enzymes 
The subject of this thesis was investigated in a three~fold 
manner: 
a. The interaction of volatile anaesthetic agents with the 
cytochromes P-450 drug metabolizing system in vitro. 
An investigation of the interactions of the volatile anaes-
thetic agents with the cytochromes P-450 drug metabolizing 
system in vitro was performed. The aim of this study was 
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to define such interactions and to discover the relation-
ships between them. In addition, it was hoped that greater 
understanding of the role of different cytochromes P-450 
in binding and metabolizing the anaesthetic agents would be 
reached, particularly with respect to those interactions 
which may result in effects deleterious to the animal. 
b. The interaction of 2,2,2-trifluoroethanol with hepatic 
enzymes 
The toxicity of fluroxene and TFEE is considered to arise as 
a consequence of the metabolism of these two agents to tri-
fluoroethanol and further biotransformation of this metabolite 
appears to be a prerequisite for development of toxic symp-
toms. Investigation of the metabolism of trifluoroethanol 
itself is therefore relevant to a study of the metabolic 
fates of fluroxene and TFEE particularly with respect to the 
toxicity of these two agents. Accordingly, the interaction 
of trifluoroethanol with enzymes postulated to be responsible 
for its metabolism was investigated in vitro. The enzymes 
with which this study was undertaken include microsomal 
cytochromes P-450, alcohol dehydrogenase, catalase and 
microsomal UDP-glucuronyl transferase. 
c. The effect of volatile anaesthetic a9"ents on hepatic drug 
metabolizing enzymes in Vivo 
The inducibility by xenobiotics of hepatic drug metabolizing 
enzymes, in particular the cytochromes P-450 system, UDP-
glucuronyl transferase and glutathione-S-transferases 
suggests the possibility that treatment of animals with 
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volatile anaesthetic agents may affect the concentrations 
and/or activities of these enzymes in vivo. Conflicting 
reports have appeared in the literature on the ability of 
volatile anaesthetic agents to induce the cytochromes P-450 
system (See Tables 36 & 37 ,DISCUSSION)~ We have therefore 
conducted an exhaustive study into the effects of methoxy-
flurane and enflurane on the cytochromes P-450 system and 
also on other hepatic drug metabolizing enzymes. The aim 
of the study was not only to assess the inducing (or 
activating) properties of the anaesthetic agents but also 
to discover whether any anaesthetic-mediated destruction 
or inhibition of hepatic drug metabolizing enzymes occurs 
in vivo. 
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II. EXPERIMENTAL PROCEDURE 
A. MATERIALS 
1. Pretreatment of animals 
Sodium phenobarbital (PB) and 3-methylcholanthrene (MC) 
were obtained from Maybaker, S.A. and Eastman-Kodak, res-
pectively. 3,4-benzpyrene (BP) was from Sigma Chemical 
Co., and 2-allyl-2-isopropylacetamide (AIA) was a generous 
gift of Hoffman-La Roche, Nutley, New Jersey. 
2. Anaesthetic agents 
Fluroxene (2,2,2-trifluoroethyl vinyl ether) was supplied 
by Ohio Medical Products, Madison, Wisconsin. 2,2,2-Tri-
fluoroethyl ethyl ether (TFEE) was prepared by hydrogenation 
of f luroxene at 30 lb/in2 hydrogen using 5 g activated 
palladium on carbon (Merck) catalyst per 250 ml fluroxene. 
Hydrogenation was continued until samples of reaction mix-
ture no longer exhibited the absorbance at 1600 cm- 1 charac-
teristic of carbon-carbon double bonds in the infrared 
spectrum. The TFEE was refluxed over sodium for at least 
24 hr and was subsequently purified by fractional distil-
lation. The fraction boiling between so.o0 and 50.4° was 
collected and stored in the dark under an atmosphere of 
nitrogen. The TFEE was found to be free of peroxides 
when tested with 5% aqueous KI (w/v) before use. Methoxy-
flurane (2,2-dichloro-1,1-difluoroethyl methyl ether) and 
enflurane (2-chloro-1,1,2-trifluoroethyl difluoromethyl 
ether) were obtained from Abbott Laboratories S.A. 
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3. Assays on rn:icro·somal suspensions 
NADH, NADPH, NADP , cytochrome E (horse heart, Type II), 
glucose-6-phosphate dehydrogenase, and enzymes for the 
coupled assay for glucuronidation were purchased from Miles 
Laboratories S.A.~ Glucose-6-phosphate was obtained from 
Koch-Light Laboratories and uridine 5'-diphosphoglucuronic 
acid (ammonium salt) was from Sigma Chemical Co. cy·linders 
of carbon monoxide, nitrogen and oxygen were purchased from 
Afrox Ltd., S.A. 
4 • · Inhibitors 
SKF 525A (2-diethylaminoethyl-2,2-diphenyl valerate) was a 
. generous gi~t from Smith Kline and French Laboratories, 
Isando, Transvaal, and metyrapone (2-methyl-l,2-b~s[3'­
pyridyl] l-propanone) was obtained from Ciba-Geigy Ltd. 
5_. Gas Liquid Chrorn:atography-
Di~~so-decylphthalate was supplied by Applied Science 
Laboratories Inc. and Chromosorb P (acid-washed) by Johns-
Manville, Denver, Colorado. 
6. Other assays 
2,2,2-Trifluoroethanol (TFE) from Merck was of the highest 
purity available. NAD , alcohol dehydrogenase (horse 
liver), catalase (beef liver) and xanthine oxidase (butter-
milk) were supplied by Miles Laboratories S.A. 
and glutathione were from Sigma Chemical Co. 
Xanthine 
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B. METHODS 
1. Treatment of animals 
Male Wistar rats weighing 160 - 220 g were used for all 
experiments. Animals were allowed free access to.Epel 
Laboratory Chow (protein min. 20%, fat 2.5%, fibre max. 6%, 
calcium 1.4%, phosphorus 0.7%) and water unless otherwise 
specified, and were bedded on shredded paper. The temp-
erature of the animal room was maintained at 22-24° and 
lighting was controlled to give 12 hr continuous light 
per day. 
Induction of drug metabolizing enzymes was by intraperi-
toneal injection of sodium phenobarbital (80 mg/kg/day 
in 0.9% sterile saline), 3-methylcholanthrene (40 mg/kg/day 
in corn oil) or 3,4-benzpyrene (40 mg/kg/day in corn oil) 
for three consecutive days. Animals treated with AIA in 
addition to the three day regimen of induction were 
injected subcutaneously in the loose skin of the neck with 
200 mg AIA/kg (20 mg/ml in 0.9% sterile saline) 1 hr prior 
to sacrifice. Animals were fasted overnight after the 
final injection as were also uninduced control rats.and 
sacrificed by cervical fracture the following morning. 
Animals were anaesthetized with methoxyflurane and enflurane 
for investigations of the effects ·of these agents on drug 
metabolizing enzymes in vivo. Anaesthesia was performed 
at sub-anaesthetic concentrations (0.1 MAC) for 6 hr on 
4, 8, 12 or 16 days and at anaesthetic concentrations 
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(1.0 MAC) for 3 hr on 1, 2, 3 or 4 days. 
The percentage concentrations (v/v) of methoxyflurane and 
enflurane used were as follows: methoxyflurane b.02% 
(0.1 MAC) and 0.2% (1.0 MAC); enflurane 0.2% (Q.l MAC) and 
2 • 0 % ( 1. 0 MAC) . The animals were anaesthetized in groups 
of twelve or less in a perspex anaesthetic chamber 
(30 x 30 x 60 cm). Animals were placed on a fenestrated 
floor raised 8 cm from the base of the chamber, the space 
below the floor being filled with standard anaesthetic 
sodalime. The anaesthetic, vapourised by a 5 l/min stream 
of oxygen through a Cyprane temperature flow compensated 
Pentec or Enfluratek vapouriser, was passed as a continuous 
stream into the anaesthetic chamber through an inlet port 
sited at one corner beneath the fenestrated floor and ex-
hausted through a port sited at the diagonally opposite 
upper corner. Concentrations of anaesthetic agents in 
gas samples taken from the exhaust port of the anaesthetic 
chamber were determined by gas-liquid chromatography on a 
Pye Unicam GCV chromatograph with a 10% di-iso-decyl-
phthalate on chromosorb P column. The column temperature 
0 0 
was 60 and 40 for methoxyflurane and enflurane determina-
tions respectively. Unanaesthetized control animals were 
exposed to oxygen alone. Animals were fasted overnight 
after the final anaesthesia and sacrificed the following 
morning. 
2. Preparation of microsomes 
Livers were excised from animals immediately after death 
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d 11 b t d Were Performed at 40. an a su sequen proce ures For 
investigations of effects of anaesthetic agents on drug 
metabolizing enzymes in vivo and production of fluoride 
from methoxyflurane and enflurane, microsomes were prepared 
by differential high speed centrifugation (4). Livers 
were homogenised in 3.0 vols 0.15 M KCl - 0.02 M Tris/HCl, 
pH 7.4. Cell debris, nuclei and mitochondria were spun 
down at 9000 g for 15 min in a Beckman J-21B centrifuge. 
The post-mitochondrial supernatant was spun at 105,000 g 
for 1 hr in a Beckman Model L ultracentrifuge. The 
resultant microsomal pellet was washed by resuspension in 
0.15 M KCl - 0.02 M Tris~HCl, pH 7.4 and further centri-
fugation at 105,000 g for 45 min. The final microsomal 
pellet was resuspended to the required protein concentra-
tion in 0.02 M Tris-HCl, pH 7.4. In one experiment in 
which kidney microsomes were required their preparation 
was performed as described above. 
Microsomes for use in all other studies were prepared by 
gel filtration according to the method of Tangen et al. 
(5). Livers were homogenized in 2.5 vols 0.25 M sucrose 
and the homogenate centrifuged at 9000 g for 15 min. The 
supernatant was layered on a Sepharose 2B column (20 cm x 7 cm) 
and microsomes eluted with 0.15 M KCl - 0.02 M Tris-HCl, 
pH 7.4, and diluted to the required protein concentration 
with 0.02 M Tris-HCl, pH 7.4. It should be noted that no 
significant differences in levels or activities of the drug 
metabolizing enzymes exist between microsomal suspensions 
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prepared by high speed centrifugation and those prepared 
by gel filtration (5). 
3. Assays performed on microsomal pre;earations 
All spectrophotometry was performed in Unicam SP1800 record-
ing spectrophotometers unless otherwise stated.. For re-
cording spectra of turbid suspensions the cell holder 
adjacent to the photomultiplier was used with cuvettes 
positioned so that the light path was through their frosted 
faces. Unless otherwise specified the buffer used in the 
assays was 0.02 M Tris-HCl, pH 7.4. 
a. Protein 
Microsomal protein concentration was determined by the 
method of Lowry et al. (158) as modified by Chaykin (159) 
using bovine serum albumin as standard. Final absorbances 
were measured at 600 nm in a Gilford spectrophotometer. 
b. Difference spectra 
Suspensions of hepatic microsomes at 2.0 mg protein/ml 
were divided equally between two 1 cm path length cuvettes. 
The anaesthetic agent or trif luoroethanol was introduced 
below the surface of the microsomal suspension in the 
sample cuvette by means of a Hamilton. syringe. The cuvette 
was then stoppered and vortex mixed for 5, 15 or 30 sec 
in order to disperse and solubilize the added trif luoro-
ethanol, methoxyflurane and enflurane, or fluroxene and 
TFEE respectively. The magnitude of the resultant dif-
ference spectrum was measured as the difference in absorb-
ance between the peak at about 390 nm and the trough at 
44 
about 420 nm and was corrected for the absorbance differ-
ences in the baseline at these wavelengths. In all cases 
maximum extents of difference spectra are reported as 
absorbance per 2.0 mg microsomal protein. Vortex mixing 
of the microsomal suspension without added anaesthetic 
agent did not produce a difference spectrum. In any one 
determination of the dissociation constant, K , sequential 
s 
additions of anaesthetic agent or trifluoroethanol were 
made to the same sample cuvette. All difference spectra 
were recorded at room temperature. 
c. NADPH oxidation 
The rates of hepatic microsomal NADPH oxidation were deter-
mined in th~ presence of anaesthetic agent or trifluoro-
ethanol. Equal quantities of microsomal suspension 
(2.0 mg protein/ml) were divided between two 1 cm path 
length cuvettes. Varying quantities of anaesthetic agent 
or trif luoroethanol were introduced into the sample cuvette 
as described for difference spectra determinations except 
when concentrations lower than 0.1 mM methoxyflurane or 
enf lurane were required in which case the anaesthetic agent 
was added to 12 - 24 ml microsomal suspension and 3.0 ml 
of the mixture taken for assay. The reaction mixtures 
were equilibrated at 27° when monitoring fluroxene, TFEE 
. and trifluoroethanol metabolism, and at 30° when monitoring 
methoxyflurane and enflurane metabolism. The reaction 
was initiated by addition of 50 - 100 µl NADPH solution to 
give a final NADPH concentration of 0.12 - 0.24 mM. NADPH 
oxidation was monitored spectrally at 340 nm using a 
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thermostatted cell compartment adjacent to the photo-
multiplier of the spectrophotometer. The extinction co-
-1 -1 
efficient for NADPH at 340 nm is 6.2 mM cm . Correc-
tion was made for non-cytochrome P-450 NADPH oxidation by 
the method of Stripp et al. (29) in which the background 
rate of NADPH oxidation is determined in the presence of 
anaesthetic agent or trifluoroethanol in an atmosphere of 
carbon monoxide-oxygen (80:20; v/v). In these experiments, 
carbon monoxide and oxygen flow was controlled by Matheson 
Gas Products model 7600 flowmeters and the mixture of gases 
was allowed to bubble through the microsomal suspension 
for 30 sec at 20 ml/min prior to addition of substrate 
and cofactor. 
d. Incubation system for production of 2,2 1 2-trifluoroethanol 
br fluoride from anaesthetic aqents 
The reaction mixture for the production of trif luoroethanol 
from fluroxene or TFEE and the production of fluoride from 
methoxyf lurane or enflurane comprised microsomal suspension 
(2.0 mg protein/ml),NADPH generating system (0.4 mM NADP, 
7.5 mM glucose-6-phosphate, 0.5 U/ml glucose-6-phosphate 
dehydrogenase, 5 mM MgC1 2 , l mM nicotinamide and 0.2 mM 
EDTA) and varying amounts of anaesthetic agent all in 
0.02 M Tris-HCl, pH 7.4. The airspace above the incubation 
mixture constituted about 15% - 20% of the total volume 
(4.0 ml) of the glass reaction vial, which was stoppered 
with a serum cap. The reaction was initiated by addition 
of the anaesthetic agent and NADPH generating system, and 
mixed by vortex for 30 sec. The vials were clamped in a 
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horizontal position and incubated with shaking (100 cycles/ 
min) at 30° in a Gallenkamp thermostatted water bath for a 
period of time (Table 4) during which the reaction was 
approximately linear. Two glass beads (diameter 5 mm) 
were included in the vial when production of trif luoro-
ethanol was studied. In experiments under conditions of 
no shaking, vials were allowed to stand upright in the 
water bath. In one experiment, the microsomal incubation 
mixture was rendered anaerobic by inclusion of electron 
transport particles prepared from beef heart by Method 2 
' 
of Crane et al. (160), as described elsewhere (161). 
Table 4. Duration of incubation of microsomal reaction 
mixtures in investigations of production of trif luoro-
ethanol or fluoride from anaesthetic agents. 
Anaesthetic Pretreatment of animal Duration of 
agent source of microsomes incubation 
(min) 
Fluroxene None 10 
All types induction 
TFEE None 10 
All types induction 
Methoxyf lurane None 15 
PB induction 
MC induction 20 
Enflurane PB induction 20 
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e. Production of 2,2,2-trifluoroethanol 
A Beckman GC-M chromatograph with a flame ionization detector 
connected to a Pye-Unicam DP 88 computing integrator was used 
for quantitative analysis of trifluoroethano~. The column 
used consisted of 3 m x 6 mm copper packed with 10% di-iso-
decylphthalate on Chromosorb P (acid-washed)· (132). Column 
0 temperature was 70 and injection port and detector compart-
0 
ment were at 200 . The carrier gas was nitrogen. Tri-
f luoroethanol standards in water gave a linear response on 
the integrator over a range of concentration including and 
well above those produced in the microsomal system (Figure 9). 
A 5 µl sample of standard or of the microsomal mixture was 
injected without further treatment onto the column. 
f. Production of fluoride 
Fluoride activities in millivolts were measured with an 
Orion solid state fluoride electrode (model 96-09) in 
combination with a single junction reference electrode 
(Orion 90-01-00) and connected to a Radiometer pH meter. 
After incubation of methoxyflurane and enflurane with 
microsomes and NADPH generating system as described in 
Section IIB.3.d., the reaction was terminated by addition 
of 0.1 ml 3M sodium acetate buffer, pH 4.9, to 3.0 ml 
microsomal mixture. The mixture was allowed to equilibrate 
to room temperature and the free fluoride concentration 
determined. Known concentrations of sodium fluoride in 
0.1 M sodium acetate buffer pH 4.9 were used to establish 
a standard curve each day; fluoride solutions in microsomes 
in 0.1 M sodium acetate, pH 4.9 gave identical mV readings 
60 
40 
Area of peak 
- ~ 
(arbitrary . ~ co 
units) 
20 
-i 
2.0 4.0 6.0 
[TFE] (xl0- 3 M) 
Figure 9. Effect of concentration of 2,2,2-trifluoroethanol on area of the peak obtained 
after gas-liquid chromatography of 2,2,2-trifluoroethanol solutions in water. 
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to those of fluoride in buffer alone; In order to deter-
mine acid-labile fluoride formed during incubation, the 
microsomal mixture was brought to pH 1.5 with 10 µl cone. 
H2so4 after measurement of free fluoride activity and 
allowed to incubate at room temperature for 85 hours, or 
as indicated. The mixture was returned to pH 5.0 with 
55 - 60 µl 6.0 M NaOH and the fluoride activity was 
measured. Solutions of fluoride in 0.1 M sodium acetate 
buffer, pH 4.9 to which 10 µl cone. H2so4 and 55 - 60 µl 
6.0 M NaOH were added were used as standards to determine 
fluoride concentrations after acid treatment. 
In reports herein of production o~ fluoride from methoxy-
flurane and enflurane, 'free fluoride' refers to the free 
fluoride ion released during incubation of anaesthetic 
agents with microsomes and NADPH generating system; 'total 
fluoride' refers to the fluoride ion measureable after acid 
treatment of the reaction mixture, and 'acid-labile fluoride' 
refers to the difference between the total and free fluoride 
ion concentrations~ 
g. Cytochromes P-450 
Microsomal cytochromes P-450 content was determined by the 
carbon monoxide difference spectral method of Omura and 
Sato (162). Microsomal protein was always 2.0 mg/ml. 
Carbon monoxide was bubbled at 10-ml/min for 30 sec. Fresh 
sodium dithionite was used to reduce the contents of reference 
and sample cuvettes and the extinction co-efficient used for 
the difference between the absorbances at 450 nm and 49U nm 
50 
-1 -1 (~A450_ 490 ) was 91 mM cm . It should be noted that total 
type P-450 cytochromes are measured by this method, and that 
these values include the contributions of both cytochromes 
P-450 and P-448 to the total. 
h. Cytochrome ~-5 
Microsomal cytochrome b 5 was determined by the NADH differ-
ence spectral method of Omura and Sato (162). Microsomal 
protein was always 2.0 mg/ml and the concentration of NADH 
was 0.2 mM. The extinction co-efficient used was 
185 mM- 1cm- 1 for the difference in absorbance between 409 nm 
and 424 nm. 
i. NADPH-cytochrome c reductase 
Microsomal NADPH-cytochrome c reductase was determined with 
microsomal protein at 0.08 mg/ml as described by Omura and 
Takesue (163}. 1 unit of enzyme is that which reduces 
1 µmol cytochrome £ /min. The extinction co-efficient 
difference between reduced and oxidized cytochrome £ is 
-1 -1 21.1 mM cm • 
j. E-Nitroanisole 0-demethylation 
Mi·crosomal 0-demethylation of E.-nitroanisole was determined 
by the method of Netter (164). Microsomal protein was 
1.3 mg/ml, E-nitroanisole at 0.7 mM unless otherwise indicated, 
and the concentrations of components of NADPH generating 
system were as described in Section IIB.3.d. The reaction 
was monitored at 420 nm in cuvettes at 25 - 21° for 3 - 4 
min and initial reaction rates calculated. The extinction 
co-efficient for E-nitrophenol at 420 nm, pH 7.4, is 7.3 
mM- 1cm-l (165). 
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k. 3,4-Benzpyrene hydro~ylation 
Hydroxylation of 3,4-benzpyrene to. 3-hydroxybenzpyrene 
was determined spectrophotometrically by the method of 
Prough et al. (166). 3,4-Benzpyrene (80 µM) and NADH 
(200 µM) were present in·both sample and reference cuvettes 
containing microsomal suspension at 2.0 mg protein/ml. 
. , 
The reaction was initiated by addition of NADPH (100 µM 
final concentration) and the increase in absorbance at 
428 nm relative to 454 nm was determined at 25 - 27°. 
The extinction co-efficient of 3-hydroxybenzpyrene at 
-1 -1 428 nm is 13.2 mM cm (166). 
1. Glucose-6-phosphatase 
The activity of glucose-6-phosphatase was determined by 
measuring the µmol inorganic phosphate (Pi) released/ 
min/mg microsomal protein during incubation of glucose-6- ·1 
phosphate (20 mM) with microsomes (1.3 mg protein/ml)(l67). 
The reaction was allowed to proceed for 20 min at 30° and 
was terminated by addition of 10% (w/v) trichloroacetic 
acid (TCA). Control samples containing microsomal sus~ 
pension and glucose-6-phosphate as above were treated with 
TCA before the start of incubation. The mixture was then 
centrifuged at 1800 g in an MSE mistral 6L centrifuge for 
5 min and the supernatant assayed for phosphorus by the 
method of King (168). Blanks and standards for the 
phosphorus assay were water and potassium dihydrogen phos-
phate respectively. The absorbance at 660 run was read in 
a Gilford spectrophotometer. 
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m. Glucuronidation of trifluoroethanol 
Monitoring concentration of free trifluoroethanoZ. Concen-
trations of free trifluoroethanol were monitored by gas-
liquid chromatography (see Section . IIB.3.e.) before and after 
incubation of microsomes with UDP-glucuronic acid and trifluoro-
ethanol. The reaction mixture comprised microsomal suspension 
(0.8 - 0.9 mg protein/ml) 1.5 mM UDP-glucuronic acid, 1 mM 
saccharo-1 1 4-lactone (inhibitor of 8-glucuronidase), and 5 mM 
MgC1 2 , in a total volume of 1.0 ml 0.075 M Tris-HCl, pH 7.3. 
Reaction blanks · contained all components except UDP-glucuronic 
acid. The reaction mi~ture, in glass vials stoppered with 
serum caps, was equilibrated at 37° and the reaction initiated 
by addition of microsomal suspension. The vials were incub-
ated with shaking (80 - 100 cycles/min) in a Gallenkamp 
water bath at 37°. In some experiments inhibitors of pyro-
phosphatase, 0.4 mM sodium pyrophosphate or 1.5 mM ATP, were 
included in the reaction mixture to prevent decreased con-
centrations of UDP-glucuronic acid (169). Activation of 
UDP-glucuronyl transferase was attempted by inclusion in 
the incubation mixture of 0.04% Triton X-100 (81), by pre-
incubation of microsomal suspensions at 37° for varied 
lengths of time (82), or by storage of microsomal pellets 
at -15° (81) for 12 days. In addition animals were pre-
treated with phenobarbital or 3-methylcholanthrene, both 
compounds having been shown to increase the activities of UDP·-
glucuronyl transferase towards certain aglycones (77). 
Coupled assay for UDP-glucuronyZ transferase activity. Attempts 
to determine glucuronidation of trifluoroethanol were made by 
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means of the assay of Mulder and van Doorn (170) based on 
measurement of UDP production from UDP-glucuronic acid 
during the glucuronidation reaction; UDP production is 
coupled to the conversion of NADH into NAD .· through pyruvat.e 
kinase and lactate dehydrogenase. The reaction mixture 
contained 0.16 mg microsomal protein/ml and 0.04% Triton 
X-100 in addition to the other components described by' 
Mulder and van Doorn (170). The reaction was allowed to 
proceed in 1 cm cuvettes at 30° and the absorbance at 340 nm 
monitored continuously for 5 min against a reference cuvette 
.. 
containing only microsomal suspension. Blanks in which 
either UDP-glucuronic acid or substrate was omitted resulted 
in a slow decrease in absorbance at 340 nm of about 0.002 
and 0.005 O.D. units/min, respectively. 
n. Glucuronidation of E-nitrophenol 
The glucuronidation of E-nitrophenol was measured essentially 
as by Lueders and Kuff (81). The reaction mixture comprised 
microsomal suspension at 0.8 mg protein/ml, 0.4 mM E-nitro-
phenol, 1.5 mM UDP-glucuronic acid and 5 mM MgC1 2 in a total 
volume of 1.0 ml 0.075 M Tris-HCl, pH 7.3. Reaction blanks 
Acti-contained all components except UDP-glucuronic acid. 
vation of UDP-glucuronyl transf erase was achieved by in-
clusion· of 0.04% Triton X-100 in the incubation mixture; 
this was considered necessary in view of the finding 
that induction of UDP-glucuronyl transferase can be better 
observed in vitro under conditions of activation of micro-
somes (171). The reaction was initiated by addition of 
microsomal suspension and reaction vials were shaken 
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(80 - 100 cycles/min') for 10 min at 30° in a Gallenkamp 
water bath. The reaction was terminated by addition of 
2.0 ml 96% ethanol, and the mixture was then spun at 
1800 g in an MSE Mistral 6L centrifuge. An aliquot of 
supernatant was added to 0.1 M NaOH and the absorbance 
I 
at 400 nm read in a Gilford spectrophotometer. The ex-
tinction co-efficient for E-nitrophenol at alkaline pH 
-1 -1 is 20.8 mM cm (81). The ra.te of disappearance of 
E-nitrophenol was calculated and taken as the rate of 
glucuronidation (172). 
o. Destruction of cytochromes P-450 
The incubation mixture for determination of the destruction 
of microsomal cytochromes P-450 by anaesthetic agents was 
the same as described in Section IIB.3.d. The concen-
tration of cytochromes P-450 was determined as described 
in Section IIB.3.g. after incubation at 30° of microsomal 
suspension with anaesthetic agent and NADPH generating 
system against a reference cuvette containing microsomes 
similarly incubated but in the absence of anaesthetic 
agent and NADPH generating system. Cytochromes P-450 
concentrations determined at zero incubation time in the 
presence of anaesthetic agent only were taken as control 
cytochromes P-450 levels. The addition of NADPH genera-
ting system to these control samples did not affect the 
~A450_ 490 at zero time. 
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4. Other assays 
a. Alcohol dehydrogenase 
Horse liver alcohol dehydrogenase oxidation of ethanol and 
trifluoroethanol was determined by monitoring the formation 
of NADH as described by Blake et al. (117). The soluble 
fraction from rat liver (post-microsomal supernatant) was 
assayed for the ability to oxidize ethanol and trifluoro-
ethanol in a similar manner except that the concentrations 
of NAD and alcohol were 5 mM and about 0.5 M respectively. 
b. Catalase 
The decomposition of hydrogen peroxide by catalase was assayed 
spectrophotometrically at 240 nm by a modification of the 
method of Bergmeyer ( 173). The reaction mixture comprised 
2.0 - 4.0 U catalase and 12 - 24 mM hydrogen peroxide in 
0.05 M sodium phosphate buffer pH 8.0. The extinction co-
-1 -1 
efficient for hydrogen peroxide at 240 nm is 0.043 mM cm . 
c. Xanthine oxidase 
The oxidation of xanthine to uric acid by xanthine oxidase 
was assayed spectrophotometrically by a modification of the 
method of Kalckar (174). The reaction mixture comprised 
0.05 mM xanthine and 0.005 U/:rp.l xanth.ine oxidase in 0.05 M 
sodium phosphate buffer pH 8.0. The increase in absorbance 
at 290 nm was monitored, the extinction co-efficient for 
-1 -1 
uric acid at this wavelength being 12.3 mM cm • 
d. Peroxidation of alcohols by catalase 
The incubation mixture for peroxidatic oxidation of trifluoro-
ethanol and other alcohols comprised 0.005 U/ml xanthine 
oxidase, 0.05 mM xanthine, 100 U catalase and alcohol at 
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concentrations as indicated, in 0.05 M phosphate 
buffer, pH 8.0. In some experiments, catalase or catalase 
plus alcohol were omitted. The reaction mixture was 
allowed to equili1¥~ at 30° and the reaction was initiated 
by addition of xanthine oxidase. Rates of oxygen uptake 
were monitored by a Clark type oxygen electrode. 
e. Glutathione-S-transferase 
Glutathione-S-transferase activity in the soluble fraction 
(post-microsomal supernatant) of rat liver was assayed 
spectrophotometrically using l-chloro-2,4-dinitrobenzene 
as substrate according to the method of Habig et al. (90). 
The reaction mixture comprised soluble fraction (0.06 -
0.09 mg protein/ml), 1.33 mM l-chloro-2,4-dinitrobenzene, 
2.5 mM glutathione in 0.1 M potassium phosphate buffer, 
pH 6.5. The reaction was allowed to proceed at 25° in 
cuvettes, and the increase in absorbance at 340 nm was 
monitored continuously for 3 - 4 min. The extinction co-
efficient for conjugated product at 340 nm is 9.6 mM- 1cm-l 
(9 0) • 
f. Glutathione 
Glutathione levels in samples of rat liver were assayed 
fluorometrically by the method of Cohn and Lyle (175). 
Glutathione was ~xtracted from the liver sample by homo-
genization of the tissue with 30 µM EDTA following which 
protein was removed by metaphosphoric acid and subsequent 
centrifugation. The resultant solution of glutathione 
was reacted with 0-phthalaldehyde at pH 8.3_yielding a 
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h.ighly fluorescent product. Standard solutions of gluta-
thione and blanks of water were similarly treated with 
O-phthalaldehyde. The fluorescence at 420 nm resulting 
from activation at 365 nm was measured in a Perkin-Elmer 
Fluorescence Spectrophotometer 203. 
s. Calculations 
Spectral dissociation constants (K ), maximum extents of 
s 
binding (AAmax)' Michaelis-Menten constants (Km) and 
maximum reaction rates (V ), were usually obtained from 
max 
Hanes plots of paired [s] and AA~ or [s] and v, values. 
[s] represents the concentration of anaesthetic agent or 
trifluoroethanol; AA represents the difference in absorb-
ance between peak and trough observed in difference spectral 
studies; and v represents the initial rate of the reaction 
under investigation. 
In all cases the data was also plotted by means of Eadie-
Hofstee plots which are more sensitive to deviations from 
linearity in cases where simple Michaelis-Menten kinetics 
are not obeyed (176). In addition, use was made of Line-
weaver-Burk or Dixon plots (177) to illustrate inhibition 
of certain reactions by trifluoroethanol. 
A computer programme was utilized which allowed calculation, 
on the basis of ~inear regression analysis,of kinetic con-
stants from the data by any of the linear transformations 
of the Michaelis-Menten equation. 
Student's t-test was utilized to determine statistical sig-
nificance (See ABBREVIATIONS, page viii). 
~---·- -- ·--~ 
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6. Structure of experimental approach to investigations of 
the interactions of volatile anae~thetic agents with the 
cytochromes P-450 drug metabolizing system in vitro 
For these studies, animals were induced for elevated levels 
of different cytochromes P-450 by pretreatment with 3,4-
benzpyrene, 3-methylcholanthrene, 3:-methylcholanthrene with 
2-allyl-2-isopropylacetamide (MC/AIA), or phenobarbital. 
Investigations using hepatic microsomes isolated from 
uninduced and induced animals followed the scheme outlined 
in Table 5. 
Table 5. Scheme for investigation of interactions of anaesthetic agents with the cytochromes 
P-450 drug metabolizing system in vitro 
Investigation Anaesthetic agent and induction 
Fluroxene TFEE Methoxyf lurane Enf lurane 
MC/ MC/ 
PB I ~ None BP MC AIA PB None BP MC AIA PB None MC None MC 
• 
Difference spectra ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ ./ 
NADPH oxidation ./ ./ ./ - ./ ./ ./ ./ - ./ ./ ./ ./ ./ ./ 
TFE production ./ ./ ./a - ./ ./a ./ ./ ./ ./ ./a - - - - -
-
./a ./a ./a ./a ./a F production - - - - - - - - - -
Cyts. P-450 ./ - ./ - ./ - - - - ./ - - ./ - -
destruction 
' a In addition, the effects of inhibitors of cytochromes P-450 were studied. 
PB 
./ 
./ 
-
./a 
./ 
U1 
\.0 
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III. RESULTS 
A. THE INTERACTION OF VOLATILE ANAESTHETIC AGENTS WITH THE 
CYTOCHROMES P-450 DRUG METABOLIZING SYSTEM IN VITRO 
1. Binding of anaesthetic agents to cytochromes P-450 
Fluroxene, TFEE, methoxyflurane and enflurane bind to cyto-
chromes P-450 of hepatic microsomes isolated from uninduced 
and induced rats resulting in the appearance of a type I 
difference spectrum (g.g. Figure 10). The extent of 
. binding of each of the anaesthetic agents increases with 
increasing.anaesthetic concentration until saturating con-
centrations are reached (~·~· Figure 11). Hanes plots of 
the data from difference spectral studies are linear for 
each 6f the anaesthetic agents for all types of induct~on 
. . 
and allow calculation of spectral dissociation constants, 
K . (55) and maximum extents of binding, b.A (e.a. Figure s max - ;/.. · 
12) • 
The effects of inducers of cytochromes P-450 on the Ks and 
b.A values for the four anaesthetic agents are presented 
max 
in Tables 6, . 7, 8 and 9 • In these tables, averages and 
mean deviations for determinations of K and b.A in three 
s max 
separate microsomal preparations are reported. Induction 
of either cytochrome P-448 with polycyclic hydrocarbons or 
-- --- ------·---~~-
of cytochrome P-450 with phenobarbital does not generally 
affect the K values for the binding of the anaesthetic agents 
s 
to microsomai cytochromes P-450 relative to the respective K 
s 
. . 
values obtained in uninduced rnicrosomes (Tables 6-9). The 
value of Ks i~ changed only for rnethoxyf lurane after pheno-
·barbi tai· induction. 
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The maximum extent of binding of each of the anaesthetic 
agents to hepatic microscimal cytochromes P-450 is identical 
. ~; . 
in uninduced and polycyclic hydrocarbon induced microsomes. 
Induction of cytochrome P-450 by phenobarbital, however, 
increases _the maximum extent of binding of each of the 
anaesthetic agents roughly in proportion to the increase 
in cytochromes P-450 levels. 
Table 6. Binding of fluroxene to cytochromes P-450 of 
hepatic microsomes from variously induced_ animals 
Induction [cyts. P-450] K b.A 
s max 
(nmol/mg microsomal (mM) 
protein)_ 
None 1.1 + 0.1 0.93 + 0.20 0.06 + 0.01 
- - -
BP 2. 3- + 0.1 0.90 + 0.18 0.06 + 0.02 
- -
-
MC 2.1 + 0.2 0.94 + 0.25 0.06 + 0. 02 _ 
- - -
PB 2.7 + 0.2 0.95 + 0.08 0.13 + 0.03 
- - -
- --
Table 7. Binding of 2,2,2-trifluoroethyl ethyl ether to 
cytochromes P-450 of hepatic microsomes from variously 
induced animals 
Inductioh [cyts .P-45~ K 
s 
b.A 
max 
{nmol/mg microsomal (mM} 
protein) 
None l. 3 + 0.1 l.5 + 0.3 0. 07 + 0.o1 
- - -
BP 1.8 + 0.1 1. 7 + 0.2 0.06 + 0.01 
- - -
MC l.9 + 0.2 2.5 + 0.4 0.09 + 0.02 
- - -
PB 2.7 + 0.2 1. 8 + 0.3 0.17 + 0.02 
- - -
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Table 8. Binding of methoxyflurane to cytochromes P~450 
of hepat~c microsomes from variously induced ~nimals 
Induction [cyts. P-450] .K /iA 
s max 
(nmol/mg microsomal (mM) 
protein) 
None 1.1 + 0.1 0.48 + 0.09 0.06 + 0.01 
- - -
MC 1. 8 + 0.1 0.62 + 0.11 0.07 + 0.01 
-
-
-
• PB 2.4 + 0.3 0.29 + o.os 0.16 + 0.02 
- -
-
Table 9. Binding of enflurane to cytochromes P-450 of 
hepatic microsomes from variously induced animals 
Induction [cyts. P-450] K /iA 
s max 
(nmol/mg microsomal (mM) 
protein) 
-
None i. i + o.i 0.49 + 0.11 0.06 + 0.01 
-
..... - -
MC 1.8 + 0.1 .Q.50 + 0.07 0 .OS + 0.01 
- - -
PB 2.4 + 0.3 0.52 + 0.08 0.16 + 0. 03 
- -
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Figure 10. Type I difference spectral changes of enflurane 
with uninduced and phenobarbital induced hepatic microsomes. 
Enflurane, O. 27 :rn..M; microsomal protein, 2. O mg/ml in 0. 02M 
Tris-HCl, pH 7.4; performed at 25°. 
/ 
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Effect of concentration of fluroxene on its 
difference spectra with hepatic microsome$ from uninduced (E} 
and phenobarbital induced (o·) animals. 
2.0 mg/ml in 0.02 M Tris-HCl, pH 7.4; 
Microsomal protein, 
0 p~rformed at 25 . 
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/1A 
x 10""" 2 
Figure 12. 
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1.0 2.0 
[ENF] (x 10- 3 M) 
Hanes plots of difference spectra of enflurane 
with hepatic microsomes from uninduced ( O ) , 3-methylcholan-
threne induced {Ii ) and phenobarbital induced ( • ) animals. 
Experimental conditions as for Figure 11. 
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2. Effects of anaesthetic agents on microsomal NADPH oxidation 
_ FJ,.uroxene,. TFE_E, methoxyflurane and enflurane stimulate carbon 
monoxide inhibitable NADPH oxidation by hepatic microsomes 
(e.~. Figure 13). The rate of NADPH oxidation by uninduced 
or induced microsomes in the presence of anaesthetic agent 
increases with increasing concentr~tion of anaesthetic agent 
until saturating concentrations are reached. Hanes plots 
of the data from these studies permit calculatibn of Michaelis 
constants, K , and maximum rates of reaction, V , for the 
m max 
anaesthetic agents with microsomes from uninduced and induced 
animals. 
Hanes plots are linear for NADPH oxidation by all types of 
microsomes in the presence of fluroxene, methoxyflurane and 
enflurane (~·£· Figure 14) but are linear only with pheno-
* barbital induced microsomes in the presence of TFEE (Figure 15) . 
The biphasic Hanes plots for NADPH oxidation by control or 
polycyclic hydrocarbon induced microsomes in the presence of 
TFEE allow calculation of two sets of K and V values. 
m max 
The effects of induction of cytochromes P-450 on the K and 
m 
Vmax values for microsomal NADPH oxidation in the presence 
of the anaesthetic agents are shown in Tables 10, 11, 12 and 
13 in which averages and mean deviations are reported for 
* When linear Hanes plots were obtained for NADPH oxidaGion 
or metabolite production, concentrations of anaesthetic 
agents were investigated that wer~ 10 to 20 times higher 
than the-Km values in ·each case in order to confirm the 
lack of biphasic character in the plots. 
0.6 
0.4 
Absorbance 
(340 nm) 
0.2 
2 4 
Time (min) 
co;o2 (80:20i v:v) plus 
0.27 mM MOF or ENF 
0.07 mM ENF 
0.07 mM MOF 
0. 27 nu\IJ. MOF 
U.27 mM ENF 
Figure 13. Oxidation of NADPH by phenobarbital induced hepatic rnicrosomes in the presence 
of methoxyflurane and enflurane. NADPH, 0.24 mM; microsomal protein, 2.0 mg/ml in 0.02 M 
Tris-HCl, pH 7.4; reaction temperature, 30°c. 
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-...J 
, 
68 
7.5 
./ 
5.0 
[MOF] · -4 
---. x 10 
v 
2.5 
1.0 2.0 
[MOF] x 10- 3 
Figure ·14. Hanes plots of NADPH oxidation by hepatic 
microsomes in the presence of methoxyflurane. 3-methyl-
cholanthrene (m) and phenobarbital (e) induced microsomes; 
[MOF], molar; v, nmol NADPH/rng rnicrosorna~ protein/min. 
Experimental conditions as for Figure 13. 
[TFEE] x 10-3 
v 
10.0 
5.0 
10 20 30 
[TFEE] x 10-3 
Figure 15. Hanes plots of NADPH oxidation by hepatic microsomes in the presence of 2,2,2-
. trifluoroethyl ethyl ether. Uninduced ( o ), 3-methylcholanthrene induced ( •) and pheno-
barbital induced ( o) microsomes; ~FEE], molar; v, nmol NADPH/mg microsomal protein/min. 
Experimental conditions as for Figure 13. 
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determinations of K and V with two or three separate 
m max 
preparations of hepatic microsomes. 
Induction of cytochrome P-448 by ·polycyclic hydrocarbons or 
of cytochrome P-450 by phenobarbital does not significantly 
affect the K values for f luroxene or enflurane relative 
. m 
to the respective values in uninduced microsomes (Tables 
10 and 13) ~ .In the case of TFEE the two K values observed 
m 
. . . 
each. for uninduqed, 3_;.methylcholanthrerre induced and 3,4-
benzpyrene induced microsomes are about 1.0 mM and 12.0 mM 
(Table 11). For methoxyflurane, phenobarbital but not 
3-methylcholanthrene inductio~, affects the value of K 
m 
(Table 12) . 
For each of the anaesthetic agents, the induction of cyto-
chrome P-448 by polycyclic hydrocarbons does not signifi-
cantly alter the v relative to that in uninduced micro-
max 
. somes. Induction of cytochrome P-450 by phenobarbital~ 
however, elevates V three to five fold. max · 
3. The production· of 2, 2, 2-trifluoroetha·nol from fluroxene or 
· '2,'2,2'-tri·fTuoroethyT ethyl etheY by hepatic microsomes 
a. ·Identifica·tion a:nd gua:ntitative a:ssa:y ·of 2 ,·2 ,2--trifluo·ro-
··ethanol 
2,2,2-trifluoroethanol was identified as a volatile product 
of the hepatic microsomal metabolism of fluroxene by gas-
* liquid chromatography in combination with mass spectrometry. 
* Identification bf trifluoroethanol was performed by Dr L.S. 
Kaminsky at N.Y. State Department of Health, Division of 
Laboratories and Research, Albany, N.Y., U.S.A. 
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Table 10. Effect of induction of cytochromes P-450 on 
hepatic microsomal NADPH oxidation in the presence of 
f luroxene 
Induction Cyts. P-450 K v 
m max 
(nmol/mg microsomal (mM) (nmol/mg microsomal 
protein) protein/min) 
.. 
None 1.1+0.l 0.76+0.40 4+1 
- - -
BP 2.3+0.l 1. 07+0. 53 4+1 
- - -
MC. 2.1+0.2 0.95+0.15 3+1 
- - -
-· 
PB 2.7+0.2 0. 63+0 .12. 13+2 
- - -
Table 11. Effect of induction of cytochromes P-450 on 
hepatic microsomal NADPH oxidation in the presence of 
2,2,2-trifluoroethyl ethyl ether 
Induction Cyts. P-450 K 
.. 
a 
b 
m 
(nmol/mg microsomal (mM) 
protein) 
K a 
m 
None 1. 3+0. 1 0.6+0.2 
- -
BP 1. 8+0 .1 l.3+0.2 
- -
MC 1.9+0.l 0.9+0.3 
- -
PB 2.7+0.2 1.9+0.5 
-
, 
-. . . . . . . . 
Smaller K and corresponding V 
m max 
Larger Km and corresponding V 
max 
v 
max 
(nmol/mg microsomal 
. protein/min} 
Kb v a v b 
m max max 
11+1 2+0.5 6+1 
- - -
14+5 2+0.5 5+1 
- - -
11+2 1+0.5 4+1 
- - -
-
10+2. -
-. . . . . . 
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Table 12. Effect 0£ induction of cytochromes P-450 on 
hepatic microsomal NADPH oxidation in the presence of 
methoxyflurane 
Induction .Cyts. P-450 K v 
m max 
(nmol/mg microsomal (mM) (nmol/mg microsomal 
protein) protein/min) 
- . -
-None 1. 3+0 .1 0.10+0.01 3+1 
- - -
MC 1.9+0.2 0.25+0.06 4+1 
- - -
PB 2.4+0.3 • 0.07+0.003 13+2 
- - -
Table 13. Effect of induction of cytochromes P-450 on 
hepatic microsomal NADPH oxidation in the presence of 
enf lurane 
Induction Cyts. P-450 K v 
m max 
(nmol/mg microsomal (mM) (nmol/mg microsomal 
protein) protein/min) 
None 1.3+0.l 0.15+0.10 3+1 
- -
MC 1.9+0.2 0.35+0.10 4+1 
- - -
PB 2.4+0.3 0.23+0.ll 18+2 
- - -
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Gas-liquid chromatography (Section IIB.3.e.) of a reaction 
mixture after incubation of either fluroxene or TFEE with 
microsomal suspension and NADPH gives rise to a peak whose 
retention time is identical with that ~f a st~ndard solution 
of trifluoroethanol. 
Representative examples of gas-liquid chromatograms obtained 
during quantification of trif luoroethanol are shown in 
Figure 16. Fluroxene or TFEE is eluted with water within 
3 to 4 min_ after injection of sample. An unidentified 
component is eluted at about 5 min. This peak is observed 
following incubation of microsomes and NADPB generating 
system in the presence or absence of fluroxene or TFEE. 
b. Effect of experimental conditions on production of 2,2,2-
trif luoroethanol from fluroxene 
The effect of a variety of experimental conditions on the 
production of trifluoroethanol from f luroxene by pheno-
barbital induced hepatic microsornes was investigated and 
the results are presented in Table 14. 
Increasing the microsomal protein concentration from 2.0 
mg/ml to 10 mg/ml decreases by 75% the production of tri-
fluoroethanol per mg microsomal protein; there is no 
difference in the K values determined at these two concen-
m 
trations of microsomal protein. Under conditions of no 
shaking, production of trifluoroethanol decreases relative 
to shaken samples by 25% and 40% for 10 m1n and 30 min 
incubation periods, respectively. Prebubbling of the 
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A. 
(min) 16 
B. 
b 
{-
8 
a 
{-
c b a 
+ 
0 Time 
Figure 16. Gas-liquid chromatograms. A. Standard solution 
of 2,2,2-trifluoroethanol (0.7 mM) in water; a, water peak 
and b, trifluoroethanol peak. B. Sample of reaction mixture 
comprising phenobarbital induced microsomes (2.0 mg protein/ml}, 
fluroxene (6.0 mM) and NADPH generating system after incubation 
at 30° fcir 10 min; a, water ~nd flurqxene peak, b, unidenti-
fied peak and c, trifluoroethanol peak. Experimental details 
in METHODS. 
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Table 14. Effect of a variety of experimental conditions 
on the production of 2,2,2-trifluoroethanol from fluroxene 
by phenobarbital induced hepatic microsomes 
Modification of Production of TF~ 
experimental (nmol/mg microsomal 
conditionsa protein) 
10 min 30 min 
None 112 + 12 227 + 17 
- -
Microsomal protein 27 + 4 N.D. 
-10.0 mg/ml 
No shaking 83 + 9 123 + 10 
- -
02 
. c 101 10 222 + 20 prebubbling + 
- -· 
Anaerobic; no shaking <l. 0 N.D. 
a Unmodified experimental conditions were as described in 
b 
c 
Section IIB.3.d; fluroxene, 30 mM. 
Averages and mean deviations for determinations in 
triplicate with one microsomal preparation. 
Oxygen bubbled through microsomal suspension for 2 min 
at 10 ml/min. 
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microsomal suspension with oxygen has no effect on the rate 
of production of trifluoroethanol. Under completely anaero-
bic conditions, trifluoroethanol is not produced. 
c.· Effect of different electron and active oxygen donors on 
' production of 2,2,2-trifluoroethanol from fluroxene 
The effect of different electron and active oxygen donors on 
production of trifluoroethandl from f luroxene by phenobarb-
ital induced hepatic microsomes is shown in Table 15. NADPH 
is the only effective electron donor for the microsomal 
production of trifluoroethanol; NADH supports the reaction 
but only to a limited extent. Periodate and hydrogen 
peroxide lead to non-enzymic degradation of fluroxene to 
trifluoroethanol. 
d. Effect of time on the production of 2,2,2-trifluoroethanol 
In order to determine a valid incubation period for kinetic 
studies of the process, production of trifluoroethanol from 
f luroxene and TFEE as a function of time was investigated 
in microsomes from phenobarbital induced animals. The 
results are illustrated in Figure 17. The production of 
trifluoroethanol from either fluroxene or TFEE is linear 
with time for 10 min after which the ~ate rapidly declines. 
e.· Effect of inhibitors on the production of\2,2,2-trifluoro-
ethanol 
The effect of inhibitors of cytochromes P-450 on production 
of trifluoroethanol from fluroxene and TFEE was investigated 
in microsornes from phenobarbital induced animals and the 
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Table 15. Effect of different electron and active oxygen 
donors on the production of 2,2,2-trifluoroethanol from 
fluroxene by phenobarbital induced hepatic microsomesa 
Electron or active Production of TFE 
oxygen donor (nmol/mg microsomal 
protein/10 min) 
None < 1.0 
10 mM Sodium dithionite < 1. 0 
10 mM Sodium ascorbate < 1. 0 
NADPHb .109 + 8 
-
0.6 mM NADH 16 + 2 
-
7.5 mM Sodium Periodate 173 
7.5 mM Sodium Periodatec 341 
0.3% H202 69 
0.3% H202c 921 
a Incubation conditions as described in Section IIB.3.d. 
b NADPH generating system. 
c Buffer used in place of rnicrosomes. 
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Figure 17. Effect of time on production of 2,2,2-trifluoro-
ethanol from fluroxene ( 0 ) and 2, 2, 2-trifluoroethyl ethyl 
ether (O) by phenobarbital induced hepatic microsomes. 
Anaesthetic agent (5.0 mM), microsomal suspension (2.0 mg 
protein/ml) and NADPH generating system incubated together 
at 30° in 0.02 M Tris-HCl, pH 7.4. 
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results are presented in Table 16. At equimolar concen-
trations (50 µM) of the inhibitors, metyrapone is a more 
effective inhibitor of trifluoroethanol production than 
SKF 525A. Carbon monoxide inhibits the production of 
trifluoroethanol from fluroxene and TFEE by approximately 
65%. 
In 3-methylcholanthrene induced microsomes the extent of 
inhibition by metyrapone (50 µM) of trifluoroethanol production 
from fluroxene decreases by about 20% relative to that 
observed in phenobarbital induced microsomes although the 
extents of inhibition by SKF 525A (50 µM) are the same in both 
types of microsomes. 
£. Effect of induction of cytochromes P-450 on production of 
· 2 ,2 ,2-trifluoroethanol 
Production of trif J.uoroethanol by microsomes as a function 
of fluroxene or TFEE concentration was investigated. The 
rate of microsomal production of trif luoroethanol increases 
with increasing concentration of anaesthetic agent until 
saturating concentrations are reached. Hanes plots of the 
data from these studies have been utilized to calculate K 
m 
and V values. 
max Hanes plots are linear for production of 
trifluoroethanol from f luroxene by all types of microsomes 
(Figures 18 and 19) and from TFEE by microsomes from 
3-methylcholanthrene induced/AIA pretreated and phenobarbital 
induced animals only (Figures 20 and 21). Biphasic Hanes 
plots for production of trif luoroethanol from TFEE by 
microsomes from uninduced or polycyclic hydrocarbon induced 
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Table 16. Effect of inhibitors of cytochromes P-450 on the 
production of 2,2,2-trifluoroethanol from fluroxene and 
2,2,2-trifluoroethyl ethyl ether by phenobarbital induced 
hepatic microsomes 
Inhibitor Production of TFE 
. . ... 
from f luroxene a from TFEEa 
(nmol/mg microsomal ( % ) (nmol/mg microsomal (%) 
protein/10 min) protein/10 min) 
None 109 + 8 100 145 + 16 100 
- -
Metyrapone 50. µM 27 + 4 25 18 + 4 15 
- -
2.3 mM 18 + 1 16 17 + 4 12 
- -
SKF 525A 50 µM 73 + 2 67 52 + 6 36 
- -
330 µM. 32 + l 29 26 + 2 18 
- -
cob 45 + 1 41 46 + 5 32 
- -
a Averages and mean deviations reported for determinations in 
triplicate on two separate microsomal preparations. Ana es-
thetic agents at 6.0 mM. 
b Carbon monoxide bubbled through reaction mixture for 2 min 
at 10 ml/min prior to incubation • 
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Figure 18. Hanes plots of production of 2,2,2-trifluoroethanol from fluroxene by hepatic 
microsomes from uninduced ( e ) ,, 3-methylcholanthrene induced ( II ) and 3-methylcholanthrene 
induced/AIA treated (A) animals; [Fluroxene], molar; v, nmol TFE/mg microsomal protein/10 min. 
Experimental conditions as for Figure 17. 
0.30 
[FluroxeneJ -3 
x 10 0.15 
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Figure. 19. Hanes plots of production of 2,2,2-trifluoroethanol from fluroxene by hepatic micro-
somes from phenobarbital ( O ) and 3, 4-benzpyrene ( o ) induced animals. [Fluroxene] , molar; 
v, nmol TFE/mg microsomal protein/ro min. Experimental conditions as for Figure 1 7. 
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Figure 20. Hanes plots of production of 2,2,2-trifluoroethanol from 2,2,2-trifluoroethyl 
ethyl ether by hepatic microsomes from· 3-methylcholanthrene induced (II) and 3-methyl-
cholanthrene induced/AIA treated (A.) animals; [TFEE] , molar; v, nmol TFE/mg microsomal 
protein/lO~in. Experimental conditions as for Figure 17. 
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Figure 21. Hanes plots of production of 2,2,2-trifluoroethanol from 2,2,2-trifluoroethyl 
ethyl ether by hepatic microsomes from uninduced ( O ) and phenobarbital induced ( e ) animals; 
[TFEE], molar; v, nmol TFE/mg microsomal protein/10 min. Experimental conditions as for 
Figure 17. 
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animals allow calculation of two K and V values in each 
m max 
case. 
The effects of induction of cytochromes P-450 on the values 
of Km and Vmax for production of trif luoroethanol from 
fluroxene and TFEE are shown in Tables 17 and 18 respectively. 
Averages and mean deviations for determinations of K and 
m 
Vmax with two or three separate preparations of hepatic 
microsomes are reported. -
For production of trifluoroethanol from either fluroxene or 
TFEE, values of K obtained after polycyclic hydrocarbon 
~-·· -·· -- -· . -- --- -------- -- - m_ . - -- --- - . . -- . -~-~--
induction are not significantly different from the K values 
m 
-~-----~ ----·---------~-~--
observed with uninduced microsomes (Tables 17 and 18) except 
for the decrease in the larger Km value observed with TFEE 
in 3,4-benzpyrene induced microsomes. AIA treatment of 
3-methylcholanthrene induced animals leads to loss of the 
smaller K value for microsomal production of trif luoroethanol 
m 
from TFEE (Table 18). Relative to values obtained with 
microsomes from uninduced animals, phenobarbital induction 
results in no significant change (p > 0.05) in the Km 
----·~- ~- --~------ ------ --------. 
value for microsomal production of trif luoroethanol from 
fluroxene (Table 17) and in the disappearance of the larger K 
m 
for production of trifluoroethanol from TFEE (Table 18). 
Values of V for production of trif luoroethanol from 
max 
fluroxene (Table 17) or TFEE (Table 18) are unaffected by 
polycyclic hydrocarbon induction of cytochrome P-448 
relative to values observed with uninduced rnicrosomes. 
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Table 17. Effect of induction of cytochromes P-450 on 
hepatic microsomal production of 2,2,2-trifluoroethanol 
from fluroxene 
Induction Cyts. P-450 K Vmax m 
(nmol/mg microsomal (mM) (nmol TFE/mg micro-
protein) somal protein/min) 
None 1.2 + 0.1 1. 4 + 0.1 3.7 + 0.5 
- - -
BP 1. 8 + 0.1 1.8 + 0.2 5.5 + 1.2 
- - -
MC 2.1 + 0.2 1. 3 + 0.3 4.8 + 0.4 
- - -
MC/AIA 1.4 + 0.1 1. 2 + 0.2 2.1 + 0.4 
-
- -
PB 2.5 + 0.3 0.7 + 0.2 14.2 + 0.8 
- - -
Destruction of cytochrome P-450 by AIA results in decreases 
in the values of V for microsomal production of trif luoro-
max 
ethanol from fluroxene and TFEE; induction of cytochrome 
P-450 by phenobarbital results in substantial increases in 
the respective V values. 
max 
4. The production of fluoride from methoxyflurane and enflurane 
by hepatic microsomes 
Free fluoride ion is produced from methoxyf lurane and enf lurane 
on incubation of either compound with microsomal suspension 
and NADPH generating system (157). During incubation, acid-
labile fluoride is produced from methoxyflurane but not 
from enflurane. Control reaction mixtures in which the 
Table 18. Effect of induction of cytochromes P-450 on hepatic microsomal production of 
2,2,2-trifluoroethanol from 2,2,2-trifluoroethyl ethyl ether 
Induction Cyts. P-450 K v 
m max 
(nmol/mg microsomal (rnM) (nmol TFE/mg microsomal 
~rotein) protein/min) 
K a Kb v a v b 
m m max max 
None 1. 2+0. 1 1. 7+0. 6 17.3+2.8 3.4+0.7 12.l+0.4 
BP 1. 8+0 .1 1.0+0.l 7.0+0.8 4.4+1.0 8.3+0.2 
MC 2.1+0.2 2.3+1.4 13.5+0.5 3.8±.0.7 10.3+0.5 
MC/AIA . 1. 4+0. l - 15. 5+1. 7 - 5. 3+1. 3 
PB 2.5+0.3 1.4+0.2 - 23.4+3.2 -
. -
a Smaller K and corresponding V . 
· m max 
b Larger Km and corresponding Vmax· 
co 
......i 
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anaesthetic agent is incubated with microsomes in the absence 
of NADPH generating system exhibit free fluoride concentra-
tions of < 1.0 µM which is the lower limit of sensitivity 
of the fluoride electrode.· Subsequent treatment of these 
reaction mixtures with cone. H2so4 for 15 to 70 hr does not 
result in increased fluoride production, indicating that 
fluoride is not produced by acid hydrolysis of methoxy-
f lurane or enflurane. 
a. Determination of acid-labile fluoride 
In order to ascertain the time required for complete hydro-
lysis of the acid-labile fluoride produced during microsomal 
metabolism of methoxyflurane, the· effect of time of incubation 
with cone. H2so4 on the concentration of total fluoride in 
the microsomal reaction mixtures was investigated. Cone en-
trations of total fluoride increase with length of time of 
the acid treatment as illustrated in Figure 22. It is 
evident that incubation with concentrated H2so4 for 85 to 
90 hr is required in order that hydrolysis of acid-labile 
fluoride proceeds nearly to completion. An incubation time 
of 18 to 20 hr used in investigations of acid-labile fluoride 
production from methoxyflurane in other laboratories (156, 
178) results in hydrolysis of only about 60% of the acid-
labile fluoride. 
b. Effect of time on production of fluoride 
In order to determine a valid incubation period for kinetic 
studies of fluoride production, the production of fluoride 
from methoxyf lurane and enflurane as a function of time was 
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Figure 22. Effect of time of incubation with H2so 4 on 
. total fluoride measureable after metabolism of methoxy-
flurane by 3:_methylcholanthrene (ti ) and phenobarbital 
induced· ( e ) rnicrosomes. Methoxyflurane (1.7 mM), micro..,. 
somal suspension (2.0 mg protein/ml) and NADPH generating 
system all in 0.02 M Tris-HCl, pH 7.4, incubated at 30° 
for 15' prior to treatment with cone. H2so 4 • 
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investigated. Time courses for production of free and 
total fluoride from methoxyflurane by uninduced,3-methyl-
cholanthrene induced and phenobarbital induced microsomes 
are illustrated in Figures 23, 24 and 25; the rates of 
production of fluoride by these microsomes are linear for 
approximately 15, 20 and 15 min respectively. The produc-
tion of free fluoride as a function of time from enflurane 
by phenobarbital induced microsomes is linear for approxi-
mately 20 min (Figure 26). 
c. Effect of inhihitors on the production of fluoride 
The effects of inhibitors of cytochromes P-450 on the micro-
I 
somal production of fluoride from methoxyf lurane and enf lurane 
was investigated. With methoxyflurane, levels of free and 
total fluoride obtained in the absence and presence of 
inhibitors are indicated in Table 19 in which are reported 
averages and mean deviations for determinations performed 
in triplicate with one preparation of microsomes each from 
uninduced and induced animals. 
Effects of the inhibitors on fluoride production from 
methoxyf lurane are demonstrated more effectively by presen-
tation of the results of such studies. in the form of 'percent-
, 
age inhibition' of free and acid-labile fluqride production. 
Accordingly, averages and mean deviations for percentage 
inhibition values determined with three different prepara-
tions of microsomes each from uninduced and induced ani.mals 
are presented in Table 20. 
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Figure 23. Effect of time on the production of free ( 0 ) 
and total ( • ) fluoride from methoxyflurane by uninduced 
microsomes. Methoxyflurane (2.9 m.M), microsomal suspension 
(2.0 mg protein/ml) and NADPH generating system all in 
0.02 M Tris-HCl, pH 7.4 incubated at 30°. 
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Figure 24. Effect of time on the production of free ( 0 ) 
and total (9) fluoride from methoxyflurane by 3-methyl-
cholanthrene induced microsomes. Experimental conditions 
as for Figure 23. 
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Figure 25. Ef feet of time on the production of free ( 0 ) 
and total ( • } fluoride from methoxyflurane by phenobarbital 
induced microsomes. Experimental conditions as for Figure 
23. 
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Figure 26. Effect of time on the production of free 
fluoride from enflurane by phenobarbital induced microsomes. 
Enflurane, 2.7 wM; other experimental conditions as for 
Figure 23. 
Table 19. Effect of inhibitors of cytochromes P-450 on the production of fluoride from 
methoxyf lurane in hepatic microsomesa 
Inhibitor Production of fluoride 
(nmol/mg microsomal protein/15 min) 
Uninduced microsomes MC induced microsomes PB induced microsomes 
- - - - - -Free F Total F Free F Total F Free F Total F 
None 3.2+0.l 14.7+1.3 1. 7+0. 3 7.8+0.6 9.6+0.2 45.0+4.5 
-Metyrapone: 
50 µM 2. 2+0 •. 0 11. 0+0. 6' 1. 2+0. 1 7.0+0.4 3.2+0.l 16.6+0.4 
200 µM i. 9+o. 1 39.4+0.7 o.a+o.o 5.5+0.6 2.0+0.1 13.2+0.8 
-
SKF 525A: 
50 µM 1.9+0.l ·a. 3+o. 4 1.2+0.0 6.3+0.2 6.0+0.l 27.3+0.9 
200 µM 1. 3+0. 0 6.1+0.5 i.o+o.o 4.9+0.3 3.1+0.1 13.2+0.6 
.. -
cob 1.0+0.2 5.5+0.6 0.9+0.0 6.5+0.l 1.5+0.3 6.7+0.2 
a Methoxyflurane 1.7 mM. 
b Carbon monoxide bubbled through reaction mixture for 2 mih at 10 ml/min prior to incubation. 
'° U1 
-
Table 20. Percentage inhibition of production of fluoride from rnethoxyflurane by hepatic 
rnicrosornes 
Inhibitor % Inhibition of fluoride production 
: 
Uninduced rnicrosornes MC induced rnicrosomes PB induced microsomes 
- - - - -
-Free F Acid-labile F Free F Acid-;Labile_ F Free F Acid-labile F 
Metyrapone: 
13+5 .. ~ 68+2. 65+2. 50 µM 28+5 24+2 35+6 
- I 
200 µM 37+3 31+3 52 24 Y1 79 • 69 • 
, 
SI<F 525A: 
24+3 • -
/ 
50 µM 33+7 37+7 27+7 42+3 43+3 
200 JJMa 49+8 52+7 43 36 
.,. 6 8 - .,. 71 
.,. 
co 62+5 62+2 57+14 • I 
~-
24+11 .-- 84+1 •• 86+1 • 
a % Inhibition determined with only one microsomal preparation except for investigations with 
control microsornes. 
x Differs from free F- production with same type of microsomal preparation, p < 0.01 
Y Differs from free F- production with same type of microsomal preparation, p < 0.05 
-~~------~ --- ---·-- ·- .. -~-~-~·-~----~· --- --- --- -~·-··~---~-~- ·~·~---- ------ - -- ' --------------~---,·- -~---- ·------~-------
\.0 
°' 
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Th~ production of free fluoride is generally inhibited to 
~-;~-- ----~-- --?· the same extent as the· production of acid-
. ..--
labile fluoride by each inhibitor in uninduced microsomes 
and in phenobarbital ·induced microsomes (Table 20). 
microsomes from 3-methylcholanthrene induced animals 
With 
however, differences ·exist i.n the extents of inhibition of 
free fluoride production relative to acid-labile fluoride 
production with the inhibitors, metyrapone and carbon 
monoxide. 
Metyrapone inhibits the production of fluoride to a lesser 
or .to the same extent within experimental error as SKF 52SA 
in microsomes from uninduced or 3-methylcholanthrene induced 
animals. In con~rast, in phenobarbital induced microsomes 
metyrapone (SO µM) inhibits fluoride production to a greater 
extent than SKF S2SA (SO µM) although this differential 
effect disappears at 200 µM concentrations of the inhibitors 
(Table 20) • 
.. - ---- ~~---~-·-~----. ·-- -~-~----~~--~- --- -~-- --- ---
Production of free and acid-labile fluoride by uninduced 
·microsomes and·production of free fluoride by 3-methylcholan:... 
threne induced microsomes are inhibited to the same extents 
by each inhibitor. In contrast,· production of acid-labile 
fluoride by 3-methylcholanthrene induced ~icrosomes is 
generally less sensitive to inhibition by all inhibitors 
while production of both free and acid-labile fluoride by 
phenobarbital induced microsomes is more sensitive to inhi-
bition (Table 2a). 
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uninduced and 3-methylcholanthrene induced microsomes 
(Table 20). 
The effect of inhibitors of cytochromes P-450 on the produc-
tion of free fluoride from enflurane was investigated in 
microsomes from phenobarbital induced animals only (Table 21). 
Production of free fluoride is inhibited to a greater extent 
by metyrapone than by SKF 525A. The percentage inhibition 
observed in both cases is ~· ;, the same as that observed 
"-------
with free fluoride production from methoxyflurane by pheno-
barbital induced microsomes. 
Table 21. Effect of inhibitors of cytochromes P-450 on 
the production of fluoride from enflurane by phenobarbital 
induced hepatic microsomesa 
Inhibitor Production of free fluoride 
(rimol/mg microsomal 
protein/20 min)b 
(%) 
• 
None 2.0 + 0.4 100 
-
50 µM Metyrapone 0.8 + 0.1 40 
-
50 µM SKF 525A 1.2 + 0.1 60 
-
coc <0.5 <25 
a Enflurane 2.4 mM. 
b Averages and mean deviations of determinations with three 
separate microsomal preparations., 
c Carbon monoxide bubbled thrqugh reaction mixture for 2 min 
at 10 ml/min prior to incubation. 
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d. Effect of induction of cytochromes P-450 on production 
of fluoride 
The production of fluoride from methoxyf lurane and enf lurane 
was investigated. in microsomes from uninduced and induced 
animals. 
The production of free and total fluoride as a function of 
methoxyf lurane concentration was studied in microsomes 
from uninduced, 3-methylcholanthrene induced and phenobarb-
ital induced animals; production of acid-labile fluoride 
was calculated in each case. Microsomal production of 
fluoride increases with increasing concentration of 
anaesthetic agent until saturating concentrations are 
reached and Hanes or Eadie-Hofstee plots of the data have 
been used to calculate K and V values for free, acid-
m max 
labile and total fluoride production by.the different 
types of microsomes. 
The production of free, acid-labile and total fluoride from 
methoxyflurane by uninduced or 3-methylcholanthrene induced 
microsomes gives rise to biphasic Eadie-Hofstee plots 
(Figures 27-32) which allow calculation of two Km and V 
max 
values in each case. The biphasic nature of the kinetics 
· of fluoride production in these cases is not always so 
readily evident when the data is treated by means of the 
Hanes plot (~.g. Figure 33). In contrast, production of 
free, acid-labile and total fluoride from methoxyflurane 
by phenobarbital induced microsomes exhibits linear Hanes 
or Eadie-Hofstee plots (Figures 34 and 35). 
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Fig·ure 27. Eadie-Hofstee plot of production of ·free 
fluoride from methoxyflurane by uninduced rnicrosomes .. 
[MOF], molar; v, nmol free F-/rng microsomal protein/15'. 
Experimental conditions as for Figure 23. 
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Figure 28. Eadie-Hofstee plot of production of acid-labile 
fluoride from methoxyflurane by uninduced microsomes. [MOP J I 
molar; v, nmol acid-labile F-/mg microsomal protein/15'. 
Experimental conditions as for Figure 23. 
102 
15.0 
v 
7.5 
6.0 12 .o 
" v 
[MOF) 
Figure 29. Eadie-Hof stee plot of production of total 
fluoride from methoxyflurane by uninduced microsomes. 
[MOF], molar; v, nmol total F /mg microsomal protein/15'. 
Experimental conditions as for Figure 23. 
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Figure 30. Eadie-Hotstee plot of production of free 
fluoride from methoxyf lurane by 3-methylcholanthrene 
induced microsomes. [MOF] , molar; v, nmol free F- /mg 
microsomal prote~n/20'~ 
Figure 23. 
Experimental·conditions as·for 
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Figure 31. Eadie-Hofstee plot of production of acid-labile 
fluoride from methoxyflurane by 3-methylcholanthrene induced 
microsomes. [MoF], molar; v, nmol acid-labile F-/mg 
microsomal.protein/20'. 
Figure 23. 
Experimental conditions as for 
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Figure 32. Eadie-Hof stee plot of production of to~al • 
fluoride from methoxyflurane by 3-methylcholanthrene induced 
microsomes. [MOF], molar; v, nmol total F-/mg microsomal 
protein/20'. Experimental conditions as for Figure 23. 
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Figure 33. Hanes plots of production of free fluoride from methoxyflurane by hepatic microsomes 
from u~induced (O) and 3-methylcholanthrene induced (8) animals. [MOF], molar; v, nmol 
free F /mg microsomal protein/15 min for uninduced microsomes and /20 min for MC induced 
microsomes. Experimental conditions as for Figure 23. 
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Figure 34. Hanes plots of production of free ( O) and total (~) fluoride from methoxy-
flurane by phenobarbital induced microsomes. [MOP], molar; v, nmol F-/mg microsomal 
protein/15 1 • Experimental conditions as for Figure 23. 
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Figure 35. Eadie-Hofstee plots of acid-labile ( O ) and 
total (8) fluoride production from methoxyflurane by 
phenobarbital induced microsomes. [MOP] , . molar; v, nmol 
F-/mg microsomal protein/15'. Experimental conditions as for 
Figure 23. 
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The effect of induction of cytochromes P-450 on the values 
of K and V for microsomal production of fluoride from 
m max 
methoxyflurane is presented in Table 22. Averages and 
mean deviations for determinations of Km and Vmax with 
three or four separate prepqrations of hepatic microsomes 
are reported. Production of free and acid-labile fluoride 
only will be considered in discussion of results; values 
of K and V for total fluoride production have been 
m max 
included in Table 22 for the sake of completeness. 
The Km values for production of free fluoride are 0-~ 
the same within experimental error as those for production 
of acid-labile fluoride in control or 3-methylcholanthrene 
induced microsomes. Except for the larger Km for free 
fluoride production, induction of cytochrome P-448 by 
3-methylcholanthrene does not significantly affect the 
values of Km for production of fluoride relative to those 
observed in uninduced microsomes. In microsomes from 
phenobarbital induced animals the K value for production 
m 
of free fluoride is significantly different from the K m 
value for production of acid-labile fluoride; these K 
m 
values differ from both of the two Km values o:Qtained_each for 
production of free., or acid-labile fluoride in uninduced 
microsomes (Table 22). 
Induction by 3-methylcholanthrene results in a decrease in 
Vmax for microsomal production of free fluoride relative to 
that observed in uninduced microsomes whilst production of 
acid-labile fluoride is increased -5'.·- <-> (Table 22). _____ ____, 
Table 22. Rffect of induction of cytochromes P-450 on hepatic microsomal production of fluoride 
from methoxyf lurane 
• 
Induction jcyts. P-4501 K v 
m max 
(nmol/mg (mM) (nmol/mg microsomal protein/15 min) 
microsomal 
protein) - Acid-labile F - - - - -Free F Total F Free F Acid-labile F Total F 
K a Kb K a Kb K a Kb v a V b v a V- b v a V 
m m m m m m max max max max max max 
None 1.0+0.l 0.04 0.4 0.06 0.7 0.06 0.4 2.3 5.4 4.6 9.6 8.8 16.3 
+0.007 +0.1 +0.01 +0.1 +0.003 +0.1 +0.4 +0.9 +l. 2 +0.4 +1.0 +l. 2 
- - - - - - - - - -
- -
• o.8• 2. 6. 12. 6. MC 1.7+0.l 0.04 0.9 0.08 0.9 0.06 0.8 4.2 4.9 16.2 
+0.01 +0.2 +0.03 +0.3 +0.02 +0.1 +0.3 +0.3 +0.7 +1.0 +1.0 +1.0 
- - - - - - - - -
-
- -
PB 2.4+0.2 0 .10. 0. 22. 0.14 15.1• 43. 9. 66.6 
+0.01 +0.01 +0.02 +1.6 +7.3 +6.0 
.-
a Smaller K and V values. 
m max 
b Larger K and V values. 
· m max 
b 
I-' 
I-' 
0 
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Induction by phenobarbital substantially increases Vmax 
values for production of free and acid-labile fluoride 
relative to uninduced microsomes. 
The production of free fluoride from enf lurane was inves-
tigated in microsomes from uninduced, 3-methylcholanthrene 
and phenobarbital induced animals at one concentration of 
enflurane (Table 23). Induction of cytochrome P-450 by 
phenobarbital elevates the rate,of fluoride production 
approximately 2.8 times that observed in uninduced micro-
somes while induction of cytochrome P-448 by 3-methyl-
cholanthrene does not affect the rate of fluoride production. 
Table 23. Effect of induction of cytochromes P-450 on 
a hepatic microsomal production of fluoride from enf lurane 
Induction Cyts. P-450 Production of free fluoride 
(nmol/mg microsomal (nmol/mg microsomal 
protein) protein/20 min) 
None 1.0+0.l 0.9+0.2 
- -
MC 1.7+0.l 0.8+0.2 
- -
PB 2.4+0.2 2.5+0.2 
- -
a Enflurane 2.7 mM. 
b Averages and mean deviations of determinations on two 
separate microsomal preparations. 
b 
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Fluoride production as a function of enflurane concentration 
was studied with phenobarbital induced microsomes; levels 
of production of fluoride were too low to allow a similar 
investigation with uninduced and 3-methylcho"'!anthrene 
induced microsomes. Hanei and Eadie-Hof stee plots for 
free fluoride production from enflurane by phenobarbital 
induced microsomes are linear (~·SL· Figure 36) and allow 
calculation of K and V values of 0.36 + 0.05 mM and 
m max 
2.6 + 0.7 nmol free fluoride/mg microsomal protein/20 min 
respectively. 
5. Effect of anaesthetic agents on levels of hepatic drug 
metabolizing enzymes in vitro 
The ability of the anaesthetic agents to degrade components 
of the hepatic drug metabolizing system in vitro was inves-
tigated with microsomes from phenobarbital induced animals, 
and the results are presented in Table 24. 
After incubation of fluroxene with microsomes and NADPH 
. generating system for 30 min the concentration of cytochromes 
P-450 is decreased by approximately 30% relative to zero 
time values. The concentration of total microsomal heme 
is decreased by an amount approximately equivalent to the 
decrease in concentration of cytochromes P~450 (179). A 
decrease in cytochromes P-450 concentration is not observed 
when NADPH is omitted from the incubation system. Incuba-
tion of TFEE, methoxyflurane or enflurane with microsomes 
and NADPH generating system does not affect the levels of 
cytochromes P-450. None of the anaesthetic agents inves-
2.0 
[ ENFJ -3 • 
x 10 
1.0 
v 
2.0 4.0 
[ENF] x 10- 3 
Figure 36. Hanes plot of production of free fluoride from enflurane by phenobarbital induced 
microsomes. [ENF], molar; v, nmol free F-/mg microsomal protein/20' •. Experimental condi-
tions as for Figure 23. 
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Table 24. Effect of incubation of anaesthetic agents with phenobarbital induced microsomes 
and NADPH on the levels of microsomal drug metabolizing enzymesa 
Anaesthetic agent ~ytochromes P-45U Cytochrome e_5 NADPH-cyt. £ reductase 
(nmol/mg microsomal (nmol/mg microsomal (units/mg microsomal 
protein) protein) protein) 
0 I 30' 0 I 30' 0' 30' 
Fluroxene (30 mM) 2.4 1. 7 0.54 0.58 0.11 0.12 
TFEE (30 mM) 2.5 2.4 N.D N.D 
Methoxyflurane (6 mM) 3.1 2.9 0.75 0.70 0.11 0.11 
Enf lurane (13 mM) 3.0 2.9 0.67 0.71 0.11 0.10 
' 
a Assay of drug metabolizing enzymes performed at zero time and after 30 min incubation at 30°; 
averages of triplicate determinations reported; mean deviations all <7%. 
I-" 
I-" 
K>-
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tigated affec~the concentrations of cytochrome ~5 or 
NADPH-cytochrome c reductase under the conditions of incu-
bation (Table 24). 
The relationship between the fluroxene mediated destruction 
of cytochromes P-450 and the metabolism of fluroxene to 
trifluoroethanol was investigated in microsomes from un-
induced, 3-methylcholanthrene and phenobarbital induced 
animals. Destruction of cytochromes P-450 and production 
of trifluoroethanol were each studied as a function of 
ti-me, the respective assays being performed on the same 
incubation mixtures usually at 5, 7, 10, 15, 20, 30 and 
60 min. Plots of nmol cytochromes P-450 destroyed/mg 
microsomal protein versus nmol trif luoroethanol produced/mg 
microsomal protein are presented for uninduced, 3-methyl-
cholanthrene and phenobarbital induced microsomes (Figure 
. 37) • For all types of microsomes there is a linear 
correlation between destruction of cytochromes P-450 and 
production of trifluoroethanol. The ratio of nmol tri-
fluoroethanol produced to nmol cytochromes P-450 destroyed 
differs, however, £or each of the three types of microsomes 
studied (Table 25). 
6. Summary of the binding and metabolism of anaesthetic agents 
by microsomal cytochromes P-450 in vitro 
A summary of the data from studies of the binding and metab-
olism of the anaesthetic agents by hepatic microsomal cyto-
chromes P-450 in vitro is presented in Table 26. This 
provides a convenient means of ref erring to the results 
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Figure 37. Relationship between 2, 2, 2-trifluoroethanol production and cytoch1romes P-450 
destruction during metabolism of fluroxene by hepatic microsomes from uninduced ( m ) , 3-methyl-
cholanthrene induced (A) and phenobarbital induced ( e ) animals. Experimental conditions as 
for footnote of Table 25 and microsomal protein 2.0 mg/ml in 0.02 M Tris-HCl, pH 7.4. 
f-' 
f-' 
O"\ 
117 
presented in the eleven tables from which the data for the 
summary are drawn; in addition, relationships between the 
different interactions of the anaesthetic agents with 
cytochromes P-450 may be observed more easily in Table 26. 
For the interaction of fluroxene with cytochromes P-450, 
Ks = Km (NADPH oxidation) = Km TFE production). With 
microsomes from 3,4-benzpyrene induced animals these cor-
relations are not so well observed (Table 26). 
Table 25. Relationship between production of 2,2,2-tri-
fluoroethanol from fluroxene and the fluroxene mediated 
destruction of cytochromes P-450 in microsomes from variously 
pretreated animalsa 
Induction Initial Cyts. P-450 nmol TFE produced 
(nmol/mg microsomal nmol Cyts.P-450 destroyed 
protein) 
None 1.4 226 
MC 2.2 107 
PB 2.6 296 
a Fluroxene, 30 mM; booster NADPH generating system con-
sisting of NADP, glucose-6-phosphate and glucose-6-phos-
phate dehydrogenase added every 8 min at concentrations 
identical with generating system added at zero time. 
Table 26. Summary of the binding and metabolism of anaesthetic agents by microsomal cytochromes 
P-450 in vitro 
Anaesthetic Induction Binding NADPH oxidation Production of metabolites 
agent K a bi.A b K a 
vmax 
c 
s max m Trif luoroethanol 
K a v c 
m max 
Fluroxene None 0.9 0.06 0.8 4 1. 4 4 
BP 0.9 0.06 1.1 4 1.8 5 
MC 0.9 0.06 1.0 3 1.3 5 
PB 0.9 0.13 0.6 13 0.7 14 
TFEE None 1. 5 0.07 0.6 11 2 6 1. 7 17 3 12 
BP 1. 7 0.06 1. 3 14 2 5 1. 0 7 4 8 
MC 2.5 0.09 0.9 11 1 4 2.3 13 4 10 
PB 1. 8 0.17 1. 9 to 1.4 23 
- -Free F Acid-labile F 
K a v c K a v c 
m max m max 
Methoxy- None 0.5 0.06 0.10 3 0.04 0.4 0.15 0.36 0.06 0.7 0.31 0.64 
f lurane MC 0.6 0.07 0.25 4 0.04 0.9 0.05 0.17 0.08 0.9 0.28 0.84 
PB 0.3 0.16 0.07 13 0.1 1. 01 0.2 2. 9 3 
Enf lurane None 0.5 0.06 0.15 3 N.D 
MC 0.5 0.05 0.35 4 N.D 
PB 0.5 0.16 0.23 18 0.4 0.13 
a mM Values quoted for K and K . 
b s m 
Maximum extent of difference spectrum. 
c Maximum rates of NADPH oxidation, TFE production or fluoride production in nmol/mg microsomal 
protein/min. · 
t-' 
t-' 
00 
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The K values obtained from the linear Hanes plots for the 
s 
binding of TFEE to cytochromes P-450 of uninduced and poly-
cyclic hydrocarbon induced microsomes are of the order of 
the smaller K values for NADPH oxidation or trif luoro-
m 
ethanol production. For the binding and metabolism of 
TFEE by phenobarbital induced microsomes, K = K (NADPH 
s m 
oxidation)= K (TFE production) (Table 26). 
m 
Values of K for methoxyflurane binding to cytochromes 
s 
P-450 in uninduced and 3-methylcholanthrene induced micro-
somes are approximately equal to the larger Km values for 
free, and acid-labile fluoride production. The Km values 
for NADPH oxidation by these microsomes in the presence of 
methoxyf lurane do not correlate with K values for binding 
s 
or with Km values for production of fluoride from methoxy-
flurane. In addition, Hanes plots for NADPH oxidation do 
not reflect the biphasic nature of the plots for fluoride 
production. For the binding and metabolism of methoxy-
flurane by phenobarbital induced microsomes, the Ks and Km 
values range between 0.07 mM and 0.3 mM. 
The ratios of V values for acid-labile fluoride and free 
max 
. 
fluoride production from methoxyf lurane by hepatic micro-
sames are presented in Table 27. It appears that 3-methyl-
cholanthrene induction results in greater production of 
~-----·- -~-----~--
acid-labile fluoride relative to free fluoride whereas 
phenobarbital induction does not (p > 0.05). 
For enflurane, correlation between the values of K 
s 
---- -~·-------~~-~--~· ·---·-~-- -·------~-----·-~-
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and K (NADPH oxidation) is not observed; with phenobarbital 
m 
induced microsomes, K = K (free F- production) (Table 26}. 
s m 
Table 27. Effect of induction of cytochromes P-450 on 
relative proportions of acid-labile and free fluoride produced 
during hepatic microsomal metabolism of methoxyflurane 
-Induction Acid-labile F 
-Free F 
None 2.la l.8b 
MC 5 .6a • 4 .9bT 
PB 2.9 
a Ratio of smaller V values. 
max 
b Ratio of larger V values. 
max 
Table 28. Relationship between oxidation of NADPH and 
production of metabolites during metabolism of anaesthetic 
agents by phenobarbital induced microsomes 
Anaesthetic agent NADPH oxidized 
Metabolite formed 
Fluroxene 0.9 
' 
TFEE 0.4 
Methoxyf lurane 13. oa 3.0b 
Enf lurane 140 
a Ratio calculated for free F production. 
b Ratio 6~16~i~ted for total F production. 
• 
I 
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The stoichiometry of NADPH oxidation and metabolite produc-
tion for the anaesthetic agents is demonstrated in Table 28 
by means of the ratios of V values for NADPH oxidation 
max 
and trifluoroeth~nol or fluoride production in phenobarbital 
induced microsomes. Although the experiments leading to 
the values in Table 28 were not designed to demonstrate 
accurately the stoichiometry of NADPH consumed and product 
formed, they should nonetheless provide a good approximation 
of this stoichiometry; in all cases, the initial linear 
portion of the progress curve for the reaction was utilizeq 
to calculate rates of reactio_n. 
Table 29. Relative effects of metyrapone and SKF 52.SA on 
the metabolism of anaesthetic agents by phenobarbital 
induced microsomes 
Anaesthetic agent Inhibition of production 
of metabolites 
Metyraponea 
SKF 525A 
Fluroxene ( 6. 0 mM) 2.3 
TFEE (6.0 mM) 1. 3 
-Methoxyf lurane ( 1. 7 ritM) (free F ) 1.6 
-(total F ) 1.5 
Enf lurane (2.4 ffil'-1) 1.5 
a Ratios of % inhibition of TFE or F production by metyra-
pone to that by SKF 525A at 50 µM concentrations of 
inhibitors (calculated from Tables 16, 20 and 21). 
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Inhibition of production of metabolites. The ratios of 
the extents of inhibition by metyrapone to that by SKF 525A 
for the production of trif luoroethanol or fluoride from the 
anaesthetic agents in phenobarbital induced microsomes are 
presented in Table 29. In all cases metyrapone inhibits 
production of metabolite to a greater extent than SKF 525A. 
B. THE INTERACTION OF 2,2,2-TRIFLUOROETHANOL WITH HEPATIC 
ENZYMES 
1. The interaction of 2, 2, 2-trif luoroethan~l "ir1i th cytochromes 
P-450 
The interaction of trifluoroethanol with cytochromes P-450 
was investigated with microsomes from phenobarbital induced 
animals. 
Trifluoroethanol binds to hepatic microsomal cytochromes P-450 
resulting in the appearance of a type I difference spectrum 
(Figure 38) • The extent of the difference spectrum increases 
with increasing concentrations of trifluoroethanol until 
saturating concentrations are reached; Hanes plots of the 
data from such studies are linear (Figure 39) and allow 
calculation of K and ~A values (Table 30). 
s max 
Carbon monoxide inhibitable NADPH oxidation by phenobarbital 
induced microsomes increases slightly in the presence of 
trifluoroethanol; NADPH oxidation increases with increasing 
concentrations of this alcohol until saturating concentra-
tions are reached. K and V values for microsomal NADPH 
m max 
12 3 
0.08 
c 
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b s:: 
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Figure 38. Type I difference speC'tral changes of 2,2,2-
trifluoroethanol with phenobarbi_tal induced microsomes. 
a, Baseline; b, 4.6 mM trifluoroethanol; c 1 _46 mM trifluoro-
ethanol. Microsomal protein, 2.0 mg/ml in 0.02 M Tris-HCl, 
pH 7.4; performed at 2s0 • 
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2.0 4.0 
-[TFEJ x 10- 2 
Figure 39. Hanes plot of difference spectra of 2,2,2-trifluoroethanol with phenobarbital 
induced microsomes. [TFE], molar. Experimental conditions as for Figure 38. 
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Table 30. The interaction of 2,i,2-trifluoroethanol with 
cytochromes P-450 in phenobarbital induced hepatic microsomes 
Interaction Affinity constant Maximum extent 
Type I difference 
spectrum 
NADPH oxidation 
Inhibition of fluroxene 
difference spectrum 
Inhibition of o-nitro-
anisole 0-demet'hylation 
(mM) 
K : 
s 
K : 
m 
23+4 
25+11 
K.: 33+7 
]. -
K.: 35 ]. 
of interaction 
IJ.A : 0. 06+0.01 
max -
V : 3.4+1.0 nmol 
max -
NADPH/mg microso-
mal protein/min 
oxidation in the presence of trifluoroethanol (Table 30) 
were obtained from Hanes plots of the data (Figure 40). 
In addition, trifluoroethanol inhibits the interactions of 
other compounds with microsomal cytochromes P-450 (Table 30). 
Trifluoroethanol inhibits the formation of a type I differ-
* ence spectrum by fluroxene (Figure 41) and inhibits the 0-
demethylation of E-nitroanisole (Figure 42). Inhibition 
is of a competitive type in both cases. 
* Ethanol at concentrations between 2.6 - 100 mM has no 
effect on the fluroxene difference spectrum (~·5.2· Figure 
41) • 
,,. 
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[TFE] -2 
x 10 1. 5 
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2.0 4.0 
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Figure 40. Hanes plot of NADPH oxidation by phenobarbital induced microsomes in the 
presence of 2,2,2-trifluoroethanol. [TFE], molar; v, nmol NADPH/mg microsomal protein/ 
min. NADPH (0.12 mM), microsomal protein (2.0 mg/ml) in 0.02 .M Tris-HCl, pH 7.4; 
reaction temperature, 210. 
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Figure 41. Lineweaver-Burk plots of inhibition by 2,2,2-
trifluoroethanol of the type I difference spectral changes of 
fluroxene with phenobarbital induced microsomes. No tri~ 
fluoroethanol ( D ) I 6. 6 mM trifluoroethano1 ( m) I 40 m..T\1 
trifluoroethanol ( e), and 100 mM eth_anol ( O) present in 
both sample and reference cuvettes; [Fluroxene], molar; 
experimental conditions as for Figure 38. 
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Figure 42. Dixon plots of inhibition by 2,2,2-trifluoroethanol of the O-demethylation of 
E-nitroanisole by phenobarbital induced microsomes. Concentration of E-nitroanisole 
7 x io-6 M (A), 2 x io-5 M ( G) and 7 x io-5 M ( m); v, nmol E-nitrophenol/mg microsomal 
protein/min. Microsomal protein, u.5 mg/ml in 0.02 M Tris-HCl, pH 7.4; reaction tempera-
tu.re, 2 50. 
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2. The interactio.n of 2,2,2-tr~fluoroethanol with alcohol 
dehydrogenase 
The NAD dependent oxidation of trif luoroethanol by alcohol 
dehydrogenase was investigated with horse liver alcohol 
dehydrogenase and the post-microsomal supernatant from rat 
liver. Trif luoroethanol is apparently not oxidized by 
horse liver alcohol dehydrogenase confirming the results of 
Blake et a 1. ( 11 7) . J:n addition, oxidation of this alcohol 
by the soluble fraction of rat liver does not appear to occur 
although oxidation of ethanol under identical conditions is 
observed as judged spectrally by increase of NADH concentra-
tion in the reaction mixture. 
Trifluoroethanol competitively inhibits the oxidation of 
ethanol by horse liver alcohol dehydrogenase with a K. value 
J_ 
of 6.4 x 10- 6M (Figures 43 and 44). 
0.45 
2.0 4.0 
l . 
[EtOH] x 102 
6.0 
Figure 43. Lineweaver-Burk plots of inhibition by 2,2,~-trifluoroethanol of the reduction 
of NAD by alcohol dehydrogenase in the presence of ethanol. No trifluoroethanol ( e ) , 
2 x 10-S M trifluoroethanol (II) and 9 x io- 5 M trifluoroethanol (.A.) present in reaction 
mixture; [Eto!{), molar; v, nrnol NAD/rnl/min. NAD, 0.07 mM; ADH, 0.03 u/ml; reaction at 
25° in 0.05 M Tris-HCl, pH 8.2. 
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Figure 44. Effect of 2,2,2-trifluoroethanol on K values for ethanol with alcohol 
dehydrogenase. Alcohol dehydrogenase activity me~sured by monitoring reduction of 
NAD; experimental conditions as for Figure 43. 
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3. The interaction of 2,2,i-trifluoroethanol with catalase 
and xanthine oxidase 
Peroxidatic oxidation of trifluoroethanol by catalase in 
combination with a hydrogen peroxide generating system was 
investigated by monitoring consumption of oxygen in a 
reaction mixture comprising catalase, xanthine oxidase, 
xanthine and trifluoroethanol. Time courses for oxygen 
uptake of various reaction mixtures are shown in Figure 45, 
and equations to illustrate the reactions occurring in the 
system in Figure 46. The maximum theoretical oxygen con-
sumption for peroxidatic oxidation is exhibited by oxidation 
of xanthine by xanthine oxidase, and zero peroxidatic oxida-
tion (or half the maximum theoretical consumption) is ex-
hibited by oxidation of xanthine by xanthine oxidase in 
the presence of catalase (180, 181). Oxygen consumptions 
of reaction mixtures in the presence of trifluoroethanol 
and in the presence of alcohols known to be peroxidatically 
oxidized are illustrated (Figure 45). 
The effect of trifluoroethanol on the catalytic activities 
of xanthine oxidase and of catalase was investigated in 
order to ascertain whether the oxygen uptake of the coupled 
peroxidatic oxidation system in the presence of trif luoro-
ethanol could be attributed to a phenomenon other than 
peroxidatic oxidation of this alcohol. Oxidation of 
xanthine to uric acid by xanthine oxidase is not inhibited 
by trifluoroethanol or by ethanol at concentrations of 
about 50 mM (Figure 47). However, decomposition of hydrogen 
peroxide by catalase is inhibited by trifluoroethanol; 
,. 
100 
o2 consumption (%) 50 
.- X, XO 
plus X,XO and 
catalase 
~----x,xo and catalase 
3 6 
Tim~ (min) 
Figure 45. Time courses for consumption of oxygen by a peroxidatic system in the absence 
and presence of alcohols. Reaction mixtures comprising xanthine (X), xanthine oxidase (XO), 
catalase and ethanol (EtOH) (44 mM), methanol (MeOH) (44 mM), trifluoroethanol (TFE) (44 mM), 
or propanol (PrOH) (88 mM). Experimental details in METHODS. 
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Figure 46. Equations to illustrate reactions occurring 
in system for peroxidatic oxidation of alcohols 
xanthine + o2 
catalase 
xanthine 
oxidase 
H2. O + ~O 2 
catalase 
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inhibition by ethanol at a similar concentration is not 
observed (Figure 47). 
Inhibition of the catalase dependent decomposition of 
hydrogen peroxide by trif luoroethanol was studied at differ-
ent concentrations of trifluoroethanol. A Dixon plot of 
the data from these experiments is presented in Figure 48. 
The inhibition of catalase by trifluoroethanol appears to 
be non-competitive and exhibits a K. value of 28 mM. 
1 
4. The interaction of 2,2,2-trifluoroeth~nol with UDP-glucuronyl 
transferase 
Trifluoroethanol does not appear to interact in any way with 
rat hepatic UDP-glucuronyl transferase in vitro. Glucuroni-
dation of trifluoroethanol by hepatic microsomes is not 
observable by either of the two assay techniques under any 
of the experimental conditions described although glucuroni-
dation of E_-ni trophenol is obs.erved under the same conditions. 
Furthermore, trifluoroethanol does not inhibit the glucuroni-
dation of E.-nitrophenol measured in the presence of 0.04% 
Triton X-100. 
The possibility that glucuronidation of trif luoroethanol 
occurs in the kidneys was investigated with a preparation 
of kidney microsomes which had been activated by storage at 
-15° for 12 days prior to use. In this experiment, 
glucuronidation of trifluoroethanol (assayed by gas-liquid 
chromatography) was not observed although glucuronidation 
of E-nitrophenol by this microsomal preparation was measure-
able spectrally. 
4.0 
2.0 
136 
0 No alcohol 
~ 46 mM 'I'FE 
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Xanthine 
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Figure 47. Effects of 2,2,2-trifluoroethanol and ethanol 
on the activities of xanthine oxida~e and catalase. 
Experimental details in METHODS. 
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Figure 48. Dixon plots of inhibition by 2,2,2-trifluoroethanol of the deco~~osition of 
hydrogen i'eroxide by catalase. Concentration of hydrogen peroxide 1. 2 x 10 M ( O ) and 
2. 4 x 10- M ( fl); v, µmol H2o2 /ml/min. · Experimental details in METHODS. 
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C. THE EFFECTS OF VOLATILE ANAESTHE'l'IC AGENTS ON LEVELS OF 
HEPATIC DRUG METABOLIZING ENZYMES AND GLUTATHIONE IN VIVO 
The effects of methoxyflurane and enf lurane anaesthesia on 
levels of drug metabolizing enzymes in subcellular fractions 
isolated from livers of animals after anaesthesia were in-
vestigated. In considering results obtained from these 
experiments trends with respect to time in the effects of 
anaesthesia during the period of treatment and changes with 
respect to the unanaesthetized animals are sought. The 
results obtained after anaesthesia of animals with methoxy-
flurane at anaesthetic (1.0 MAC) and sub-anaesthetic (0.1 MAC) 
concentrations are shown respectively in Tables ·31 and 32 
in which averages and mean deviations are reported for 
determinations with liver fractions from three anaesthetized 
or two unanaesthetized animals in each case. Included in 
the tables is the activity of microsomal glucose-6-phosphatase, 
an enzyme which is not involved in drug metabolism and which 
is not usually inducible by compounds which induce drug 
metabolizing enzymes (181). Results of investigations 
with enflurane (Tables 33 and 34) are presented in the same 
manner as those with methoxyflurane. 
During anaesthesia with methoxyflurane at 1.0 MAC for one 
to four days (3 hr/day) animals were observed to gain slightly 
less weight than unanaesthetized control animals. There 
appear to be no.trends in levels or activities of any of the 
enzymes investigated during the four day period of treatment 
with methoxyflurane at 1.0 MAC (Table 31). Enzyme levels 
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and activities generally remain unchanged relative to those 
of unanaesthetized animals during the one to four days of 
treatment with methoxyflurane; exceptions to this occur 
only on isolated days. Hepatic glutathione levels increase 
in unanaesthetized control animals as well as ·during the 
treatment with anaesthetic; there are no significant 
differences between these two group's on ·any one day. 
NADPH-cytochrome c reductase activity is increased after_ 
the third day of anaesthesia only; whilst_ after the fourth 
day of anaesthesia there are apparent decreases in levels 
of hepatic microsomal cytochromes P-450, E-nitroanisole 
demethylation, 3,4-benzpyrene hydroxylation and glucose-6-
phosphatase activity relative to unanaesthetized control 
values. These decreases, however, may be related to the 
fact that this group of anaesthetized and control rats 
were not starved before sacrifice. The apparent degrada-
tion of microsomal enzymes is being investigated further. 
Anaesthesia of animals with methoxyflurane at 0.1 MAC for 
four to sixteen days (6 h~/day} does· not affect the levels 
or activities of any of the hepatic enzymes investigated 
relative to unanaesthetized controls (Table 32). Hepatic 
glutathione levels are ~lso· not significantly changed 
(p>0.05). There are generally no differences in gain 
of body weight between anaesthetized and unanaesthetized 
animals at 0.1 MAC methoxyflurane. 
--------- -- ------------ '" ____ _ 
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The effects of anaesthesia with enflurane at anaesthetic 
concentrations (1.0 MAC) on hepatic enzymes and glutathione 
are shown in Table 33. During the one to four days of 
anaesthesia (3 hr/day) no trends are noted in the results 
of any of the assays>and levels or activities cif hepatic 
drug metabolizing enzy~es and glutathione generally remain 
the same as those in the livers from unanaesthetized 
animals. The only change brought about by anaesthesia 
with enflurane at 1.0 MAC appears to be the increase in 
microsomal E-nitroanisole O-demethylation, a change which 
is not accompanied by any increase in cytochromesP-450 or 
"NADPH-cytochrome c reductase. Differences in gain of body 
weight between anaesthetized and unanaesthetized animals 
become evident only after four days of anaesthesia.with 
enflurane (1.0 MAC, 3 hr/day) when control animals exhibit 
a slightly greater weight gain than anaesthetize~ animals. 
Anaesthesia.with enflurane at 0.1 MAC for four to sixteen days 
(6 hr/day) does not affect the levels 6r activities of any 
of the hepatic enzymes investigated relative to the values 
obtained for unanaesthetized animals excepting for day 
. . 
twelve {Table 34). The apparent increases relatiye to un-
anaesthetized controls in enzyme levels and activities on 
day twelve cannot be ascribed.to induction; the enzyme 
levels and activities of day twelve .are the same {p > o·.os) 
as those for day eight which were not.significantly differ-
ent. !rom control values for that day .. Microsomal E~nitro-
anisole 0-demethylation activity in livers from urianaes-
thetized animals decreased continuously from the fourth to 
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sixteenth day of anaesthesia;· a- similar decrease in this 
enzyme activity was observed in ~naesthetized animals only 
after sixteen days of anaesthesia. M~crosomai 3,4-benz-
pyrene hydroxyiation activity decreased similarly in both , 
anaesthetized and unanaesthetized·animals from.days four to 
sixteen. The decreases in cytochromes P-450 mediated -
reactions are not accompanied by decreases in cytochrornes 
P-450 or NADPH-cytochrorne .£ reductase.- No differences 
may be observed ih gain of body weight between anaesthetized 
and unanaesthetized animals at 0.1 MAC enflurane. 
: 
~~~-----------------· ____ J 
Table 31. Effect of anaesthesia with methoxyflurane at 1.0 MAC on concentrations and activities 
of h~patic enzymes and glutathione 
a Methoxyflurane/02 ( 3 hr/day) No anaesthetic agent/o2 (3 hr/day) Assay 
DAY 1 DAY 2 DAY 3 DAY 4 DAY 1 DAY 2 DAY 3 DAY 4 
Cytochromes P-450 ... 0.94+.01 (nmol/mg) 0.81+.13 0.87+.16 0.91+.12 0.62+.02 0.65+.ll 0.87+.05 0.99+.04 
Cytochrome e,5 (nmol/mg) 0.41+.06 0.46+.10 0.47+.06 0.39+.01 0.32+.02 0.36+.0l 0.42+.02 0.49+.03 
NADPH-cytochrome c • 
reductase(U/mg)xl0- 1 0.68+.14 0.79+.14 0.87+.ll 0.73+.07 0.52+.04 0.78+.04 0.57+.03 0.63+.08 
E.-Nitroanisole 
• demethylation 1. 13+. 24 1.05+.31 1. 00+ .16 0.61+.23 0.73+.21 0.98+.02 0.97+.09 1.14+.13 
(nmol/mg/min) 
I I . 
· 3,4-Benzpyrene ... 
0.30+.0310.27+.04 1 0.38+.02 hydroxylation 0.49+.20 0.45+.10 o .. 34:t,.03 0.23+.02 0.23+.0l 
(nmol/mg/min)xl0- 1 I 
UDP-glucuronyl I transferase 19+3 19+1 18+2 21+2 17+1 16+2 19+1 17+2 
(nmol/mg/min) 
Glucose-6-phosphatase ... 3.9+0.4 (µg Pi/mg/min) 3.7+0.2 5.0+0.3 4.2+0.4 2.9+0.4 3.3+0.l 4.3+0.l 5.5+0.3 
Glutathione-S-trans- 70+7 . 51+7 54+3 69+3 70+4 56+6 59+3 73+3 f erase (nmol/mg/min) - - - - -
Glutathione 97+6 120+14 121+11 167+9 119+7 151+11 - 153+5 (µg/100 mg wet liver) 
,. 
a Levels of enzymes reported /mg microsomal protein or /mg cell supernatant. For details see 
METHODS. 
'""" .i::.. 
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Table 32. Effect of anaesthesia with methoxyflurane at 0.1 MAC on concentrations and activities 
of hepatic enzymes and glutathione 
Methoxyflurane/o2 (6 hr/day) No anaesthetic agent/0 2 (6 hr/day) Assays a 
DAY 4 DAY 8 DAY 12 DAY 16 DAY 4 DAY 8 DAY 12 DAY 16 
Cytochromes P-450 1. 03+. 07 0.86+.18 0.89+.09 1.15+.08 0.96+.03 0.68+.04 0.91+.12 1.03+.08 (nmol/mg) 
Cytochrome e,5 (nmol/mg) 0.44+.02 0.44+.05 0.41+.02 0.50+.04 0.35+.oo 0.36±_.03 0.39+.03 0.51+.04 
NADPH-cytochrome c 
reductase(U/mg)x10- 1 0.60+.05 0.66+.05 0.64+.03 0.88+.0l 0.62+.02 0.60+.ll 0.56+.10 0.91+.0l 
.E_-Nitroanisole 
demethylation 0.57+.05 0.59+.ll 0.37+.06 0.51+.06 0.57+.10 - 0.39+.04 o.so+.02 (nmol/mg/min) 
3,4-Benzpyrene 
hydroxylation _ 0.19+.0l 0.23+.04 0.19+.02 0.30+.02 0.23+.02 0.23+.04 0.23+.04 0.32+.03 (nmol/mg/min)xlO 1 I ! 
-
.. _ 
UDP-glucuronyl 
transferase 21+3 17+0 19+1 20+1 15+2 18+5 16+3 17+2 
(nmol/mg/min) 
·-
Glucose-6-phosphatase 8.7+0.9 7.5+0.4 7.5+0.2 6.9+0.5 7.4+0.l 8.3+0.2 7.6+0.8 6.6+0.3 (µg Pi/mg/min) - -... 
Glutathione-S-trans- 71+6 69+4 50+6 70+3 65+3 74+6 63+3 74+11 £erase (nmol/mg/min) - - - - .. - - -
Glutathione 129+21 187+9 123+5 172+16 136+3 161+4 127+2 135+10 (µg/100 mg wet liver) 
a Levels of enzymes reported/mg microsomal protein or /mg cell supernatant. For details see 
METHODS. 
,_. 
.i::. 
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Table 33. Effect of anaesthesia with enflurane at 1.0 MAC on concentrations and activities of 
hepatic enzymes and glutathione 
·-· 
Assays a 
Enflurane/02 (3 hr/day) No anaesthetic agent/o2 (3 hr/day) 
--
DAY 1 DAY 2 DAY 3 DAY 4 DAY l* DAY 2 DAY 3 DAY 4 
Cytochromes P-450 1.17+.10 1.00+.12 1. 25+ .15 1.13+.14 1.13 0.78+.09 0.96+.20 0.90+.07 (nmol/mg) 
Cytochrome £5 0.49+.03 0.41+.03 0.54+.04 0.47+.07 0.45 0.37+.02 0.38+.03 0.42+.05 (nmol/mg) 
NADPH-cytochrome c 
reductase(U/mg)xl0- 1 0.71+.09 0.68+.06 0.65+.05 0.79+.05 0.67 0.54+.02 0.45+.03 0.83+.08 
--· 
E_-Nitroanisole 
'Y 
demethylation 0.80+.24 0.69+.05 0.69+.08 1. 2 4+ .11 0.71 0.68+.30 0.50+.02 0.75+.09 
(nmol/mg/min) 
.-
3,4-Benzpyrene 
hydroxylation 0.53+.04 0.23+.02 0.45+.04 0.53+.02 0.49 0.23+.04 0. 2 3+. 0 8 0.57+.02 
(nmol/mg/min)xl0- 1 - - - -
UDP-glucuronyl 
transf erase 16+1 11+2 21+4 15+2 12 15+6 24+1 18+0 
(nmol/mg/min) 
-- I 
Glucose-6-phosphatase 5.1+0.8 5.4+0.5 6.2+0.2 6.1+0.5 6.3 6.5+0.8 7.3+0.2 6.3+0.l (µg Pi/mg/min) 
___ , -"-·"""-·· 
Glutathione-S-trans- 51+9 62+9 56+7 61+6 64 61+0 52+1 61+3 f erase (nmol/rng/miri) 
Glutathione 128+21 115+1. 4 123+11 (µg/100 mg wet liver) 99+12 120 109+8 109+3 93+1 
a Levels of enzymes reported /mg microsomal protein or /mg cell supernatant. For details see 
METHODS. 
* Values for one animal. 
f-' 
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Table 34. Effect of anaesthesia with enflurane at 0.1 MAC on concentrations and activities of 
hepatic enzymes and glutathione 
a Enflurane/02 (6 hr/day) . ' . ' . .No . .an.aesthetic agent/o2 (6 hr/day) Assays 
DAY 4 DAY 8 DAY 12 DAY 16 DAY 4 DAY 8 DAY 12 DAY 16 
,. 
Cytochromes P-450 1.05+.06 1.19+.0l 1.13+.04 0.99+.05 1.16+.05 1.24+.03 0.81+.09 0.99+.02 (nmol/mg) 
Cytochrome e,5 • 0.38+.0l 0.53+.04 0.51+.00 0.48+.04 0.46+.04 0.52+.06 0.39+.03 0.47+.oo (nmol/mg) .--. 
NADPH-cytochrome £ 
reductase(U/mg)xlo- 1 0.62+.08 0.64+.02 0.65+.02 0.68+.06 0. 62+. 06 0.60+.ll 0.56+.10 0.65+.03 
·~·· 
E.-Nitroanisole 
• demethyla.tion 1.19+.ll 1.27+.18 1.28+.11 0.69+.07 1.26+.09 0.99+.04 0.64+.10 0.50+.02 
(nmol/mg/min) 
3,4-Benzpyrene I I 
0.27±.02
1
0.15±.02 I hydroxylation 0.38+.03 - Io. 30±. 02 0.15+.02 ·o.3B+.03 -(nmol/mg/min)xl0- 1 
UDP-glucuronyl 
transferase 14+1 17+2 20+3 17+1 15+2 18+5 16+3 15+1 
(nmol/mg/min) 
Glucose-6-phosphatase 7.5+0.4 8.1+0.l 9-1±0.4 7.3±0.5 8.9+0.7 9.6+0.l 6.5+0.8 6.7+0.2 (µg Pi/mg/min) 
Glutathione-S-trans- 51+5 71+6 74+2. 65+5 60+5 74+6 63+3 60+5 ferase (nmol/mg/min) 
Glutathione 80+2 127+3 133+6 112+ 11 97+3 123+13 12 3+1 7 133+25 (µg/100 mg wet liver) 
a Levels of enzymes reported /mg microsomal protein or /mg cell supernatant. For details see 
METHODS. 
.... 
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IV. DISCUSSION 
Elucidation of the pathways by which volatile anaesthetics 
are metabolized and identification of the enzymes involved 
in these pathways is a prerequisite to an understanding not 
only of the effectiveness of the compounds as anaesthetic 
agents but also of their potential as toxic compounds. 
Information on the metabolism of these compounds and their 
effect on drug metabolizing enzymes is necessary if safe 
clinical usage is to be assured. Investigations of the 
interactions of anaesthetic agents with drug metabolizing 
enzymes are relevant for both patients and operating 
theatre personnel, the former undergoing acute exposure at 
anaesthetic concentrations of agent and the latter under-
going chronic exposure at very low concentrations of agent. 
Study.of the metabolism of volatile anaesthetic agents or 
of any other xenobiotic is of importance not only for an 
understanding of the effects of that particular compound 
but also for an increased understanding of the mechanisms 
of drug metabolism in general. In this regard, the four 
anaesthetic agents under investigation may be useful as 
probes of the functioning of the cytochrornes P-450 drug 
metabolizing system. 
Binding of anaesthetic agents to hepatic microsomal cyto-
chromes P-450. The four halogenated ethyl ethers studied 
all interact with cytochromes P-450 of rat hepatic micro-
somes to elicit a type I difference spectrum indicative 
of the binding of these compounds to the protein moiety 
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of the cytochrome. This confirms the observation of 
previous workers that methoxyf lurane and enflurane give 
rise to a type I spectrum with phenobarbital induced micro-
somes (18 3, 184) • 
The similarity in binding constants for the four ethers 
(Table 26) is surprising in view of the importance of the 
hydrophobic nature of the compound in giving rise to a 
type I difference spectrum (59, 185). The lipid solubili-
ties of the anaesthetic agents relative to each other are 
illustrated in Table 35 which demonstrates that methoxy-
flurane is very much more lipophilic than enflurane or 
fluroxene (TFEE is presumed to possess solubility coeffi-
cients of the order of those for fluroxene). 
Table 35. Some physical constants for volatile anaesthetic 
agents 
Anaesthetic Boiling pointa Oil/gas solubilityb Oil/water 
agent (OC) coefficient solubility a 
coefficient 
Fluroxene 4 3 .2 48 90 
TFEE 50.3 - -
Methoxyf lurane 104.6 970 440 
Enf lurane 56.5 98 120 
a From reference 119 
b f 86 From re erence 1 
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In studies of the binding of a series of haloalkanes to 
hepatic microsomal cytochromes P-450 (185, 187) ~t was 
demonstrated that the more 1ipophilic the haloalkane, the 
greater was its affinity of binding as measured by the K 
s 
value. It is evident that in the case of the halogenated 
ethyl ethers factors other than the lipophi.lic character-
istics of the compounds play a major role in determining 
the affinity of binding to cytochromes P-450. 
The linearity of the Hanes plots for difference spectra 
and the fact that the K values remain unchanged by induc~ 
s 
tion of either cytochrome P-450 or P-448 probably indicates 
that only one species of·cytochromes P-450 is involved in 
the spectrally observable binding of each anaesthetic agent. 
In contrast, biphasic Hanes and Lineweaver-Burk plots for 
difference spectra with other halocarbon compounds have 
been noted as well as changes in K values after induction 
s 
(185, 187). 
Involvement of cytochromes P-450 in metabolism of anaesthetic 
agents. Inhibition of microsomal NlmPH oxidation by carbon 
monoxide demonstrates that the enhanced rate of NADPH 
oxidation by hepatic microsornes in the presence of the 
anaesthetic agents arises as a result of interaction of 
these agents with cytochromes P-450. The results of in-
hibition studies with potassium cyanide in our laboratory 
(188) indicate that activity of the stearate desaturase 
system of hepatic microsomes is not responsible for the 
NADPH oxidation observed in the presence of any of the 
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agents under investigation although the desaturase system 
has been implicated in the enhancement of NADPH oxidation 
observed in the presence of another volatile anaesthetic 
agent, halothane (CF 3CHBrCl) (189). 
The involvement of cytochromes P-450 in the production of 
trif luoroethanol or fluoride from the anaesthetic agents 
is indicated from the requirement of these processes for 
NADPH and from their inhibition by compounds which are 
accepted inhibitors of cytochromes P-450. In addition, 
in view of the method of preparation of microsomes used, 
it is highly unlikely that there is any contamination of 
microsomal suspensions by glutathione-S-transf erase which 
has been implicated in defluorination of methoxyflurane 
in Vitro (190, 191). 
Production of metabolites from anaesthetic agents: some 
consideration of experimental techniques. The importance 
of performing assays of microsomal drug metabolism under 
optimal incubation conditions is stressed by Fouts (192) 
because of the significant effects of experimental £actors 
(~.g. protein concentration, shaking) on rates of drug 
metabolism; under certain conditions the effects of in-
ducing agents on microsomal drug metabolism may be masked 
(192). The incubation conditions for assay of production 
of metabolites of the anaesthetic agents were chosen after 
due consideration of the recommendations of Fouts and of 
the results presented in Table 14. In addition, the 
reaction was allowed to proceed for only that length of 
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time during which the reaction rate was linear with time. 
Previous workers have noted that in rat hepatic microsomes 
the rates of cytochromes P-450 mediated reactions are 
linear with time for relatively short periods (!·~· 5 to 
20 min) before tailing off is observed (193). This early 
deviation from linearity has been ascribed to the destruc- , 
tion of cytochromes P-450 which results from peroxidation 
of microsomal lipids in the presence of NADPH and oxygen 
(194). "Inclusion of EDTA, a known inhibitor of lipid 
peroxidation, in the reaction mixture inhibits the destruc-
tion of cytochromes P-450 by lipid peroxides and extends 
the linearity of a number of cytochromes P-450 catalysed 
reactions (194, 195). 
Although EDTA is included in the in vitro incubation system 
utilized to study trif luoroethanol or fluoride production 
from the anaesthetic agents, the progress curves for the 
respective reactions are linear with time for 10 to 20 min 
only. Inactivation of co-factors might explain in part 
this deviation from linearity; evidence for this suggestion 
arises from an observation in our laboratory that production 
of trifluoroethanol from TFEE is linear for 30 min if booster 
NADPH generating system is added at intervals during the 
incubation (188). In addition, in the case of metabolism 
of fluroxene to trifluoroethanol, the fluroxene mediated 
destruction of cytochromesP-450, which does not arise from 
or result in lipid peroxidation (161), is probably partially 
responsible for the early deviation from linearity. 
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Cytochromes P-450 mediated metabolism of fluroxene and 
2,2,2-trifluoroethyl ethyl ether. It may be observed 
from Table 26 that per unit time, 1.6-fold more trifluoro-
ethanol is produced from TFEE than from fluroxene although 
NADPH consumption in the presence of TFEE is in fact slightly 
less than that in the presence of fluroxene. In this 
regard, it should be noted that NADPH-independent production 
of trifluoroethanol from TFEE does not occur in vitro. 
The discrepancy observed between rates of production of tri-
fluoroethanol from fluroxene and TFEE probably arises as a 
result of the destruction of cytochromes P-450 which occurs 
during metabolism of fluroxene but not during metabolism 
of TFEE (Table 24). During the 10 min reaction time allowed 
for assay of trifluoroethanol production, 25 to 30% of the 
cytochromes P-450 initially present may be destroyed 
thereby resulting in decreased rates of trifluoroethanol 
production. Assay of rates of NADPH oxidation in the 
presence of fluroxene would not be expected to be affected 
by the degradation of cytochromes P-450 because less than 
5% loss of the cytochromes occurs in the 2 to 3 min reaction 
time required for the assay . If correction to rates of 
. trifluoroethanol production is made for fluroxene mediated 
destruction of cytochromes P-450, rates of NADPH oxidation 
for fluroxene become less than those of trif luoroethanol 
production (Table 26) and the stoichiometry of NADPH 
oxidation and trifluoroethanol production for fluroxene 
becomes similar to that for TFEE (Table 28). 
That the observed stoichiometry for NADPH to trifluoro-
ethanol is less than the expected ratio of 1:1 may be 
accounted for not only by differences in the methods of 
* monitoring NADPH oxidation and trifluoroethanol production 
but also by the finding that metabolism of both fluroxene 
and TFEE is not completely inhibited by carbon monoxide 
(Table 16). The correction for background NADPH consump-
tiori in the presence of substrate and carbon monoxide by 
the method of Stripp et al. (29) in these cases may be an 
overcorrection and may result in calculation of rates of 
NADPH oxidation which are accordingly too low. In experi-
ments which are designed to demonstrate accurately stoichio-
metry between NADPH oxidation and product formation, inves-
tigations into the extent of inhibition of metabolism by 
carbon monoxide should be undertaken beforehand in order 
that a valid correction for background rates of NADPH 
consumption be made. 
The major role played by cytochrome P-450, the predominant 
type P-450 cytochrome induced by phenobarbital, in the 
binding and metabolism of f luroxene and TFEE is demonstrated 
by the observation that only phenobarbital pretreatment of 
animals leads to increased extents of interaction of these 
* Incubation temperatures for studies of metabolism of flurox-
ene and TFEE were 27° when NADPH oxidation was monitored, 
and 30° when trifluoroethanol production was followed; 
shaking of the reaction mixtures occurred only when metab-
olite production was monitored. 
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anaesthetic agents with cytochromes P-450 in vitro. Further 
evidence for the role of cytochrome P-450 in the metabolism 
of these compounds is obtained from the investigations ·of 
trif luoroethanol production by microsomes from 3-,methyl-
. 
cholanthrene/AIA treated animals. As a result of specific 
destruction of cytochrome P-450 by.AIA (13, 179), treatment 
of 3-methylcholanthrene induced animals with AIA gives rise 
to a preparation of microsomes whose content of cytochrome 
P-450 is considerably depleted relative to uninduced or 
3-methylcholanthrene induced animals and which has a corres-
pondingly decreased ability to metabolize fluroxene and 
. . 
TFEE relative to uninduced or 3'-methylcholanthrene induced 
microsomes (Tables 17 and 18). 
Cytochrome P-448, the predominant type P-450 cytochrome 
induced by polycyclic hydrocarbons generally appears to 
play no role (or only a very limited role) in the binding 
and metabolism of fluroxene and TFEE as demonstrated by the 
lack of effect of polycyclic hydrocarbon induction on the 
~A and V values for interactions of these anaesthetic 
max max 
agents with cytochromes P-450 (Table 26). 
The K value for fluroxene binding to cytochromes P-450 
s . . . 
appears to reflect formation of the enzyme-substrate complex 
which is prerequisite to both NADPH oxidation and trifluoro-
ethanol production (Table 26). The observation that induc-
tion of cytochromes P-450 generally does not affect the 
values of K or K for fluroxene indicates that the same 
s m 
type P-450 cytochrome(s} is (are) responsible for interactions 
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of fluroxene in the different types of microsomes; the 
values of K and K for f luroxene probably reflect pre-
s m 
dominantly the activity of cytochrome P-·4 50 (Table 2 6) • 
For metabolism of TFEE by uninduced and polycyclic hydro-
carbon induced microsomes, the type P-450 cytochrome ref-
lected by the larger Km values for NADPH oxidation and 
trifluoroethanol production does not appear to bind TFEE 
in a manner which gives rise to a readily observable 
difference spectrum; the single K values correspond 
s 
rather to the smaller K values for TFEE metabolism by 
m 
these microsomes (Table 26). The K value for binding of 
s 
TFEE in phenobarbital induced microsomes appears to reflect 
formation of the enzyme-substrate complex for both NADPH 
oxidation and trifluoroethanol production. 
Differences in the cytochromes P-450 involved in metabolism 
of TFEE by uninduced and phenobarbital induced microsornes 
are immediately evident from the difference in the form of 
the respective Hanes plots (Figure 21). With uninduced 
(or polycyclic hydrocarbon induced} microsomes the involve-
ment of at least two cytochromes P-.450 or two binding sites 
on one type P-450 cytochrome is indicated by the biphasic 
nature of the Hanes plots·· for NADPH oxidation and trifluoro-
ethanol production, in contrast to the apparent involvement 
of only one type P-450 cytochrome in phenobarbital induced 
microsomes. In addition, a qualitative difference in the 
polycyclic hydrocarbon induced cytochromes P-450 involved 
in metabolism of TFEE is suggested in rnicrosomes from 
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3,4-benzpyrene induced animals where the smaller K for 
m 
trifluoroethanol production is decreased in value relative 
to the corresponding values in uninduced and 3-methylcholan-
threne induced animals. This difference, however, is not 
reflected in the corresponding K value for NADPH consump-
m 
tion (Table 26). 
In view of the inducibility by phenobarbital of the compon-
ent giving rise to the smaller K values for TFEE metabolism 
m 
by uninduced microsomes and its destruction by AIA treatment 
(Table 18) it appears that the smaller K reflects the 
m 
activity of cytochrome P-450 while the larger K reflects 
m 
the activity of a type P-450 cytochrome which is not in-
ducible by either phenobarbital or polycyclic hydrocarbons. 
Of the two (or more) type P-450 cytochromes apparently in-
volved in the metabolism of TFEE in uninduced and polycyclic 
hydrocarbon induced microsomes, cytochrome P-450 would ob-
viously play a major role in metabolism in vivo as it is 
unlikely that concentrations of TFEE obtained in vivo 
would be high enough that metabolism by the second type 
P-450 cytochrome were to become significant. 
The production of trif luoroethanol from fluroxene and TFEE 
by hepatic microsomes in vitro correlates well with the 
observed effects of these two agents on uninduced and pheno-
barbital induced animals in vivo (116); for uninduced 
animals anaesthesia is non-toxic, while for phenobarbital 
induced animals it proves toxic. The death of phenobarbital 
induced animals after fluroxene or TFEE anaesthesia may be 
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explained by elevated rates of production of trifluoro-
ethanol such that toxic concentrations of the compound are 
reached ( 11 7) . · 
Cytoahromes P-450 mediated ·metabolism of methoxyflurane 
and enflurane. Rates of production of total fluoride by 
hepatic microsomes represent the sum of the rates of free 
fluoride and acid-labile fluoride production during metab-
olism of methoxyflurane. The existence of an acid-labile 
metabolite which gives rise to inorganic fluoride has been 
reported both in vivo (196) and in vitro (156) for rnethoxy-
flurane. Methoxydifluo·roacetic acid has been characterized 
as a urinary metabolite of methoxyflurane (151) and is the 
only metabolite identified which is acid-labile {156). 
The possible significance of production of acid-labile and 
free fluoride with respect to the postulated pathways of 
metabolism of methoxyflurane .should be mentioned. If 
methoxydifluoroacetic acid is considered to be the only 
acid-lahile compound produced during the microsomal metab-
olism of methoxyflurane ,· the possibility then exists that 
production of acid-labile fluoride arises from the initial 
dechlorination reaction of pathway II (Figure 7) and.is a 
measure of this reaction. Production of free fluoride 
could reflect either a direct defluorination reaction or 
the initial 0-dealkylation of pathway I including spontaneous 
15.7 
hydrolysis of the products of this reaction (Figure 7). 
The inability to detect oxalic acid after metabolism of 
methoxyflurane in vitro (138) provides some basis for 
assuming that metabolism of methoxyflurane by hepatic 
microsomes· in vitro proceeds only as far as the initial 
reactions of pathways I and II. 
Interpretation of the stoichiometry of NADPH to fluoride 
for the metabolism of methoxyflurane and enflurane is not 
straightforward in that NADPH consumption in vitro reflects 
a number of reactions the immediate products of which are 
not known. According to the postulated pathways of metab-
olism of these anae$thetic agents, however (Figures 7 and 8), 
a ratio greater than 1.0 for NADPH oxidized to fluoriqe 
produced (either free or including acid-labile) would not 
be expected. The ratios of NADPH to fluoride observed 
for methoxyflurane and enflurane (Table 28) are far from 
fulfilling the stoichiometric requirements of Figures 7 and 
8. In addition, an overcorrection is probably made in the 
measurement of rates of NADPH oxidation with methoxy-
flurane and enflurane in a similar manner to that described 
for fluroxene and TFEE (page 152); the observed ratios of 
NADPH to fluoride are therefore probably lower than they 
should actually be. 
Possible explanations of the greater than expected .con-
sumption lf NADPH relative to production of fluoride by 
I 
h~patic m~crosomes in the presence of methoxyflurane and 
. I -
enflurane; should be considered.· Firstly, methoxyflurane and 
I 
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enf lurane_ may act to uncouple electron transport and oxygen 
activation from substrate oxidation. Uncouplers of micro-
somal oxidation£·~· perfluorohexane (197), are known to 
stimulate microsomal NADPH and oxygen consumption without 
themselves being oxidized; water and hydrogen peroxide 
\ 
have been postulated as products of uncoupling (197, 198, 
19 9) ~ The existence of partial uncouplers which function 
to dissociate to a greater or lesser extent NADPH and 
oxygen consumption from substrate oxidation has been postu-
lated (199), and it is into this category that methoxy-
flurane and enflurane may fit. I- A-~second possible 
explanation for the observed stoichiometry of NADPH and 
fluoride is that the pathways of metabolism as represented 
in Figures 7 and 8 may be incorrect in a number of respects 
so that the theoretical stoichiometry is not actually that 
predicte~ by the pathways as postulated. 
Methoxyflurane may function to uncouple to a limited extent 
the cytochromes P-450 mediated substrate oxidation from the 
-- --- ---- r - -- -- ~- - ... ---------- ----
·Oxidation of NADPH. However, the data for metabolism of 
anaesthetics shown in Table 3 (144) indicate that more 
! 
organic ~han inorganic fluoride is formed from methoxy-
! 
flurane ~n man (in contrast to the situation predicted by 
FiCiure. 7 l The!:efore, in view of this observation and 
our demo:qstration of a stoichiometry of 13 for NADPH 
oxidized ito free fluoride formed in vitro,·it seems Jn-
' 
likely t~at spontaneous hydrolysis of products of the 
hepatic microsomal metabolism of methoxyf lurane to free 
fluoride \<as Figure 7) occurs _to a significant extent. 
------·-·-
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The possibility of fluoride arising as a primary product of 
a cytochromes P-450 catalysed reaction should perhaps be 
considered. In addition, however, the possibility that 
NADPH consumption in the presence of methoxyf lurane also 
reflects involvement of enzymes other than cytochromes P-450 
should not be overlooked . 
.. 
~~--~~~~~----~---~_,__..~--~~'----~~~~~~---~--~-~-
In contrast to the situation with methoxyflurane, a large 
proportion of the microsomal NADPH oxidation observed in 
the presence of enflurane appears likely to result from 
uncoupling by this agent. The ratio for NADPH oxidation 
to fluoride production (Table 28) is too high to be accounted 
for by postulating other pathways of metabolism for enflurane; 
the possibility that metabolism of the compound occurs with-
out concomitant free fluoride production is discredited to 
a large extent by the results of in vivo studies (albeit 
in man) demonstrating a ratio of 4:1 for organic to in-
organic fluoride metabolites after enflurane anaesthesia 
(Table 3) (145). The presence of C-F bonds in a compound 
is known to confer chemical stability on that compound (119); 
enflurane has five out of a possible eight C-X bonds as C-F, 
and this may render it refractory to oxidation by cytochromes 
P-450. Further studies are being performed to establish 
whether enflurane acts as an uncoupling agent for microsomal 
cytochromes P-450 electron transfer. 
Although a compound such as enflurane may be relatively 
biologically inert, it may st111 participate in drug-drug 
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interactions: inhibition of the metabolism of other drugs 
may occur as a result of-binding of the inert compound to 
cytochromes P-450 or by depletion of NADPH due to uncoupling 
of microsomal drug oxidation. In this respect, enflurane 
has been shown to inhibit metabolism of compounds in vivo 
(184) and in vitro (183) to the same extent as methoxyflurane. 
The major role of phenobarbital induced cytochrome P-450 
in the binding and metabolism of methoxyflurane and 
enflurane is demonstrated in the same manner as for fluroxene 
and TFEE by the results of the effects of induction on ~A 
max 
and V values for the interaction of these agents with 
max 
cytochromes P-450 (Table 26); only induction with pheno-
barbital leads to increases in extents of the interaction 
of methoxyflurane or enflurane with cytochromes P-450. With 
regard to the extent of induction by phenobarbital pretreat-
ment of animals, Greenstein et ~l. (157) concluded from in 
vitro studies at a single concentration of anaesthetic that 
the 'specific activity' of methoxyflurane defluorinase in 
microsomes from Fischer 344 rats was increased 7.3 times 
and that for enflurane defluorinase 1.6 times relative to 
uninduced controls. The.results presented herein (either 
V values in Table 26, or values determined at a single 
max 
concentration of anaesthetic in Tables 19 and 23) demonstrate 
that defluorination of both methoxyflurane and enflurane 
in vitro is increased by phenobarbital induction about 2.5 
to 3.0 times the rate observed in uninduced controls. The 
difference in the results possibly arises from the species 
differences inherent in cytochromes P-450 catalysed reactions 
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or from failure by Greenstein et al. to utilize optimum 
conditions of assay in vitro, i.e. with respect to time, 
protein concentration and anaesthetic concentration. 
Cytochrome P-448, the predominant cytochrome induced by 
3-methylcholanthrene appears to play a limited role in 
the interactions of methoxyflurane and enflurane with 
cytochromes P-450 as demonstrated by the observation that 
induction of elevated levels of cytochrome P-448 generally 
has no effect on the extents of the interactions observed 
relative to those in uninduced microsomes. Induction by 
3-methylcholanthrene does have an effect, however, on the 
relative proportions of acid-labile and free fluoride 
formed from methoxyflurane (Table 27) indicating that there 
are qualitative differences in the cytochromes P-450 res-
ponsible for methoxyflurane metabolism in uninduced and 
3-methylcholanthrene induced microsomes. It could be 
speculated that the amount of anaesthetic metabolized via 
Pathway II (indicated by acid-labile fluoride production) 
relative to that metabolized via Pathway I (indicated by 
free fluoride production) (Figure 7) is increased by 
3~methylcholanthrene pretreatment of animals. · This inter-
pretation of the results of Table 27 receives some corrobo-
ration from a report of the effect of induction with pheno-
barbital and 3-methylcholanthrene on O-dealkylation (i.e. 
Pathway I} and dechlorination (i.~. Pathway II} of nethoxy-
flurane in vitro (152). From data in this report we have 
calculated the ratios of dechlorination to 0-dealkylation 
in microsomes from uninduced, 3-methylcholanthrene induced 
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and phenobarbital induced animals to be 10, 16 and 6 
respectively. These ratios and the results presented in 
Table 27 appear to indicate that induction with 3-methyl-
cholanthrene increases metabolism of methoxyflurane via 
Pathway II relative to Pathway I. 
--~- ·-~ --~- ~ ...;,,- - -
Differences in the cytochromes P-450 involved in the 
binding and metabolism of methoxyf lurane in uninduced (or 
3-methylcholanthrene induced) and phenobarbital induced 
microsomes are apparent from investigations of binding, 
NADPH oxidation and fluoride production. The biphasic 
nature of the Eadie-Hofstee and Hanes plots for fluoride 
production from methoxyf lurane by uninduced and 3-methyl-
cholan threne induced microsomes (Figures 27-33) may result 
from involvement of at least two cytochromes P-450 catalysing 
one reaction, from the occurrence of two different reactions 
leading to free fluoride (and acid-labile fluoride) produc-
tion, or from conformational changes of the enzyme at high 
substrate concentratitins. In contrast, in phenobarbital 
induced microsomes the activity of one type P-450 cyto-
chrome appears to predominate in the production of free or 
acid-labile fluoride from methoxyflurane (Figures 34 and 
35). Phenobarbital treatment of animals does not ·appear 
to induce either of the two type P-450 cytochromes whose 
activity is reflected by the two K values obtained each 
m 
for free and acid-labile fluoride production by 
uninduced microsomes; this is demonstrated by the lack 
of correspondence between these K values and the single m . 
-------------~------~--
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K values obtained each for free and acid-labile fluoride 
m 
production by phenobarbital induced microsomes (Table 26). 
In addition, a difference between uninduced and 3-methyl-
cholanthrene induced microsomes apparently exists for the 
type P-450 cytochrome represented by the larger Km for 
free fluoride production (Table 26). 
The binding and metabolism of methoxyf lurane and enflurane 
by microsomal cytochromes.P-450 is evidently much more 
complex than that of fluroxene or TFEE. In contrast to 
the situation observed with the latter agents, simple 
correlations between K and K values are not found for 
s m 
the interaction of methoxyflurane or enflurane with cyto-
chromes P-450 (Table 26). 
While the investigations reported in this thesis were in 
progress, results of a study of the metabolism of methoxy-
' flurane in vitro were published (178); Km and Vmax 
values are quoted for the production of free and total 
fluoride from methoxyflurane by uninduced and phenobarbital 
induced rat hepatic microsomes. These results are in-
validated, however, by the fact that these workers deter-
mined free and total fluoride concentrations after a 30 
min reaction time when rates of fluoride production are 
no longer linear (see Figures 23 and 25). In addition, 
the concentration of total fluoride was determined by 
Adler et al. (178) after treatment of reaction mixtures 
with H2so 4 for only 18 hr which we have shown 
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results in release of about 60% of the acid-labile fluoride 
present (Figure 22). Furthermore, the rates of production 
of free fluoride from methoxyflurane reported by these 
authors are at least ten times higher than the equivalent 
values reported herein and by other workers (156, 157, 200, 
201). 
Effect of inhibitors on production of metabolites from 
volatile anaesthetic agents. The compounds SKF 525A, 
metyrapone and carbon monoxide are accepted inhibitors of. 
cytochromes P-450 (202, 203). The mechanism of the 
inhibitory action of SKF 525A is still not completely under-
stood (203). SKF 525A itself is oxidatively metabolized 
by the cytochromes P-450 mixed function oxidase system and 
has been shown to inhibit competitively the metabolism of 
other drug substrates (204). In addition, however, mixed 
or noncompetitive inhibition kinetics for SKF 525A have 
been observed under certain conditions and other mechanisms 
of inhibition by SKF 525A have been proposed involving 
membrane disruption, uncoupling of electron transport or 
formation of a stable cytochromes P-450 - SKF 525A complex 
(202, 203, 205). 
In contrast, metyrapone is not itself subject to oxidation 
but combines with both the oxidized and reduced forms of 
cytochromes P-450 to form a complex which absorbs at 446 nm 
(202). It has been suggested that metyrapone mimics the 
interaction of carbon monoxide with reduced cytochromes 
P-450 by ligandirig to the iron atom of cytochromes P-450 
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to form a complex nonfunctional in substrate oxidation (206). 
However, while carbon monoxide inhibits all cytochromes 
P-450 catalysed reactions to a greater or lesser extent, 
~etyrapone diminishes the activity of only certain reactions 
(206) and actually stimulates the oxidation of type II 
substrates in vitro (203). 
There have been reports which indicate that SKF 525A and 
metyrapone react selectively with different species of 
microsomal cytochromes P-450. Cytochrome P-450 induced 
by phenobarbital binds metyrapone tightly and SKF 525A 
weakly while the predominant type P-450 cytochrome(s) 
present in uninduced microsomes is (are) able to bind 
SKF 525A more tightly than is cytochrome P-450 (207). 
In addition, SKF 525A is considered to bind preferentially 
to the same species of cytochromes P-450 with which metab-
olites of amphetamines form inhibitory complexes absorbing 
at 455 nm (208). In this regard, 3,4-benzpyrene hydroxylase 
in phenobarbital induced microsomes was the most sensitive 
to inhibition by amphetamines and ethylmorphine N-demethyl-
ase the least sensitive of the mixed-function oxidase 
reactions investigated in vitro (209). Differences in the 
sensitivity of type P-450 cytochromes to inhibition by 
carbon monoxide have been suggested by a report on 3,4-benz-
pyrene hydroxylation in microsomes from phenobarbital and 
3-methylcholanthrene treated animals (210). 
The predominant role of the metyrapone sensitive cytochrome 
P-450 in the metabolism of the four anaesthetic agents is 
\ 
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indicated by the relative effects of metyrapone and SKF 525A 
on the production of trif luoroethanol and fluoride by 
phenobarbital induced microsomes (Table 29). In addition, 
it appears that there are differences between the cyto-
chromes P-450 metabolizing f luroxene and the other anaes-
thetic agents: the metyrapone sensitive cytochrome P-450 
plays a relatively greater role in the metabolism of 
fluroxene than in that of TFEE, methoxyflurane or enflurane. 
Investigations into the inhibition of trifluoroethanol 
production from fluroxene in microsomes from differently 
induced animals provide the only evidence that the same 
type P-450 cytochromes may not be involved in the metabolism 
of fluroxene by different types of microsomes. The cyto-
chromes P-450 present in 3-methylcholanthrene induced 
microsomes are less sensitive to metyrapone inhibition of 
trif luoroethanol production from fluroxene than are those 
in phenobarbital induced microsomes (RESULTS, page 79). 
Inhibition of the metabolism of methoxyflurane was investi-
gated more extensively than that of fluroxene with evidence 
presented for differences between the cytochromes P-450 
responsible for fluoride production in uninduced, 3-methyl-
cholanthrene induced and phenobarbital induced microsomes 
(Table 20). Support for the proposal (DISCUSSION, page 161) 
that 3-methylcholanthrene induces a type P-450 cytochrome 
• 
that differs from those present irt uninduced rnicrosornes 
with respect to acid-labile fluoride production is provided 
by the demonstration that acid-labile fluoride production 
' 
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in 3-methylcholanthrene induced microsomes is considerably 
less sensitive to metyrapone and carbon monoxide inhibition 
than that in uninduced microsomes (Table 20). The observa-
tion that fluoride production by uninduced or 3-methyl-
cholanthrene induced microsomes is equally or less sensitive 
to metyrapone than to SKF 525A possibly indicates that 
cytochrome P-450 does not play a dominant role in fluoride 
production in these microsomes. This proposal is consis-
tent with the observation that phenobarbital treatment of 
animals does not appear to induce the type P-450 cytochromes 
involved in fluoride production in uninduced or 3-methyl-
cholanthrene induced microsomes (Table 26 and DISCUSSION, 
page 162). 
The ability of metyrapone or SKF 525A to inhibit specific 
type P-450 cytochromes appears to decrease as the concen-
tration of the inhibitor increases • At inhibitor concen-
.. 
trations of 50 µM, differences in the sensitivity to inhibi-
tion of cytochromes P-450 present in the different types of 
microsomes are usually readily evident, while at inhibitor 
concentrations greater or equal to 200 µM, inhibition of 
type P-450 cytochromes appears to become less specific 
(Tables 16 and 20). 
Destruction of cytochromes P-450 by fluroxene in vitro. 
Destruction of microsomal cytochromes P-450 in vitro by 
carbon tetrachloride (211), halothane (212) and allyl-
containing compounds such as allyl-iso-propylacetamide (213) 
and .secobarbital (14) have been reported. Carbon tetra-
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chloride results in a non-specific type of degradation 
which affects not only levels of cytochromes P-450 but 
also levels of other components of the endoplasmic reticulum, 
whilst halothane and the allyl-containing compounds destroy 
only cytochromes P-450. 
Of the four anaesthetic agents investigated, only fluroxene 
is found to be capable of degrading hepatic microsomal 
.cytochromes P-450 and this destruction is specific in that 
it is limited to cytochromes P-450 (Table 24). Anaesthesia 
of animals with fluroxene leads to destruction of cytochromes 
P-450 in vivo (116) which parallels that observed in vitro. 
The f luroxene mediated destruction of cytochromes P-450 
in vitro requires concomitant metabolism of fluroxene as 
demonstrated from studies with inhibitors (214) and the 
absence of destruction when NADPH or oxygen is omitted from 
the reaction mixture (161). In addition, the dependence 
of destruction of cytochromes P-450 on metabolism of flurox-
ene is indicated by the linear correlation between cyto-
chromes P-450 destroyed and metabolite (trifluoroethanol) 
formed (Figul:'e 37). It appears that both cytochromes P-450 
and P-448 are destroyed by fluroxeme· (161) although the 
metabolism of fluroxene to trifluoroethanol is catalysed. 
predominantly by cytochrome P-450; this situation is 
reflected in the lack of correlation between cytochromes 
P-450 destruction and trifluoroethanol production in micro-
somes from-differently pretreated animals (Table 25). The 
observation that destruction of cytochromes P-450 in 
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microsomes ·from different sources does not depend on the 
absolute amounts of trif luoroethanol formed from fluroxene 
could indicate that:-
(1) the reactive metabolite of fluroxene which brings 
about the destruction of cytochromes P-450 is produced 
in different proportions to trif luoroethanol in the 
differently induced microsomes, or 
(2) the cytochromes P-450 present in microsomes from 
3-methylcholanthrene induced animals are more readily 
destroyed than those present in microsomes. from 
phenobarbital induced microsomes. 
These possibliities are being further investigated in our 
laboratory. 
Metabolism of 2,2,2-trifZuoroethanoZ. The appearance of 
a type I difference spectrum and enhanced NADPH oxidation 
with hepatic microsomes in the presence of trifluoro-
ethanol (Table 30) is of interest with regard to its 
possible metabolism by the microsomal alcohol oxidizing 
system. 
. It has been established that a microsomal ethanol oxidizing 
system (MEOS) exists which is distin6t from alcohol dehydrog-
enase and catalase (215). After purification of constit-
uents of the microsomal membranes, the activity of .MEOS has 
been reconstituted with the components, cytochromes P-450, 
NADPH-cytochrome c reductase a.nd phospholipids in a way 
similar to the reconstitution of other drug metabolizing 
activities (215, 216, 217). The NADPH-dependent microsomal 
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alcohol oxidizing system exhibits a broad substrate speci-
ficityi in addition to ethanol, .other primary alcohols 
such as methanol, propanol, butanol and pentanol have been 
shown to be metabolized to the corresponding aldehydes (215). 
The interaction of trifluoroethanol with cytochromes P-450 
differs, however, from that of ethanol. Trif luoroethanol 
exhibits a type I difference spectrum while ethanol exhibits 
a modified type II difference spectrum although longer chain 
alcohols are considered to exhibit dual interaction (type 
I and modified type II) with cytochromes P-450 (61). 
Furthermore, trifluoroethanol competitively inhibits the 
type I difference spectrum of fluroxene·while ethanol at 
similar concentrations does not. The latter finding is 
surprising in view of the inhibition observed with lOO'mM 
ethanol of the type I binding spectrum of hexobarbital (218). 
The similarity between the values of K and K and the 
s m 
values of K. determined for trifluoroethanol interactions 
l. 
with cytochromes P-450 (Table 30) indicates that trifluoro-
ethanol is possibly functioning as an alternative substrate 
to the type I compounds whose interactions are inhibited. 
The type I difference spectrum elicited by trifluoroethanol 
appears to reflect formation of the enzyme-substrate complex 
as judged by the identity of the K and K values (Table 30). 
s m 
For metabolism of fluroxene in vivo and in vitro, the signi-
ficance of inhibition by trifluoroethanol (product) of 
fluroxene (substrate) binding to cytochromes P-450 is 
probably negligible because of the much greater affinity of 
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cytochromes P-450 for fluroxene than for trifluoroethanol. 
The binding of hydroxylated product by cytochromes P-450 
has been reported previously in the case of the metabolism 
of the substrate, desmethylimipramine (219); in addition, 
the hydroxylated product at high concentrations inhibited 
the metabolism of desmethylimipramine. 
It appears from the results of our studies in vitro that 
of the enzymes postulated to be responsible for the oxida-
tive metabolism of trifluoroethanol to trifluoroacetaldehyde 
only the cytochromes P-450 dependent microsomal alcohol 
oxidizing system is likely to be effective. As a result 
\ 
of investigations reported herein and from the evidence 
of other workers using purified preparations of alcohol 
dehydrogenase from yeast, animals (11 7) and man (220) , it 
' 
appears extremely unlikely that alcohol dehydrogenase is 
involved in the metabolism of trifluoroethanol. Alcohol 
dehydrogenase has in fact been shown to catalyse the reduc-
tion of trifluoroacetaldehyde to trifluoroethanol at an 
extremely slow rate (121, 188). We have demonstrated that 
alcohol dehydrogenase binds trifluoroethanol with a high 
affinity K. resulting in inhibition of ethanol oxidation. 
J_ 
There has been a report of the existence of a bacterial 
alcohol dehydrogenase which is able to oxidize trifluoro-
ethanol at the same rate as ethanol (221) but it appears 
that this species of alcohol dehydrogenase has been lost 
in higher organisms. 
Although catalase is extremely active in the oxidation of 
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ethanol in vitro, this enzyme is not considered to play a 
significant role in ethanol metabolism in vivo (222). The 
possibiiity that catalase is active in the oxidation of 
trifluoroethanol.either in vivo or in vitro is eliminated 
by our finding that catalase may be inhibited by trifluoro-
ethanol. Oxygen consumption in a peroxidatic system in 
the presence of trifluoroethanol (Figure 45) therefore 
arises as a result of inhibition of catalase rather than 
from peroxidatic oxidation of trifluoroethanol. 
- ------ _,,.,.._.__--... --· .... "' .-·- -· --------
Our evidence suggesting that cytochromes P-450 may be 
involved in oxidation of trifluoroethanol rather than 
alcohol dehydrogenase or catalase is consistent with the 
observed effects of compounds which modify the toxicity of 
fluroxene and trifluoroethanol (Table 2); most of the 
agents listed are known to inhibit cytochromes P-450 reac-
tions and could therefore also inhibit cytochromes P-450 
mediated oxidation of trifluoroethanol. The proposal 
that metabolism of trifluoroethanol itself is required in 
order that toxic symptoms develop during or after treatment 
of animals with fluroxene or trifluoroethanol is therefore 
not invalidated by our findings. From our work and the 
results of other workers (Table 2), it appears that the 
toxicity of fluroxene and trifluoroethanolpossibly arises 
as a result of "-"'-~ 1 cytochromes P-450 mediated oxidation of 
trifluoroethanol. 
Metabolis~ of trifluoroethanol may_also occur via a conjuga~ 
tion reaction. Conjugation with glucuronic acid provides 
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a mechanism by which the potentially toxic trifluoroethanol 
may be converted to a less toxic compound which can be 
rapidly excreted by the kidneys. In mice, glucuronidation 
appears to be the more important of the metabolic routes 
for trifluoroethanol in vivo as demonstrated by the recovery 
of 80% of a dose of c14-trifluoroethanol as urinary glucuron-
ide and 15% as urinary trifluoroacetate (117). In man the 
•t t• 80° f .. t d c14 '•fl reverse si ua ion occurs: ~ o inJeC e -tri uoro-
ethanol is recovered as urinary trifluoroacetate and 15% 
as urinary trifluoroethanol-glucuronide (223). 
Our failure to observe glucuronidation of trifluoroethanol 
in rat microsomal preparations may result from our inability 
to monitor rates less than 1-2 nmol/mg microsomal protein/ 
min. The species of rats with which these experiments 
were performed may be relatively deficient in the ability 
·to glucuronidate trifluoroethanol so that rates of reaction 
are too low to be monitored. Experiments in vivo would 
now be required in order to establish the existence of 
enzymes capable of glucuronidating trifluoro_ethanol in 
these rats. 
The effects of volatile anaesthetic agents on the levels 
and activities of hepatic drug metabolizing enzymes and 
glutathione in vivo. As a result of studies demonstrating 
increased drug metabolizing activities after anaesthesia, 
the volatile anaesthetic agents fluroxene, rnethoxyflurane 
and enflurane have been proposed to induce hepatic drug 
metabolizing enzymes (103, 224, 225). 
• 
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We have shown that anaesthesia with fluroxene (3% for 2 hr) 
leads in fact to decreased levels of hepatic microsomal 
cytochromes P-450 in phenobarbital and 3-methylcholanthrene 
induced animals; in addition, anaesthesia of uninduced 
animals with fluroxene does not affect levels of cytochromes 
P-450 relative to unanaesthetized animals at 2 or 24 hr 
after anaesthesia (116). The decrease in hexobarbital 
sleeping time observed 20 to 22 hr after fluroxene anaes-
thesia (1.5% for 7 hr) (224) cannot therefore be explained 
by postulating induction by fluroxene of enzymes of the 
cytochromes P-450 drug metabolizing system. 
A number of investigations into the effects of anaesthesia 
with methoxyflurane and enflurane on drug metabolizing 
activities have been reported in the literature and the 
results of these studies, some of which conflict with each 
other, are summarized in Tables 36 and 37. Differences 
in the characteristics of drug metabolizing enzymes are 
known to exist ·between species and between different age-
groups bf one species (231) and these differences possibly 
/ 
play a major role in differences observed between the 
various reports of the effects of anaesthetic agents on 
the activities of drug metabolizing enzymes • It is doubt-
ful whether any conclusions regarding the inducibility of 
drug metabolizing enzymes by methoxyflurane or enflurane 
may be drawn from the results presented in Tables 36 and 37. 
Hexobarbital sleeping time (224, 226, 229), the lethal dose 
of anaesthetic (226) and the ratio of urinary 6-s-hydroxy-
cortisol to 17-hydroxycorticosteroids may be altered by 
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Table 36. Effects of methoxyflurane anaesthesia on drug 
metabolizing enzymes and activities 
Dosage Animal Effect a Ref. 
' 0.03% ?hr/day Wistar t Dechlorination of 152 
(10 days) (195-200 g) methoxyflurane in vitro 
0 • 13 % 7hr I day Sprague-Dawley + Hexobarbi tal sleeping 2 2 6 
(15 days) (40-50 g) time 
(10 days) 
1.0 g/kg/day Mice 
i.p. (5 days) 
t LD50 methoxyflurane 
t Aminopyrine demethyl-
ation in vitro 
No change in fraction 
of dose of methoxy-
f lurane defluorinated 
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0.03 and 0.1% Sprague-Dawley + Cyt. P-450, 227 
7 hr/day (170-180 g) tNADPH-cyt. c reductase, 
(10 days) 
(40-50 g) 
Unspecified Sheep 
+ He:Xobarbi tal oxidation, 
No change in aniline 
hydroxylation, in vitro 
No change in Cyt. P-450, 
t NADPH-cyt. c reductase, 
No change in hexobarb-
i tal oxidation, 
t Aminopyrine demethyl-
ation, 
No change in aniline 
hydroxylation, in vitro 
t Cyt. P-450 in lung 228 
a Increase or decrease in enzyme concentration or activity 
indicated by t and + respectively. 
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Table 37. Effects of enflurane anaesthesia on drug 
metabolizing enzymes and activities 
Dosage Animal .Ef.fect a Ref. 
0.6% 7 hr/day Sprague-Dawley + Hexobarbi tal sleeping 224 
( 1-4 days) (40-60) g time 
0.2% for 1, 2, Sprague-Dawley tCyt. P-450, 225 
-4, 8 days Fischer 344 tSerum inorganic F 
unspecified over 1-8 days 
weight 
Repeated doses Wistar No change in Cyt. 229 
at anaesthetic (200-250 
& subanaesthetic 
concentrations 
9.6 MAC-hours Man 
g) P-450, 
+Hexobarbital sleeping 
time,. 
fRatio of urinary 230 
6-S-hydroxycortisol 
to 17-hydroxycortico-
steroids 
a Increase or decrease in enzyme concentration or activity 
indicated by t and + respectively 
177, 
effects of the anaesthetics on physiological processes 
unrelated to specific induction of drug metabolizing 
enzymes. Other factors which may invalidate conclusions 
that induction occurs are: dechlorination of methoxy-
flurane in vitro (152) was assayed using a mixture of 
microsomes and soluble fraction; in one case, cytochromes 
P-450 levels were assayed two weeks after exposure to 
methoxyflurane (228); Hitt et al. (225), who report that 
enflurane anaesthesia results in a two to three fold 
increase in cytochromes P-450 levels comparable to that 
after phenobarbital induction, have not reported values 
for unanaesthetized control animals and performed cyto-
chromes P-450 assays after storage of livers in the frozen 
state; and, the increasing levels of serum inorganic 
fluoride observed during 1 to 8 days of enflurane anaes-
thesia (225) may be attributed to the additive effect on 
serum fluoride levels of repeated doses of enflurane (see 
Figure 3, in ref. 142). 
The results reported in this thesis indicate that neither 
methoxyf lurane nor enflurane is able to induce enzymes of 
the cytochromes P-450 mixed function oxidase system such 
that it may be classed in either of the two groups of 
accepted inducing agents (INTRODUCTION, page 17). Treat-
ment of animals with either anaesthetic at 0.1 MAC for 4 
----~----~---- ---·-·-~---- -- ------------ ----- ---~~- ---- -·- ------- -----· 
to 16 days re~ults in few changes in levels or activities 
of drug metabolizing enzymes (Tables 32 and 34). The only 
. indication bf iridu'ction bf. elevated levels of . enzymes after 
anaesthesia by these agents is seen in the rnethoxyflurane 
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(1.0 MAC) induced slight elevation of NADPH-cytochrome c 
reductase after the third day of treatment (Table 31). 
This result is not in agreement with that of Brown and 
Sagalyn (227) who report activity of NADPH-cytochrome c 
reductase increased by methoxyf lurane to the same extent 
as by phenobarbital induction. Cytochromes P-450 levels 
.and drug metabolizing activities are in fact decreased 
after the fourth day of treatment with methoxyflurane· 
(1.0 MAC) to levels below those observed in unanaesthetized 
animals (Table 31). Since the levels of the microsomal 
marker enzyme glucose-6-phosphatase are also decreased 
following methoxyflurane anaesthesia, it would appear that 
relatively non-specific damage to the proteins of the 
endoplasmic reticulum may follow exposure to methoxyflurane. 
Treatment of animals with enflurane (1.0 MAC for 3 hr/day) 
for four days appears to result in increased drug metaboli-
zing activity, viz. E-nitroan~sole-0-demethylation (Table 
33), but again this increase in activity cannot be correla-
ted with induction by enflurane of elevated levels of the 
drug metabolizing enzymes. 
The apparent increases in drug metabolizing activities 
observed after anaesthesia with fluroxene, methoxyflurane 
or enflurane (224) (Tables 33, 36, 37) may be due to a 
mechanism unknown as yet and which is not related to 
induction per ~ of enzymes of the cytochromes P-450 drug 
metabolizing system. Alternatively, the relative amounts 
of different species of cytochrornes P-450 may be altered 
by treatment with the anaesthetic agents such that levels 
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of total cytochromes P~450 remain unchanged but metabolism 
of particular compounds may be either increased or decreased. 
Further investigations are required in order to elucidate 
the mec-hanism of. the apparent stimulation of activities of 
drug metabolizing enzymes by the volatile anaesthetic 
agents. • 
The variation in levels and activities of drug metabolizing 
enzymes observed in control unanaesthetized animals during 
the two month period of the investigations (Tables 31-34) 
indicates the importance of performing control experiments 
at the same time and with the same batch of animals as 
those used in experiments with anaesthetic agents or other 
xenobiotics. 
Decreased levels of glutathione in the liver immediately 
.·after treatment of an animal by. a particular ·compound is 
usually. t_aken as. an ;i,ndication that that compound is toxic 
or potentially .toxic and may· result in damage to liver 
cells (91). Glutathione levels were measured 16. to 22 hr 
after the last anaesthetic treatment and may not therefore 
be a true reflection of the situation. existing immediately 
after anaesthesia. 
Summary of the interaction of volati.Ze anaesthetic agents 
with hepatic drug metabolizing enzymes. Each of. the 
anaesthetic agents under investigation interacts with 
cytochromes P-450 of hepatic microsomes resulting in the 
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appearance of a type I difference spe~trum, enhancement of 
NADPH oxidation and production of potentially toxic 
.. 
metabolites, trifluoroethanol or fluoride. Enf lurane is 
·' : 
proposed to interact with cytochromes P-450 to a large 
extent as an uncoupler of sub'strate oxidation and NADPH 
and oxygen consumption. In addition, fluroxene in the 
presence of NADPH causes the degradation of cytochromes 
P-450; the process.of degradation requires concomitant 
metabolism of fluroxene but is not related to the produc-
tion of trifluoroethanol in different types of microsomes. 
For fluroxene and enflurane, cytochrome P-450 appears to 
be the predominant type P-450 cytochrome. involved in 
spectrally observable binding of the agent, enhanced micro-
somal NADPH oxidation and production of metabolites in 
different types of microsomes. Although activity of 
6ytochrome P-450 also appears predominant in the spectrally 
observable binding of TFEE, involvement of at least one 
other type P-450 cytochrome is evident in th~ interaction 
leading to NADPH oxidation or pf9duction of trif ltioro-
ethanol in uninduced or polycyclic hydrocarbon induced 
microsomes. For methoxyflurane,, differences in the cyto-
chromes P-450 involved in its binding and metabolism by 
microsomes from differently pretreated· animals are evident 
from studies of binding, NADPH oxidation and production 
of metabolites. 
----··- ---·--··--· -----·----
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For the binding and metabolism of methoxyflurane, it 
------~------
appe~rs that cytochrome P-450 plays a major role only in 
phenobarbital induced microsomes; in uninduced and 3--methyl-
cholanthrene induced microsomes the activity of other type 
P-450 cytochromes is evident. 
For the interaction of f luroxene or TFEE with cytochromes 
P-450 in phenobarbital iriduced microsomes, the enzyme-
substrate complex, of which the difference spectrum is a 
spectral manifestation, appears to lead to both NADPH 
oxidation and trifluoroethanol production; this is demon-
strated by the relationship, K = K (NADPH oxidation) = 
. . s m . 
K'. (TFE production). 
m 
The same relationship is obse.rvable 
fer fluroxene in uninduced and 3-methylcholanthrene induced 
microsomes. ~or TFEE, the type P-450 cytochrome represented 
by the larger K for NADPH oxidation and trif luoroethanol 
m 
production in uninduced and polycyclic hydrocarbon induced 
microsomes appears not to bind TFEE in a manner which gives 
rise to a difference spectrum. For methoxYf lurane and 
enflurane interactions with cytochromes P-450, simple 
correlatio~s between Ks _and Km values are not observed and 
this situation probably reflects the greater complexity of 
the metabolism of these two agents relative to that of 
fluroxene or TFEE. 
As a result of.studies -0f the interactions of trifluoro-
- - ~-~------ -- - -· - - --------;; ------ ---- - --
ethanol with hepatic enzymes in vitro we suggest that 
\ 
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the major pathway by which trifluoroethanol may be oxidatively 
--··------- -------- - -~-· - -_ ---
metabolized involves the activity of the cytochromes P-450 
mixed function oxidation system and that alcohol dehydrogen-
ase and catalase are not active in this respect. Glucuroni-
dation of trif luoroethanol is not observed in hepatic 
microsomes from the rats investigated; the reaction there-
fore occurs, if at all, at a very low rate in these 
animals. 
Finally, it appears that fluroxene, methoxyflurane and 
enflurane may not be classified as inducers of hepatic 
drug metabolizing enzymes including enzymes responsible 
- ----·-·-·- -- •• - ·------ ~- .--~ • ---- -------- - ------·---- - - - ----- •• - .... -~-- --- - - •• -,,.< -- - -·- -
for conjugation with glucuronic acid or glutathione. The 
mechanism by which apparent increases in drug metabolizing 
activities are observed after a;naesthesia with.these agents 
does not appear to involve induction of enzymes of the 
cytochromes P-450 system. 
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